

CITATION REPORT

List of articles citing

The genomic landscapes of human breast and colorectal cancers

DOI: 10.1126/science.1145720
Science, 2007, 318, 1108-13.

Source: <https://exaly.com/paper-pdf/43054573/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2280	.		
2279	Index to Volumes 34, 35 and 36 (1950, 1951 and 1952). 1952 , 36, 1807-1875		
2278	THE POSTOPERATIVE STATUS OF THE DEPENDENT LUNG. 1955 , 30, 713-718		2
2277	AIR DRYERS. 2000 , 232-241		0
2276	Essential roles of the bHLH transcription factor Hrt2 in repression of atrial gene expression and maintenance of postnatal cardiac function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 7975-80	11.5	92
2275	Cancer. The gene topography of cancer. <i>Science</i> , 2007 , 318, 1079-80	33.3	5
2274	Cancer genome analysis: a landscape seen from many angles. 2007 , 4, 269-276		
2273	Audio Production and Studio Technology. 2007 , 375		
2272	APC and colon cancer: two hits for one. 2007 , 13, 1286-7		13
2271	Combing the genome for cancer genes. 2007 , 8, 910-910		
2270	Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. 2007 , 12, 501-13		154
2269	Common integration sites for MMTV in viral induced mouse mammary tumors. 2008 , 13, 309-21		38
2268	Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. 2008 , 39, 283-94		40
2267	Endogenous retroviruses and cancer. 2008 , 65, 3366-82		112
2266	Identifying cancer genes from cancer mutation profiles by cancer functions. 2008 , 51, 569-74		0
2265	The Pathobiology of Kr�ppel-like Factors in Colorectal Cancer. 2008 , 4, 59-64		36
2264	Cancrogen�se. Accroissement des connaissances et �volution des concepts. 2008 , 10, 319-347		2

2263	Hereditary breast cancer: new genetic developments, new therapeutic avenues. 2008 , 124, 31-42	233
2262	Network-based model weighting to detect multiple loci influencing complex diseases. 2008 , 124, 225-34	25
2261	Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells. 2008 , 6, 7	22
2260	Reasons for breast cancer heterogeneity. 2008 , 7, 6	57
2259	New cancer susceptibility loci: population and familial risks. 2008 , 123, 1726-9	11
2258	Inactivation of the p19(ARF) tumor suppressor affects intestinal epithelial cell proliferation and integrity. 2008 , 104, 2228-40	3
2257	Chromosome instability and tumor lethality suppression in carcinogenesis. 2008 , 105, 1327-41	3
2256	Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. 2008 , 47, 890-905	52
2255	The gene-centric concept: a new liability?. 2008 , 30, 196-7	13
2254	A searchable database of genetic evidence for psychiatric disorders. 2008 , 147B, 671-5	30
2253	Proteomics-driven cancer biomarker discovery: looking to the future. 2008 , 12, 72-7	88
2252	More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. 2008 , 15, 956-60	80
2251	An integrated genomic analysis of human glioblastoma multiforme. <i>Science</i> , 2008 , 321, 1807-12	33.3 4419
2250	A comprehensive assay for targeted multiplex amplification of human DNA sequences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 9296-301	11.5 58
2249	Tumor cell dormancy: implications for the biology and treatment of breast cancer. 2008 , 116, 742-53	37
2248	Endocytosis and cancer: an 'insider' network with dangerous liaisons. 2008 , 9, 2011-21	93
2247	Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. 2008 , 18, 1128-40	84
2246	Translating insights from the cancer genome into clinical practice. 2008 , 452, 553-63	235

2245	Somatic mutations affect key pathways in lung adenocarcinoma. 2008 , 455, 1069-75	2280
2244	Identification of Holliday junction resolvases from humans and yeast. 2008 , 456, 357-61	307
2243	Cancer: Deconstructing oncogenesis. 2008 , 453, 995-6	9
2242	Organic electronics: On the border. 2008 , 453, 996-7	7
2241	Polymorphic markers associated with genes responsible for lipid and carbohydrate metabolism disorders and insulin resistance in cancer patients. 2008 , 42, 843-851	7
2240	Associations between obesity and changes in adult BMI over time and colon cancer risk. 2008 , 16, 1099-104	36
2239	AKT1(E17K) in human solid tumours. 2008 , 27, 5648-50	165
2238	Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. 2008 , 27, 6729-37	76
2237	Next-generation DNA sequencing. 2008 , 26, 1135-45	3040
2236	What would you do if you could sequence everything?. 2008 , 26, 1125-33	155
2235	Molecular screening for new fusion genes in cancer. 2008 , 40, 685-6	31
2234	New susceptibility genes for ulcerative colitis. 2008 , 40, 686-8	12
2233	Circulating mutant DNA to assess tumor dynamics. 2008 , 14, 985-90	1718
2232	Ca ²⁺ signalling checkpoints in cancer: remodelling Ca ²⁺ for cancer cell proliferation and survival. 2008 , 8, 361-75	500
2231	Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. 2008 , 8, 438-49	709
2230	Comparing whole genomes using DNA microarrays. 2008 , 9, 291-302	159
2229	New pharmacological strategies against metastatic spread. 2008 , 22, 465-92	16
2228	beta-catenin is strongly elevated in rat colonic epithelium following short-term intermittent treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and a high-fat diet. 2008 , 99, 1754-9	12

2227	Evaluation of human gene variant detection in amplicon pools by the GS-FLX parallel Pyrosequencer. 2008 , 9, 464		18
2226	Somatic mutation analysis of MYH11 in breast and prostate cancer. <i>BMC Cancer</i> , 2008 , 8, 263	4.8	21
2225	High-resolution array CGH clarifies events occurring on 8p in carcinogenesis. <i>BMC Cancer</i> , 2008 , 8, 288	4.8	36
2224	Network evaluation from the consistency of the graph structure with the measured data. 2008 , 2, 84		18
2223	All along the watchtower: is the cilium a tumor suppressor organelle?. 2008 , 1786, 114-25		25
2222	Deregulation of signaling pathways in acute myeloid leukemia. 2008 , 35, 336-45		117
2221	The impact of next-generation sequencing technology on genetics. 2008 , 24, 133-141		1600
2220	Low duplicability and network fragility of cancer genes. 2008 , 24, 427-30		56
2219	Whole chromosome instability and cancer: a complex relationship. 2008 , 24, 457-66		125
2218	Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. 2008 , 8, 587-97		75
2217	Epigenomics and breast cancer. 2008 , 9, 1879-902		135
2216	Integrative Pathway Analysis of Disease Molecular Data. 2008 , 121-148		
2215	Clinical utility of contemporary molecular cytogenetics. 2008 , 9, 71-86		68
2214	An oncogene-induced DNA damage model for cancer development. <i>Science</i> , 2008 , 319, 1352-5	33.3	1377
2213	Transformation of MCF-10A cells by random mutagenesis with frameshift mutagen ICR191: a model for identifying candidate breast-tumor suppressors. 2008 , 7, 51		20
2212	Occurrence of cancer at multiple sites: towards distinguishing multigenesis from metastasis. 2008 , 3, 14		3
2211	From cytogenetics to next-generation sequencing technologies: advances in the detection of genome rearrangements in tumors. 2008 , 86, 81-91		28
2210	Network-based global inference of human disease genes. 2008 , 4, 189		475

2209	Mistakes make history: visualizing intestinal tectonics. 2008 , 134, 628-31		
2208	Genomic and epigenetic instability in colorectal cancer pathogenesis. 2008 , 135, 1079-99		666
2207	Cancer as an endocrine problem. 2008 , 22, 539-50		13
2206	Receptor tyrosine kinase inhibitors in thyroid cancer. 2008 , 22, 1023-38		31
2205	Regulation of cancer stem cells by p53. 2008 , 10, 304		11
2204	Prioritizing functional modules mediating genetic perturbations and their phenotypic effects: a global strategy. 2008 , 9, R174		4
2203	Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo. 2008 , 9, R180		12
2202	Genomics. 2008 ,		
2201	Cancer proliferation gene discovery through functional genomics. <i>Science</i> , 2008 , 319, 620-4	33.3	323
2200	Defining the steps that lead to cancer: replicative telomere erosion, aneuploidy and an epigenetic maturation arrest of tissue stem cells. 2008 , 71, 126-40		12
2199	Cancer: shift of the paradigm. 2008 , 71, 839-50		8
2198	Specificity in cancer immunotherapy. 2008 , 20, 276-85		76
2197	Tumor-specific immune responses. 2008 , 20, 265-6		2
2196	Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. <i>Science</i> , 2008 , 321, 1801-6	33.3	3223
2195	Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. 2008 , 263, 170-81		106
2194	Side population cells in human cancers. 2008 , 268, 1-9		280
2193	Molecular alterations in prostate cancer. 2008 , 271, 13-24		32
2192	Advances in translational research in breast cancer; a bridge to future therapies. 2008 , 44, 2705-6		2

2191	High-content analysis of cancer genome DNA alterations. 2008 , 18, 68-72		13
2190	Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. 2008 , 133, 727-41		149
2189	An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. 2008 , 135, 852-64		366
2188	Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. 2008 , 8, 359-62		25
2187	Nuclear pore composition regulates neural stem/progenitor cell differentiation in the mouse embryo. 2008 , 14, 831-42		132
2186	Cancer DNA microarray analysis considering multi-subclass with graph-based clustering method. 2008 , 106, 442-8		4
2185	Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. 2008 , 8, 29-39		75
2184	Linking contralateral breast cancer with genetics. 2008 , 86, 139-41		65
2183	Cell type-specific DNA methylation patterns in the human breast. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 14076-81	11.5	191
2182	Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. 2008 , 68, 8852-60		53
2181	Tumorigenic activity and therapeutic inhibition of Rheb GTPase. 2008 , 22, 2178-88		92
2180	Mapping DNA structural variation in dogs. 2009 , 19, 500-9		109
2179	The conflict between complex systems and reductionism. 2008 , 300, 1580-1		64
2178	Newer cytotoxic agents: attacking cancer broadly. 2008 , 14, 1610-7		87
2177	A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 19432-7	11.5	70
2176	Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. 2008 , 28, 6223-33		103
2175	From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. 2008 , 4, 569-77		24
2174	Clonal selection in malignant transformation of human fibroblasts transduced with defined cellular oncogenes. 2008 , 68, 1417-26		18

2173	Genome-wide functional synergy between amplified and mutated genes in human breast cancer. 2008 , 68, 9532-40		72
2172	Cancer. Quo vadis, specificity?. <i>Science</i> , 2008 , 319, 164-5	33.3	5
2171	Somatic mutations to CSMD1 in colorectal adenocarcinomas. 2008 , 7, 609-13		35
2170	Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. 2008 , 7, 1496-506		64
2169	A naturally occurring cancer with molecular connectivity to human diseases. 2008 , 7, 2286-9		22
2168	DNA methylation and cancer pathways in gastrointestinal tumors. 2008 , 9, 1917-28		41
2167	Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. 2008 , 7, 3081-91		130
2166	Mouse models for the study of colon carcinogenesis. 2009 , 30, 183-96		279
2165	Nested Patch PCR enables highly multiplexed mutation discovery in candidate genes. 2008 , 18, 1844-50		49
2164	Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. 2008 , 283, 35295-304		32
2163	Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 3443-8	11.5	314
2162	A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 9697-702	11.5	143
2161	A DNA transposon-based approach to validate oncogenic mutations in the mouse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 19904-9	11.5	15
2160	Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 2358-62	11.5	42
2159	Genetic variation in an individual human exome. 2008 , 4, e1000160		205
2158	Prioritization of candidate cancer genes--an aid to oncogenomic studies. 2008 , 36, e115		27
2157	BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. 2008 , 93, 2194-201		107
2156	Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. 2008 , 9, 349-60		28

2155	Commentary: Novel therapies for cancer: why dirty might be better. 2008 , 13, 277-83		47
2154	Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board. 2008 , 100, 159-61		5
2153	Defining the blueprint of the cancer genome. 2008 , 29, 1087-91		51
2152	Total number of genome alterations in sporadic gastrointestinal cancer inferred from pooled analyses in the literature. 2008 , 29, 343-50		16
2151	Mechanisms of malignant progression. 2008 , 29, 1092-5		131
2150	A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. 2008 , 68, 8113-21		64
2149	TRAB: testing whether mutation frequencies are above an unknown background. 2008 , 7, Article11		2
2148	Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. 2008 , 68, 10300-6		97
2147	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 16224-9	11.5	230
2146	Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. 2008 , 14, 8263-9		50
2145	The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. 2008 , 68, 4321-30		52
2144	Comparative lesion sequencing provides insights into tumor evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 4283-8	11.5	616
2143	A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin. 2008 , 68, 6727-33		44
2142	The new paradigm of flow cell sequencing. 2008 , 18, 839-46		165
2141	Genome-wide promoter analysis uncovers portions of the cancer methylome. 2008 , 68, 2661-70		120
2140	Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. 2008 , 9, 1903-16		21
2139	Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones?. 2008 , 4, 207-10		12
2138	Mining the epigenome for methylated genes in lung cancer. 2008 , 5, 806-10		31

2137	Translational control and cancer therapy. 2008 , 7, 2791-4	22
2136	Cancer stem cells: Models, mechanisms and implications for improved treatment. 2008 , 7, 1360-70	77
2135	Basic science: (OCTOBER 2007). 2008 , 11,	
2134	Plasma membrane phospholipid labeling to estimate tumor burden and kinetics. 2008 , 7, 748-9	
2133	Septins and Human Disease. 295-317	3
2132	Statistical Methods for Functional Analysis of Omics Experimental Data. 2008 , 269-287	
2131	Application of Serial Analysis of Gene Expression in cancer research. 2008 , 9, 375-82	12
2130	Is the UK public ready for genetic medicine?. 2008 , 5, 65-76	11
2129	. 2008 ,	19
2128	Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling?. 2008 , 6, 239-259	14
2127	Generation of small ³² P-labeled peptides as a potential approach to colorectal cancer therapy. 2008 , 3, e2508	2
2126	Functional copy-number alterations in cancer. 2008 , 3, e3179	129
2125	Viral organization of human proteins. 2008 ,	
2124	Divide and conquer: progress in the molecular stratification of cancer. 2009 , 50, 464-73	4
2123	Promoter methylation in the genesis of gastrointestinal cancer. 2009 , 50, 309-21	19
2122	Altering chemosensitivity by modulating translation elongation. 2009 , 4, e5428	71
2121	Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in <i>Saccharomyces cerevisiae</i> . 2009 , 4, e5830	35
2120	Mutator mutations enhance tumorigenic efficiency across fitness landscapes. 2009 , 4, e5860	29

2119	Distinct high-profile methylated genes in colorectal cancer. 2009 , 4, e7012		111
2118	Sequence and structure signatures of cancer mutation hotspots in protein kinases. 2009 , 4, e7485		57
2117	Parallel routes of human carcinoma development: Implications of the age-specific incidence data. 2009 ,		
2116	Functional genomic screens identify CINP as a genome maintenance protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 19304-9	11.5	48
2115	A Protein-Phenotype Mutual Information Based Identification of Human Disease Genes. 2009 ,		
2114	Prediction of Human Disease Genes Based on Associations between Phenome and Proteins. 2009 ,		
2113	Epigenetic biomarker development. 2009 , 1, 99-110		94
2112	Array-based evolution of DNA aptamers allows modelling of an explicit sequence-fitness landscape. 2009 , 37, e6		85
2111	MtDNA mutation pattern in tumors and human evolution are shaped by similar selective constraints. 2009 , 19, 576-80		28
2110	Right pelvic mass in a patient with a radically resected carcinoid of the appendix. 2009 , 58, 1200, 1259		
2109	High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. 2009 , 34, 489-506		31
2108	5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. 2009 , 75, 437-46		207
2107	Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. 2009 , 69, 4036-42		143
2106	Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients. 2009 , 69, 4959-61		17
2105	Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. 2009 , 9, 1163-76		84
2104	Cancer genome sequencing--an interim analysis. 2009 , 69, 4948-50		60
2103	Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 4828-33	11.5	108
2102	Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 1886-91	11.5	93

2101	Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. <i>Science</i> , 2009 , 324, 217	33.3	608
2100	Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo. 2009 , 29, 104-15		70
2099	Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. 2009 , 27, 5861-2		42
2098	Protective roles of matrix metalloproteinases: from mouse models to human cancer. 2009 , 8, 3657-62		103
2097	Copy number variation has little impact on bead-array-based measures of DNA methylation. 2009 , 25, 1999-2005		32
2096	Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 16387-92	11.5	67
2095	Clonal expansions in ulcerative colitis identify patients with neoplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 20871-6	11.5	53
2094	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 18351-6	11.5	226
2093	Mechanisms of tumor resistance to EGFR-targeted therapies. 2009 , 13, 339-62		66
2092	Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. 2009 , 15, 7471-7478		191
2091	PCR-free method detects high frequency of genomic instability in prostate cancer. 2009 , 37, 7441-6		7
2090	Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. 2009 , 69, 7357-65		96
2089	Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. 2009 , 69, 2026-33		37
2088	A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. 2009 , 69, 8150-6		140
2087	Biomarkers in Osteosarcoma. 2009 , 3, 13-23		36
2086	Integrative analysis of genome-wide RNA interference screens. 2009 , 2, pt4		8
2085	Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. 2009 , 15, 7492-7501		42
2084	The protein tyrosine phosphatase receptor D, a broadly inactivated tumor suppressor regulating STAT function. 2009 , 8, 3063-4		14

2083	Systematically linking drug susceptibility to cancer genome aberrations. 2009 , 8, 3652-6	3
2082	Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. 2009 ,	6
2081	Many colorectal cancers are "flat" clonal expansions. 2009 , 8, 2187-93	24
2080	RNA-binding motif protein 35A is a novel tumor suppressor for colorectal cancer. 2009 , 8, 490-7	35
2079	Origin of carcinoma associated fibroblasts. 2009 , 8, 589-95	94
2078	Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis. 2009 , 5, 1477-86	74
2077	A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. 2009 , 69, 7459-65	121
2076	Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase. 2009 , 284, 22436-22443	21
2075	A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. 2009 , 5, e1000640	20
2074	Genetic mutations associated with cigarette smoking in pancreatic cancer. 2009 , 69, 3681-8	88
2073	MoKCa database--mutations of kinases in cancer. 2009 , 37, D824-31	45
2072	Saturation density of skin fibroblasts as a quantitative screen for human cancer susceptibility. 2009 , 18, 2366-72	4
2071	The PTEN/PI3 Kinase Pathway in Human Glioma. 2009 , 315-357	
2070	Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. 2009 , 20, 1596-1603	166
2069	A systems perspective of ras signaling in cancer. 2009 , 15, 1510-3	35
2068	Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. <i>PLoS Computational Biology</i> , 2009 , 5, e1000487	5 63
2067	Exploiting synthetic lethal interactions for targeted cancer therapy. 2009 , 8, 3112-9	87
2066	Align human interactome with phenome to identify causative genes and networks underlying disease families. 2009 , 25, 98-104	80

2065	Emerging roles of the EBF family of transcription factors in tumor suppression. <i>Molecular Cancer Research</i> , 2009 , 7, 1893-901	6.6	63
2064	Mutation patterns in cancer genomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 21766-70	11.5	62
2063	Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. 2009 , 69, 4926-34		66
2062	A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. <i>Science</i> , 2009 , 323, 1747-50	33.3	285
2061	Heterogeneity of the MYCN oncogene in neuroblastoma. 2009 , 15, 2085-90		39
2060	The forest and the trees: pathways and proteins as colorectal cancer biomarkers. 2009 , 27, 5866-7		8
2059	Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. 2009 , 122, 1788-99		81
2058	The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. 2009 , 284, 34179-88		186
2057	Discovery and validation of colonic tumor-associated proteins via metabolic labeling and stable isotopic dilution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 17235-40	11.5	29
2056	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. 2009 , 27, 5650-9		103
2055	Bioinformatics construction of the human cell surfaceome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 16752-7	11.5	91
2054	Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. 2009 , 69, 4260-9		47
2053	Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. 2009 , 8, 827-45		86
2052	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. 2009 , 69, 3802-9		340
2051	Mutation-associated fusion cancer genes in solid tumors. 2009 , 8, 1399-408		44
2050	Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. 2009 , 14, 1176-84		22
2049	Identification of rare cancer driver mutations by network reconstruction. 2009 , 19, 1570-8		80
2048	Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 12921-5	11.5	112

2047	Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. 2009 , 69, 4691-9		182
2046	In vivo/ex vivo and in situ assays used in cancer research: a brief review. 2009 , 37, 114-22		32
2045	Identification of novel small-molecule compounds that inhibit the proliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening. 2009 , 8, 563-70		28
2044	A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 3964-9	11.5	234
2043	Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. 2009 , 43, 143-55		56
2042	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. 2009 , 69, 4885-93		403
2041	Genetic pathways to colorectal cancer. 2009 , 670, 96-8		11
2040	DNA methylation patterns in lung carcinomas. 2009 , 19, 181-7		85
2039	Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. 2009 , 18, 31-50		53
2038	Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. 2009 , 240, 355-66		27
2037	Deciphering the genetic landscape of cancer--from genes to pathways. 2009 , 25, 455-62		30
2036	Detection of recurrent copy number alterations in the genome: taking among-subject heterogeneity seriously. 2009 , 10, 308		11
2035	Extraction of human kinase mutations from literature, databases and genotyping studies. 2009 , 10 Suppl 8, S1		30
2034	Comparative expression pathway analysis of human and canine mammary tumors. 2009 , 10, 135		117
2033	Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. <i>BMC Cancer</i> , 2009 , 9, 374	4.8	201
2032	Anticancer drug discovery in the future: an evolutionary perspective. 2009 , 14, 1136-42		67
2031	Cancer gene discovery in mouse and man. 2009 , 1796, 140-61		8
2030	A systems biology view of cancer. 2009 , 1796, 129-39		44

2029	Cancer-causing karyotypes: chromosomal equilibria between destabilizing aneuploidy and stabilizing selection for oncogenic function. 2009 , 188, 1-25	46
2028	Low frequency of MLL3 mutations in colorectal carcinoma. 2009 , 189, 140-1	6
2027	Chromosomal changes in aggressive breast cancers with basal-like features. 2009 , 193, 29-37	36
2026	On the karyotypic origin and evolution of cancer cells. 2009 , 194, 96-110	49
2025	Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression. 2009 , 15, 477-88	70
2024	Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. 2009 , 16, 463-74	241
2023	PI3K regulatory subunits lose control in cancer. 2009 , 16, 449-50	25
2022	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
2021	Words of wisdom. Re: sequence variant on 8q24 confers susceptibility to urinary bladder cancer. 2009 , 55, 1237	0
2020	Words of wisdom. Re: Evaluating the learning curve for robot- assisted laparoscopic radical cystectomy. 2009 , 55, 1237-9	0
2019	Computational prediction of the functional effects of amino acid substitutions in signal peptides using a model-based approach. 2009 , 30, 99-106	19
2018	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. 2009 , 30, E451-9	37
2017	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 2009 , 30, 7-11	320
2016	Pathogenic or not? And if so, then how? Studying the effects of missense mutations using bioinformatics methods. 2009 , 30, 703-14	184
2015	Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. 2009 , 30, 1167-74	34
2014	Candidate mechanisms accounting for effects of physical activity on breast carcinogenesis. 2009 , 61, 895-901	38
2013	Prostate cancer regulatory networks. 2009 , 107, 845-52	31
2012	Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. 2009 , 219, 288-300	77

2011	Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. 2009 , 220, 538-47	129
2010	Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells. 2009 , 221, 171-82	21
2009	Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. 2009 , 1, 338-51	37 ¹
2008	Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. 2009 , 48, 1-9	31
2007	Integrative approach for prioritizing cancer genes in sporadic colon cancer. 2009 , 48, 953-62	42
2006	Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. 2009 , 48, 1077-92	26
2005	Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. 2009 , 455, 485-94	111
2004	Mutational spectra of human cancer. 2009 , 125, 493-506	143
2003	Analytical methods for inferring functional effects of single base pair substitutions in human cancers. 2009 , 126, 481-98	17
2002	Biomechanics: cell research and applications for the next decade. 2009 , 37, 847-59	147
2001	Adoptive transfer of virus-specific and tumor-specific T cell immunity. 2009 , 21, 224-32	56
2000	The pace of evolution across fitness valleys. 2009 , 259, 613-20	33
1999	Surveying germline genomic landscape of breast cancer. 2009 , 113, 601-3	3
1998	Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. 2009 , 54, 2109-17	90
1997	The epigenome of colorectal cancer. 2009 , 5, 84-89	1
1996	Wip1, an oncogene targeting tumor suppressors expressed in intestinal stem cells. 2009 , 5, 197-202	2
1995	Genexpressionsprofile in der onkologischen Diagnostik. 2009 , 2, 44-52	
1994	Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. 2009 , 58, 1545-56	26

1993	Cancer-associated mutations are preferentially distributed in protein kinase functional sites. 2009 , 77, 892-903	25
1992	Inferring human stem cell behaviour from epigenetic drift. 2009 , 217, 199-205	37
1991	Older individuals appear to acquire mitotically older colorectal cancers. 2009 , 217, 483-8	7
1990	Fusion genes and chromosome translocations in the common epithelial cancers. 2010 , 220, 244-54	85
1989	Tumor biology and cancer therapy - an evolving relationship. 2009 , 7, 19	10
1988	The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. 2009 , 2, 20	18
1987	Network analysis of human glaucomatous optic nerve head astrocytes. 2009 , 2, 24	40
1986	Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line. 2009 , 2, 26	7
1985	Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. 2009 , 90, 558-74	56
1984	Complexity and health--yesterday's traditions, tomorrow's future. 2009 , 15, 543-8	41
1983	From cancer genomes to cancer models: bridging the gaps. 2009 , 10, 359-66	29
1982	C/EBPalpha or C/EBPalpha oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-kappaB p50 bound to the bcl-2 and FLIP gene promoters. 2009 , 23, 365-74	32
1981	Exclusion of ABCB8 and ABCB10 as cancer candidate genes in acute myeloid leukemia. 2009 , 23, 1000-2	3
1980	Transcriptome sequencing to detect gene fusions in cancer. 2009 , 458, 97-101	709
1979	The cancer genome. 2009 , 458, 719-24	2272
1978	Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. 2009 , 461, 809-13	879
1977	Complex landscapes of somatic rearrangement in human breast cancer genomes. 2009 , 462, 1005-10	684
1976	Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. 2009 , 16, 1426-37	61

1975	p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. 2009 , 16, 1203-14	100
1974	Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. 2009 , 16, 807-9	69
1973	High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. 2009 , 9, 389-99	102
1972	Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. 2009 , 8, 33-40	812
1971	Targeting the phosphoinositide 3-kinase pathway in cancer. 2009 , 8, 627-44	1895
1970	Integrative biology--a strategy for systems biomedicine. 2009 , 10, 64-8	10
1969	Carcinogenesis: evolution of concepts. 2009 , 74, 353-61	7
1968	APC and the three-hit hypothesis. 2009 , 28, 146-55	47
1967	Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. 2009 , 28, 2969-78	89
1966	Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. 2009 , 28, 3681-8	51
1965	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. 2009 , 101, 465-72	243
1964	A study of pyrimidine base damage in relation to oxidative stress and cancer. 2009 , 101, 452-6	17
1963	Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"? 2009 , 16, 774-5; author reply 776-7	85
1962	Reply to "Human Genetic and Structural Genomic Variation: Would Genomewide Association Studies be the Solution of Cancer Complexity Like Alexander the Great for the "Gordian Knot"?" 2009 , 16, 776-777	1
1961	Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. 2009 , 16, 1771-82	80
1960	Genotoxic effect of 2,4,6-trichlorophenol on p53 gene in zebrafish liver. 2009 , 28, 603-8	13
1959	Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform. 2009 , 563, 177-96	63
1958	Not gene therapy, but genetic surgery-the right strategy to attack cancer. 2009 , 24, 93-113	4

1957	Mechanisms of bone metastases of breast cancer. 2009 , 16, 703-13	86
1956	KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. 2009 , 8, 834-43	127
1955	Identifying Candidate Cancer Genes Based on Their Somatic Mutations Co-Occurring with Cancer Genes in Cancer Genome Profiling. 2009 ,	
1954	The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. 2009 , 30, 377-86	922
1953	Pharmaceutical Perspectives of Cancer Therapeutics. 2009 ,	11
1952	Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. 2009 , 71, 409-19	944
1951	Cancer driver mutations in protein kinase genes. 2009 , 281, 117-27	65
1950	Principles of cancer therapy: oncogene and non-oncogene addiction. 2009 , 136, 823-37	1328
1949	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. 2009 , 137, 821-34	454
1948	Commonality but diversity in cancer gene fusions. 2009 , 137, 391-5	58
1947	Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells. 2009 , 390, 60-4	9
1946	Common vs. rare allele hypotheses for complex diseases. 2009 , 19, 212-9	490
1945	Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. 2009 , 20, 869-76	349
1944	Design and analysis issues in genome-wide somatic mutation studies of cancer. 2009 , 93, 17-21	75
1943	Finding disease-specific coordinated functions by multi-function genes: insight into the coordination mechanisms in diseases. 2009 , 94, 94-100	15
1942	KRAS et cancer colorectal : un pas de gant vers la médecine personnalisée. 2009 , 24, 196-209	
1941	A genomic strategy to elucidate modules of oncogenic pathway signaling networks. 2009 , 34, 104-14	91
1940	KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. 2009 , 36, 131-40	277

1939	Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition. 2009 , 46, 1824-9	6
1938	Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. 2009 , 681, 230-240	64
1937	Molecular origins of cancer: Molecular basis of colorectal cancer. 2009 , 361, 2449-60	1331
1936	The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. 2009 , 417, 411-21	78
1935	Proteomic methodologies and their application in colorectal cancer research. 2009 , 46, 319-42	17
1934	Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. 2009 , 96, 858-74	39
1933	Epigenetic progenitors in tumor initiation and development. 2009 , 6, 5-12	1
1932	Tumor-Targeted Macromolecular Drug Delivery Based on the Enhanced Permeability and Retention Effect in Solid Tumor. 2009 , 93-120	11
1931	Systems pathology--taking molecular pathology into a new dimension. 2009 , 6, 455-64	52
1930	Loss of the Ras regulator RASAL1: another route to Ras activation in colorectal cancer. 2009 , 136, 46-8	9
1929	Next-generation sequencing. 2009 , 11 Suppl 3, S12	102
1928	Highlights from: The 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. 2009 , 8, 72-6	
1927	No effect of cancer-associated SNP rs6983267 in the 8q24 region on co-expression of MYC and TCF7L2 in normal colon tissue. 2009 , 8, 96	21
1926	Ovarian cancer. 2009 , 4, 287-313	505
1925	Genome and proteome annotation: organization, interpretation and integration. 2009 , 6, 129-47	36
1924	The DNA repair gene APE1 T1349G polymorphism and cancer risk: a meta-analysis of 27 case-control studies. 2009 , 24, 507-12	50
1923	New trends in molecular biomarker discovery for breast cancer. 2009 , 13, 565-71	31
1922	Structural interactomics: informatics approaches to aid the interpretation of genetic variation and the development of novel therapeutics. 2009 , 5, 1456-72	8

1921	PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture. 2009 , 11, R29	12
1920	The breast cancer somatic 'muta-ome': tackling the complexity. 2009 , 11, 301	21
1919	Genome-wide prioritization of disease genes and identification of disease-disease associations from an integrated human functional linkage network. 2009 , 10, R91	172
1918	Translational disease interpretation with molecular networks. 2009 , 10, 221	17
1917	Integrated analysis of breast cancer cell lines reveals unique signaling pathways. 2009 , 10, R31	48
1916	A decade of cancer gene profiling: from molecular portraits to molecular function. 2010 , 576, 61-87	9
1915	In vitro models of pancreatic cancer for translational oncology research. 2009 , 4, 429-443	24
1914	Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. 2009 , 69, 6713-20	132
1913	Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. 2009 , 9, 217-21	85
1912	Targeting DNA methylation. 2009 , 15, 3938-46	328
1911	Genome-wide transcriptome analysis of 150 cell samples. 2009 , 1, 99-107	14
1910	Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2. 2009 , 58, 1250-9	19
1909	Insights into gliomagenesis: systems biology unravels key pathways. 2009 , 1, 101	1
1908	Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. 2009 , 113, 1315-25	336
1907	Applications of new sequencing technologies for transcriptome analysis. 2009 , 10, 135-51	392
1906	Triple negative breast cancers: clinical and prognostic implications. 2009 , 45 Suppl 1, 27-40	173
1905	Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. 2009 , 69, 6660-7	344
1904	Molecular pathways in tumor progression: from discovery to functional understanding. 2009 , 5, 902-8	26

1903	Applications of genomics in melanoma oncogene discovery. 2009 , 23, 397-414, vii		21
1902	Translation initiation: a critical signalling node in cancer. 2009 , 13, 1279-93		40
1901	Cancer genome sequencing: a review. 2009 , 18, R163-8		154
1900	Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. 2009 , 8, 387-97		61
1899	Recombinant activated factor VII in abdominal aortic emergencies. 2009 , 249, 692; author reply 692-3		
1898	Negative Appendectomy and Perforation Rates in the SCOAP Trial. 2009 , 249, 699-700		2
1897	Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. <i>Cancer Journal (Sudbury, Mass)</i> , 2009 , 15, 406-20	2.2	133
1896	In Favor of the Jarnagin-Blumgart Classification. 2009 , 249, 698-699		
1895	Physician-specific OPPE models in academic medical centers. 2009 , 249, 700-1		3
1894	The Association Between Overall Survival and the Total Number of Dissected Lymph Nodes: An Artifact Caused by the Surgical Pathologist?. 2009 , 249, 695		
1893	ERRATUM. 2009 , 249, 701		2
1892	Recombinant Activated Factor VII in Abdominal Aortic Emergencies. 2009 , 249, 692-693		
1891	Sequence-based advances in the definition of cancer-associated gene mutations. 2009 , 21, 47-52		9
1890	The association between overall survival and the total number of dissected lymph nodes: an artifact caused by the surgical pathologist?. 2009 , 249, 693-4; author reply 695		9
1889	.		
1888	Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer. 2009 , 19, 513-25		17
1887	Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. 2009 , 114, 589-95		925
1886	The "timely" development of Rexin-G: First targeted injectable gene vector (Review). 2009 ,		0

1885	Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. 2009 , 9, 673-82		24
1884	Laparoscopic Colectomy Survival Benefit for Colon Cancer: Is Evidence From a Randomized Trial True?. 2009 , 249, 697		
1883	In favor of the Jarnagin-Blumgart classification. 2009 , 249, 697-8; author reply 698-9		2
1882	Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true?. 2009 , 249, 695-6; author reply 697		50
1881	Negative appendectomy and perforation rates in the SCOAP trial. 2009 , 249, 699; author reply 699-700		2
1880	Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. 2010 , 251, 186-7		2
1879	Can Sentinel Node Biopsy Be Avoided in Some Elderly Breast Cancer Patients?. 2010 , 251, 181-182		
1878	Therapeutic Potentials of Recently Identified PLD Inhibitors. 2010 , 4, 244-249		1
1877	Finding Recurrent Copy Number Alteration Regions: A Review of Methods. <i>Current Bioinformatics</i> , 2010 , 5, 1-17	4-7	31
1876	Residents' operative experience in general surgery programs. 2010 , 251, 182; author reply 182-3		1
1875	A Bioinformatics Pipeline for Cancer Epigenetics. <i>Current Bioinformatics</i> , 2010 , 5, 153-163	4-7	2
1874	The effect of mesh removal and selective neurectomy on persistent postherniotomy pain. 2010 , 251, 180; author reply 180-1		
1873	Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?. 2010 , 251, 183; author reply 184-5		3
1872	Ischemic complications after pancreatoduodenectomy: incidence, prevention and management. 2010 , 251, 178; author reply 178		
1871	Ischemic Complications after Pancreatoduodenectomy: Incidence, Prevention and Management. 2010 , 251, 178		
1870	Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. 2010 , 251, 185-6; author reply 186		9
1869	Laparoscopic and Robotic Rectal Cancer Resection: Expectations for Improving Oncological Outcomes. 2010 , 251, 186		
1868	N-acetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer. 2010 , 19, 100-9		20

- 1867 Visceral Injury and Systemic Inflammation in Patients Undergoing Extracorporeal Circulation During Aortic Surgery. **2010**, 251, 187
- 1866 Targeting Tumor Stroma Using Engineered Mesenchymal Stem Cells Reduces the Growth of Pancreatic Carcinoma. **2010**, 251, 187 0
- 1865 The unfulfilled promise of molecular diagnosis in colorectal cancer. **2010**, 22, 362-3
- 1864 Can sentinel node biopsy be avoided in some elderly breast cancer patients?. **2010**, 251, 181; author reply 181-2
- 1863 The Effect of Mesh Removal and Selective Neurectomy on Persistent Postherniotomy Pain. **2010**, 251, 180-181
- 1862 Letters to the Editor. **2009**, 251,
- 1861 Minimally invasive esophagectomy. **2010**, 251, 178-9; author reply 179 2
- 1860 Minimally Invasive Esophagectomy. **2010**, 251, 179 1
- 1859 Should Total Number of Lymph Nodes be Used as a Quality of Care Measure for Stage III Colon Cancer?. **2010**, 251, 184-185
- 1858 Genotype-confirmed alanine aminotransferase deficiency in a Chinese patient with acute liver failure: a potential diagnostic pitfall. **2010**, 42, 94-5 3
- 1857 Human variation databases. **2010**, 2010, baq015 17
- 1856 Lymphocyte homing and the dissemination of lymphoid malignancies. **2010**, 293-306
- 1855 Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?. **2010**, 115, 1490-9 48
- 1854 HER-2-negative breast cancer limitations and next-generation sequencing technology promises. **2010**, 17, 1720 3
- 1853 Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. **2010**, 10, 33-48 82
- 1852 Profiling the cancer genome. **2010**, 11, 133-59 36
- 1851 Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. **2010**, 88, 1095-100 19
- 1850 Mixed-type gastric cancer and its association with high-frequency CpG island hypermethylation. **2010**, 456, 625-33 31

1849	DNA methylation changes in ex-adenoma carcinoma of the large intestine. 2010 , 457, 433-41	16
1848	Favorable outcomes with laparoscopic surgery for rectal cancer. 2010 , 24, 1217-8	3
1847	Hope from Japan for esophagogastric cancers: esophagectomy and endoscopic submucosal dissection for gastric tube cancer. 2010 , 24, 2924-5	
1846	The Role of PIK3CA Mutations as A Predictor of Outcomes and A Therapeutic Target. 2010 , 2, 167-173	
1845	Cancer: evolutionary, genetic and epigenetic aspects. 2010 , 1, 85-100	12
1844	Challenges in Understanding Genome-Wide DNA Methylation. 2010 , 25, 26-34	4
1843	Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. 2010 , 120, 581-92	102
1842	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. 2010 , 121, 53-64	207
1841	Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. 2010 , 123, 747-55	40
1840	Mutation and association analysis of GEN1 in breast cancer susceptibility. 2010 , 124, 283-8	7
1839	Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families. 2010 , 693, 32-45	44
1838	An "Omics" based survey of human colon cancer. 2010 , 693, 3-18	56
1837	DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer. 2010 , 693, 61-76	15
1836	Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. 2010 , 128, 488-98	10
1835	Transposon-based screens for cancer gene discovery in mouse models. 2010 , 20, 261-8	25
1834	Towards elucidation of functional molecular signatures of the adhesive-migratory phenotype of malignant cells. 2010 , 20, 146-52	7
1833	All y'all need to know 'bout retroelements in cancer. 2010 , 20, 200-10	138
1832	Lethal mutagenesis: targeting the mutator phenotype in cancer. 2010 , 20, 353-9	61

1831	Passenger mutations as a marker of clonal cell lineages in emerging neoplasia. 2010 , 20, 294-303		22
1830	Functional modules, mutational load and human genetic disease. 2010 , 26, 168-76		81
1829	An integrated analysis of molecular aberrations in NCI-60 cell lines. 2010 , 11, 495		6
1828	PETALS: Proteomic Evaluation and Topological Analysis of a mutated Locus' Signaling. 2010 , 11, 596		8
1827	Extending pathways and processes using molecular interaction networks to analyse cancer genome data. 2010 , 11, 597		34
1826	Extracting consistent knowledge from highly inconsistent cancer gene data sources. 2010 , 11, 76		41
1825	Fluorescence in situ hybridization analysis with a tissue microarray: 'FISH and chips' analysis of pathology archives. 2010 , 60, 543-50		26
1824	A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. <i>BMC Cancer</i> , 2010 , 10, 101	4.8	102
1823	A simple algebraic cancer equation: calculating how cancers may arise with normal mutation rates. <i>BMC Cancer</i> , 2010 , 10, 3	4.8	40
1822	Cryopreservation of human colorectal carcinomas prior to xenografting. <i>BMC Cancer</i> , 2010 , 10, 362	4.8	57
1821	Multi-level reproducibility of signature hubs in human interactome for breast cancer metastasis. 2010 , 4, 151		30
1820	Inferring genetic interactions via a nonlinear model and an optimization algorithm. 2010 , 4, 16		16
1819	Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. 2010 , 4, 163		70
1818	Oral supplementation of silibinin prevents colon carcinogenesis in a long term preclinical model. 2010 , 643, 93-100		27
1817	Mechanisms of chromosomal instability. 2010 , 20, R285-95		368
1816	MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity?. 2010 , 1805, 72-86		35
1815	Tumor heterogeneity: causes and consequences. 2010 , 1805, 105-17		750
1814	Analysis of the frequency of GNAS codon 201 mutations in advanced colorectal cancer. 2010 , 202, 67-9		17

1813	Integrative genomic profiling of human prostate cancer. 2010 , 18, 11-22	2666
1812	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. 2010 , 2, 146-58	333
1811	High-resolution analysis of genomic alteration on chromosome arm 8p in urothelial carcinoma. 2010 , 49, 642-59	20
1810	CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer. 2010 , 116, 3645-55	51
1809	Inferring the functional effects of mutation through clusters of mutations in homologous proteins. 2010 , 31, 264-71	38
1808	The Roche Cancer Genome Database (RCGDB). 2010 , 31, 407-13	11
1807	dbCPCO: a database of genetic markers tested for their predictive and prognostic value in colorectal cancer. 2010 , 31, 901-7	16
1806	Somatic mutations and germline sequence variants in patients with familial colorectal cancer. 2010 , 127, 2974-80	24
1805	Emerging roles of deubiquitinases in cancer-associated pathways. 2010 , 62, 140-57	111
1804	The evolutionary mechanism of cancer. 2010 , 109, 1072-84	62
1803	More is less: inactivation and deletion events and the search for tumor suppressor genes. 2010 , 110, 281-7	2
1802	Modulators of cancer cell invasiveness. 2010 , 111, 791-6	7
1801	Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers. 2010 , 224, 549-58	22
1800	Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. 2010 , 73, 1873-95	92
1799	An Integrative Pathway-based Clinical-genomic Model for Cancer Survival Prediction. 2010 , 80, 1313-1319	18
1798	Immunity to stemness genes in human cancer. 2010 , 22, 245-50	24
1797	The overmethylated genes in Helicobacter pylori-infected gastric mucosa are demethylated in gastric cancers. 2010 , 10, 137	8
1796	Prostaglandin E2-induced colonic secretion in patients with and without colorectal neoplasia. 2010 , 10, 9	12

1795	The (r)evolution of cancer genetics. 2010 , 8, 74	11
1794	Colorectal cancer proteomics, molecular characterization and biomarker discovery. 2010 , 4, 159-78	38
1793	Proteome profiling reveals gender differences in the composition of human serum. 2010 , 10, 2678-91	37
1792	The (non)malignancy of cancerous amino acidic substitutions. 2010 , 78, 518-29	14
1791	Prognostic relevance of DNA copy number changes in colorectal cancer. 2010 , 220, 338-47	41
1790	Our changing view of the genomic landscape of cancer. 2010 , 220, 231-43	64
1789	Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. 2010 , 221, 411-24	34
1788	The Sir Hans Krebs Lecture. How a lipid mediates tumour suppression. Delivered on 29 June 2010 at the 35th FEBS Congress in Gothenburg, Sweden. 2010 , 277, 4837-48	8
1787	Aberrant DNA methylation in contrast with mutations. 2010 , 101, 300-5	81
1786	Epigenetic aberrations and therapeutic implications in gliomas. 2010 , 101, 1331-6	20
1785	DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. 2010 , 56, 167-79	162
1784	Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. 2010 , 29, 380-91	77
1783	Characterization of a major colon cancer susceptibility locus (Ccs3) on mouse chromosome 3. 2010 , 29, 647-61	18
1782	The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways. 2010 , 29, 4567-75	73
1781	Whole-genome cancer analysis as an approach to deeper understanding of tumour biology. 2010 , 102, 243-8	8
1780	Gene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases. 2010 , 102, 774-82	12
1779	Mutated genes, pathways and processes in tumours. 2010 , 11, 805-10	27
1778	A comprehensive catalogue of somatic mutations from a human cancer genome. 2010 , 463, 191-6	1303

1777	International network of cancer genome projects. 2010 , 464, 993-8	1613
1776	Genome remodelling in a basal-like breast cancer metastasis and xenograft. 2010 , 464, 999-1005	935
1775	Diverse somatic mutation patterns and pathway alterations in human cancers. 2010 , 466, 869-73	1003
1774	Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. 2010 , 10, 310-23	36
1773	The (un)targeted cancer kinome. 2010 , 6, 166-169	234
1772	Targeting the cancer kinome through polypharmacology. 2010 , 10, 130-7	542
1771	Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. 2010 , 10, 842-57	529
1770	Integrating molecular diagnostics into anticancer drug discovery. 2010 , 9, 523-35	45
1769	Advances in understanding cancer genomes through second-generation sequencing. 2010 , 11, 685-96	890
1768	Statistical analysis strategies for association studies involving rare variants. 2010 , 11, 773-85	378
1767	Genomic instability--an evolving hallmark of cancer. 2010 , 11, 220-8	1393
1766	The emerging mechanisms of isoform-specific PI3K signalling. 2010 , 11, 329-41	1225
1765	The promise of bone cancer proteomics. 2010 , 1192, 222-9	14
1764	From genomic landscapes to personalized cancer management-is there a roadmap?. 2010 , 1210, 34-44	14
1763	Intratumoral patterns of genomic imbalance in glioblastomas. 2010 , 20, 936-44	52
1762	Identification of some human genes oppositely regulated during esophageal squamous cell carcinoma formation and human embryonic esophagus development. 2010 , 23, 260-70	22
1761	The Roles of Ras Family Small GTPases in Breast Cancer. 2010 , 2763-2772	1
1760	In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of Egal Glycolipids. <i>Cancers</i> , 2010 , 2, 773-93	6.6 9

1759	Germline mutations and polymorphisms in the origins of cancers in women. 2010 , 2010, 297671	32
1758	The <i>Caenorhabditis elegans</i> homolog of Gen1/Yen1 resolvases links DNA damage signaling to DNA double-strand break repair. 2010 , 6, e1001025	74
1757	Increasing alternative promoter repertoires is positively associated with differential expression and disease susceptibility. 2010 , 5, e9482	13
1756	Multidimensional gene set analysis of genomic data. 2010 , 5, e10348	53
1755	Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. 2010 , 5, e11137	28
1754	Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. 2010 , 5, e11408	73
1753	Positive feedback regulation between phospholipase D and Wnt signaling promotes Wnt-driven anchorage-independent growth of colorectal cancer cells. 2010 , 5, e12109	35
1752	Role of JNK in a Trp53-dependent mouse model of breast cancer. 2010 , 5, e12469	36
1751	Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. 2010 , 5, e12653	11
1750	Frequent MAGE mutations in human melanoma. 2010 , 5, e12773	22
1749	A network of cancer genes with co-occurring and anti-co-occurring mutations. 2010 , 5, e13180	26
1748	A knowledge-based weighting framework to boost the power of genome-wide association studies. 2010 , 5, e14480	39
1747	Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. 2010 , 5, e15094	15
1746	Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. 2010 , 5, e15661	169
1745	Targeting Ras for Anticancer Drug Discovery. 2010 , 2837-2857	
1744	Proteomics of Bone Cancer. 2010 , 171-180	1
1743	Targeting genetic instability in cancer cells. 2010 , 11, 1293-5	
1742	Phospholipase D. 2010 , 1167-1176	4

1741	Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. 2010 , 70, 7253-63	37
1740	Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease. 2010 , 84, 7675-82	8
1739	Role of double-stranded DNA translocase activity of human HLTF in replication of damaged DNA. 2010 , 30, 684-93	132
1738	[Search for new genes involved in breast tumorigenesis by "Omics" analysis]. 2010 , 97, 1365-80	
1737	Protein microarrays for cancer diagnostics and therapy. 2010 , 19, 247-54	13
1736	Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. 2010 , 9, 1638-46	34
1735	Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. 2010 , 38, 1061-70	72
1734	Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. 2010 , 3, 1427-34	72
1733	Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. 2010 , 30, 1852-63	22
1732	Clinical implications of the cancer genome. 2010 , 28, 5219-28	156
1731	Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. 2010 , 9, 3396-409	90
1730	Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. 2010 , 24, 2612-9	25
1729	Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. 2010 , 16, 5972-80	98
1728	Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. 2010 , 16, 4031-7	15
1727	Androgen regulates ADAMTS15 gene expression in prostate cancer cells. 2010 , 28, 698-710	10
1726	MIRAGAA--a methodology for finding coordinated effects of microRNA expression changes and genome aberrations in cancer. 2010 , 26, 161-7	14
1725	Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. 2010 , 2, 319-29	28
1724	Voltage-gated Na ⁺ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. 2010 , 70, 6957-67	182

1723	Expression of the tumor suppressor Krüppel-like factor 4 as a prognostic predictor for colon cancer. 2010 , 19, 2631-8	52
1722	Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues. 2010 , 58, 857-70	118
1721	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. 2010 , 31, 208-15	65
1720	Making sense of missense in Lynch syndrome: the clinical perspective. 2010 , 3, 1371-4	8
1719	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. 2010 , 70, 9391-401	143
1718	Drug Discovery in Pancreatic Cancer. 2010 ,	
1717	Analysis of next-generation genomic data in cancer: accomplishments and challenges. 2010 , 19, R188-96	102
1716	Stem cells of the breast and cancer therapy. 2010 , 6, 205-19	4
1715	Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. 2010 , 56, 623-32	82
1714	Network of Cancer Genes: a web resource to analyze duplicability, orthology and network properties of cancer genes. 2010 , 38, D670-5	23
1713	Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 20780-5	71
1712	Systematic interpretation of comutated genes in large-scale cancer mutation profiles. 2010 , 9, 2186-95	11
1711	Systems Pharmacology in Cancer. 2010 , 377-397	
1710	Oncogenic mutations of PIK3CA in human cancers. 2010 , 347, 21-41	164
1709	Comprehensive mapping of the human kinome to epidermal growth factor receptor signaling. 2010 , 285, 21134-42	28
1708	The role of SnoN in transforming growth factor beta1-induced expression of metalloprotease-disintegrin ADAM12. 2010 , 285, 21969-77	30
1707	miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. 2010 , 285, 35293-302	207
1706	Vaccine prevention of cancer: can endogenous antigens be targeted?. 2010 , 3, 410-5	20

1705	Cell selection as driving force in lung and colon carcinogenesis. 2010 , 70, 6797-803		29
1704	Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 15547-52	11.5	119
1703	Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes. 2010 , 70, 520-31		27
1702	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. 2010 , 28, E6		40
1701	Ultradeep sequencing of a human ultraconserved region reveals somatic and constitutional genomic instability. 2010 , 8, e1000275		21
1700	[Colorectal oncogenesis]. 2010 , 97, 1311-21		8
1699	The Salmonella mutagenicity assay: the stethoscope of genetic toxicology for the 21st century. 2010 , 118, 1515-22		101
1698	Genome-wide association study for colorectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. 2010 , 31, 1612-9		48
1697	Targeted deep resequencing of the human cancer genome using next-generation technologies. 2010 , 27, 135-58		10
1696	A growing family: adding mutated Erbb4 as a novel cancer target. 2010 , 9, 1487-503		30
1695	Noninvasive prenatal chromosomal aneuploidy detection using plasma cell-free nucleic acid. 2010 , 5, 581-590		1
1694	Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. <i>Molecular Cancer Research</i> , 2010 , 8, 1513-25	6.6	41
1693	Methylation destiny: Moira takes account of histones and RNA polymerase II. 2010 , 5, 89-95		21
1692	Extracting multi-function features for cancer genes. 2010 ,		
1691	Accurate confidence aware clustering of array CGH tumor profiles. 2010 , 26, 6-14		7
1690	Viewing cancer genes from co-evolving gene modules. 2010 , 26, 919-24		2
1689	[Personalized therapy of gastrointestinal cancers--possibilities and limitations]. 2010 , 135, 1687-91		
1688	Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?. 2010 , 10, 247-50		57

1687	Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. 2010 , 10, 824-33	22
1686	Systems medicine: a real approach for future personalized oncology?. 2010 , 11, 283-7	62
1685	Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results. 2010 , 10, 737-57	9
1684	Phosphatidylinositol 3-kinase: the oncoprotein. 2010 , 347, 79-104	76
1683	Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. 2010 , 4, 525-9	17
1682	Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). 2010 , 95, 4449-54	29
1681	PLCD1 is a functional tumor suppressor inducing G(2)/M arrest and frequently methylated in breast cancer. 2010 , 10, 520-7	42
1680	Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 2598-603	11.5 97
1679	Clinical application of gene expression profiling in breast cancer. 2010 , 19, 581-606	17
1678	Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. 2010 , 10, 1187-95	16
1677	Personalized medicine in oncology: tailoring the right drug to the right patient. 2010 , 4, 523-33	26
1676	Making Mountains out of Molehills: Moving from Single Gene to Pathway Based Models of Colon Cancer Progression. 2010 , 73-87	
1675	PROBING CANCER SIGNALING WITH RESONANT WAVEGUIDE GRATING BIOSENSORS. 2010 , 5, 1237-1248	22
1674	Nonrandom Chromosome Abnormalities in Cancer—An Overview. 2010 , 25-43	4
1673	Application of genetic/genomic approaches to allergic disorders. 2010 , 126, 425-36; quiz 437-8	15
1672	Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1. 2010 , 4, 126-34	32
1671	Whole genome sequencing. 2010 , 628, 215-26	116
1670	Personalized therapies in the cancer "omics" era. 2010 , 9, 202	39

1669	Krüppel-like factor 5 is a crucial mediator of intestinal tumorigenesis in mice harboring combined ApcMin and KRASV12 mutations. 2010 , 9, 63	42
1668	The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. 2010 , 138, 241-54	78
1667	Microsatellite instability in colorectal cancer. 2010 , 138, 2073-2087.e3	1249
1666	The chromosomal instability pathway in colon cancer. 2010 , 138, 2059-72	505
1665	Molecular detection of colorectal neoplasia. 2010 , 138, 2127-39	105
1664	Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. 2010 , 138, 2357-67	105
1663	Loss of single immunoglobulin interleukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. 2010 , 139, 574-85	49
1662	Systems Biology in Drug Discovery and Development. 2010 ,	2
1661	Mutational analysis of UBR5 gene encoding an E3 ubiquitin ligase in common human cancers. 2010 , 42, 93-4	5
1660	Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. 2010 , 70, 2789-98	314
1659	Accumulation of driver and passenger mutations during tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 18545-50	11.5 574
1658	Ras history: The saga continues. 2010 , 1, 2-27	457
1657	Heterogeneity of Liver Cancer Stem Cells. 2010 , 301-317	
1656	Mutational heterogeneity in human cancers: origin and consequences. 2010 , 5, 51-75	172
1655	Optimization aspects of carcinogenesis. 2010 , 74, 922-7	2
1654	Cancer gene discovery in hepatocellular carcinoma. 2010 , 52, 921-9	152
1653	Simplistic pathways or complex networks?. 2010 , 20, 15-22	37
1652	Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. 2010 , 20, 336-41	4

1651	Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. 2010 , 46, 2166-77	62
1650	Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. 2010 , 22, 105-12	37
1649	Colon cancer stem cells: promise of targeted therapy. 2010 , 138, 2151-62	369
1648	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. <i>Science</i> , 2010 , 330, 228-31	33-3 915
1647	The molecular pathology of cancer. 2010 , 7, 251-65	182
1646	Molecular diagnostics for personal medicine using a nanopore. 2010 , 2, 367-81	14
1645	Cancer systems biology: a network modeling perspective. 2010 , 31, 2-8	274
1644	Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice. 2010 , 176, 1421-32	11
1643	Multiple genetic variants in telomere pathway genes and breast cancer risk. 2010 , 19, 219-28	42
1642	Frequent mutation of BAP1 in metastasizing uveal melanomas. <i>Science</i> , 2010 , 330, 1410-3	33-3 1014
1641	Cancer Genetics. 2010 , 451-470	
1640	Waiting Time Models of Cancer Progression. 2010 , 17, 115-135	18
1639	An Omics Perspective on Cancer Research. 2010 ,	9
1638	Nanopore Sequencing: Electrical Measurements of the Code of Life. 2010 , 9, 281-294	71
1637	Systems Biology and Systems Medicine. 2010 , 131-141	1
1636	Genomics in the Management of Lymphomas. 2010 , 407-420	
1635	Colorectal Cancer. 2010 , 457-476	
1634	mTOR Pathway and mTOR Inhibitors in Cancer Therapy. 2010 ,	2

1633	Cancer systems biology. 2010 , 662, 245-63	15
1632	Modern Molecular Biology. 2010 ,	2
1631	Cancer Genome and Tumor Microenvironment. 2010 ,	2
1630	Identification of novel SNPs by next-generation sequencing of the genomic region containing the APC gene in colorectal cancer patients in China. 2010 , 14, 315-25	7
1629	HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. 2010 , 12, R46	87
1628	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. 2010 , 12, R41	58
1627	Tracking the genomic evolution of breast cancer metastasis. 2010 , 12, 302	
1626	Patient-oriented gene set analysis for cancer mutation data. 2010 , 11, R112	54
1625	Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing. 2010 , 11, R114	32
1624	Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level. 2010 , 11, R118	23
1623	Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. 2010 , 11, R82	144
1622	A human functional protein interaction network and its application to cancer data analysis. 2010 , 11, R53	453
1621	Identification of functional modules that correlate with phenotypic difference: the influence of network topology. 2010 , 11, R23	60
1620	A novel candidate disease genes prioritization method based on module partition and rank fusion. 2010 , 14, 337-56	22
1619	Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. 2010 , 82, 5610-20	62
1618	Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. 2010 , 70, 1306-13	199
1617	High-throughput analysis of chromosome translocations and other genome rearrangements in epithelial cancers. 2010 , 2, 19	1
1616	The 1-carbamoyl-2-oxo-4,5-dihydroxyimidazolidine component of ROS-induced DNA damage in white blood cells. 2010 , 174, 101-6	6

1615	Breast cancer risk from different mammography screening practices. 2010 , 174, 367-76		11
1614	Bisulfite Patch PCR enables multiplexed sequencing of promoter methylation across cancer samples. 2010 , 20, 1279-87		52
1613	Clinical outcomes and correlates of TP53 mutations and cancer. 2010 , 2, a001016		191
1612	PI3K: from the bench to the clinic and back. 2010 , 347, 1-19		57
1611	The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. 2010 , 30, 5071-85		185
1610	Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. 2010 , 10, 541-5		60
1609	A pathway-based classification of human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 6994-9	11.5	258
1608	From tumor size and HER2 status to systems oncology for very early breast cancer treatment. 2010 , 10, 123-8		64
1607	Uncover disease genes by maximizing information flow in the phenome-interactome network. 2011 , 27, i167-76		61
1606	Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinic. 2011 , 4, 579-81		1
1605	. 2011 ,		1
1604	Mutations in CIC and FUBP1 contribute to human oligodendroglioma. <i>Science</i> , 2011 , 333, 1453-5	33.3	399
1603	Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. 2011 , 48, 856-9		370
1602	Fibroblast growth factors and their receptors in cancer. 2011 , 437, 199-213		404
1601	Probabilistic Methods in Cancer Biology. 2011 , 17, 483-511		8
1600	Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E. 2011 , 13, 467-73		31
1599	Algorithms for detecting significantly mutated pathways in cancer. 2011 , 18, 507-22		333
1598	Mutant proteins as cancer-specific biomarkers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 2444-9	11.5	136

1597	Genetic-based biomarkers and next-generation sequencing: the future of personalized care in colorectal cancer. 2011 , 8, 331-345	20
1596	Pushing the envelope in the mTOR pathway: the second generation of inhibitors. 2011 , 10, 395-403	117
1595	Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. 2011 , 141, 1003-1013.e1-10	90
1594	Targeting PI3K signaling as a therapeutic approach for colorectal cancer. 2011 , 141, 50-61	85
1593	Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities. 2011 , 54, 2668-79	43
1592	Genetic and Epigenetic Heterogeneity in Cancer. 2011 ,	6
1591	Is carcinogenesis a form of speciation?. 2011 , 10, 2100-14	96
1590	Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view. <i>PLoS Computational Biology</i> , 2011 , 7, e1001087	19
1589	Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. 2011 , 12, R103	140
1588	Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. 2011 , 51, 289-310	41
1587	Genomics and the continuum of cancer care. 2011 , 364, 340-50	247
1586	Exome sequencing reveals comprehensive genomic alterations across eight cancer cell lines. 2011 , 6, e21097	27
1585	Inhibition of Ras for cancer treatment: the search continues. 2011 , 3, 1787-808	296
1584	Germline mutations in BAP1 predispose to melanocytic tumors. 2011 , 43, 1018-21	562
1583	Experimental and Applied Immunotherapy. 2011 ,	
1582	Spatial structure increases the waiting time for cancer. 2011 , 13,	63
1581	Colorectal cancer epigenetics: complex simplicity. 2011 , 29, 1382-91	158
1580	Cancer epigenetics: linking basic biology to clinical medicine. 2011 , 21, 502-17	223

1579	Prediction of the biological effect of polymorphisms within microRNA binding sites. 2011 , 676, 197-210	17
1578	Dissecting cancer heterogeneity. 2011 , 29, 1095-6	9
1577	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. 2011 , 1, 508-23	668
1576	Molecular genetics of colorectal cancer. 2011 , 6, 479-507	1163
1575	The genetic landscape of the childhood cancer medulloblastoma. <i>Science</i> , 2011 , 331, 435-9	33.3 576
1574	Tumor Models in Cancer Research. 2011 ,	10
1573	mTOR regulation by JNK: rescuing the starving intestinal cancer cell?. 2011 , 140, 1387-91	7
1572	Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. 2011 , 11, 81-92	58
1571	Nanomedicine Approaches for Cancer Stem Cell Targeting and Personalized Cancer Treatment. 2011 , 135-144	
1570	The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. 2011 , 10, 54	38
1569	Multiplicity: an organizing principle for cancers and somatic mutations. 2011 , 4, 52	3
1568	Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control. 2011 , 7, 1158-66	8
1567	Molecular tumor clocks to study the evolution of drug resistance. 2011 , 8, 2050-4	3
1566	Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. 2011 , 71, 6195-207	163
1565	Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 17087-92	11.5 211
1564	MOLECULAR BASIS OF HEREDITARY COLORECTAL CANCER. 2011 , 22, 65-70	2
1563	Disease Gene Prioritization Based on Topological Similarity in Protein-Protein Interaction Networks. 2011 , 54-68	2
1562	Drugs for HER-2-positive Breast Cancer. 2011 ,	

1561	COLD-PCR: improving the sensitivity of molecular diagnostics assays. 2011 , 11, 159-69	41
1560	Cancer Stem Cells in Solid Tumors. 2011 ,	6
1559	Phosphoinositide 3-kinase in Health and Disease. 2011 ,	
1558	Cancer Systems Biology, Bioinformatics and Medicine. 2011 ,	3
1557	Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. 2011 , 474, 318-26	347
1556	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. 2011 , 43, 964-968	242
1555	Evolutionary mechanisms and diversity in cancer. 2011 , 112, 217-53	72
1554	Use of gene expression and pathway signatures to characterize the complexity of human melanoma. 2011 , 178, 2513-22	12
1553	Protein kinase signaling networks in cancer. 2011 , 21, 4-11	169
1552	Neo-angiogenesis and the premalignant micro-circulatory augmentation of early colon carcinogenesis. 2011 , 306, 205-13	18
1551	Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy. 2011 , 47, 1420-31	17
1550	The EGFR/ErbB Family in Breast Cancer: From Signalling to Therapy. 2011 , 1-32	
1549	Exploring the genomes of cancer cells: progress and promise. <i>Science</i> , 2011 , 331, 1553-8	33.3 488
1548	High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. 2011 , 29, 1109-13	162
1547	The inverted pyramid of biomarker-driven trials. 2011 , 8, 562-6	14
1546	Histologic characteristics of non-microsatellite-instable colon adenomas correlate with distinct molecular patterns. 2011 , 42, 244-53	5
1545	Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. 2011 , 42, 153-65	5
1544	Structural and functional impact of cancer-related missense somatic mutations. 2011 , 413, 495-512	33

1543	Decoding the genome beyond sequencing: the new phase of genomic research. 2011 , 98, 242-52	73
1542	A new disease-specific machine learning approach for the prediction of cancer-causing missense variants. 2011 , 98, 310-7	56
1541	Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. 2011 , 70, 898-907	509
1540	Correction of microtubule-kinetochore attachment errors: mechanisms and role in tumor suppression. 2011 , 22, 559-65	8
1539	Reverse phase protein microarrays for clinical applications. 2011 , 785, 3-12	15
1538	Unraveling the genetics of cancer: genome sequencing and beyond. 2011 , 12, 407-30	73
1537	The origins of cancer robustness and evolvability. 2011 , 3, 17-30	114
1536	Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. 2011 , 7, 1149-67	162
1535	ERK1/2 and p38 β signaling in tumor cell quiescence: opportunities to control dormant residual disease. 2011 , 17, 5850-7	148
1534	Clinical effect of point mutations in myelodysplastic syndromes. 2011 , 364, 2496-506	1169
1533	The Mechanics of Blood Vessel Growth. 2011 ,	3
1532	. 2011 , xvii-xxiv	
1531	Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer. 2011 ,	0
1530	What Next? The Next Transit from Biology to Diagnostics: Next Generation Sequencing for Immunogenetics. 2011 , 38, 308-317	9
1529	High-order chromatin architecture determines the landscape of chromosomal alterations in cancer. 2011 ,	0
1528	Translational Research on Breast Cancer: miRNA, siRNA and Immunoconjugates in Conjugation with Nanotechnology for Clinical Studies. 2011 ,	
1527	Elevated PI3K signaling drives multiple breast cancer subtypes. 2011 , 2, 435-47	44
1526	Integrated Network Analysis of Genetic and Epigenetic Factors in Glioblastoma Multiform. 2011 ,	

1525	. 2011,	22
1524	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. 2011, 2, 627-37	330
1523	Inherited and acquired alterations in development of breast cancer. 2011, 4, 145-58	19
1522	BTRC (beta-transducin repeat containing). 2011,	0
1521	Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma. 2011, 91, 568-73	6
1520	A framework for the study of multiple realizations: the importance of levels of analysis. 2011, 2, 79	11
1519	Protease addiction and synthetic lethality in cancer. <i>Frontiers in Oncology</i> , 2011, 1, 25	5-3 15
1518	Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in \hat{a} line cetuximab-based therapy of colorectal cancer patients. 2011, 6, e15980	101
1517	Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. 2011, 6, e24114	23
1516	Apc mutation enhances PyMT-induced mammary tumorigenesis. 2011, 6, e29339	21
1515	Predicting disease phenotypes based on the molecular networks with condition-responsive correlation. 2011, 5, 131-42	4
1514	Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 325-30	2.2 29
1513	Progress in sequencing human cancer genomes: advancements in childhood medulloblastoma. 2011, 69, N13-5	
1512	Development of RET kinase inhibitors for targeted cancer therapy. 2011, 18, 162-75	44
1511	Embryonic morphogenetic field induces phenotypic reversion in cancer cells. Review article. 2011, 12, 243-53	26
1510	Phosphatidylinositol 3-kinase isoforms as novel drug targets. 2011, 12, 1056-81	34
1509	Genetic alterations in uveal melanoma. 2011, 6, 129-132	
1508	Genome-based and transcriptome-based molecular classification of breast cancer. 2011, 23, 93-9	12

1507	Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. 2011 , 118, 4771-9	453
1506	Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. 2011 , 1, 161	327
1505	Traveling waves of selective sweeps. 2011 , 21,	14
1504	A novel potent tumour promoter aberrantly overexpressed in most human cancers. 2011 , 1, 15	13
1503	Representing Cancer Cell Trajectories in a Phase-Space Diagram: Switching Cellular States by Biological Phase Transitions. 2011 , 377-403	3
1502	Remarkable difference of somatic mutation patterns between oncogenes and tumor suppressor genes. 2011 , 26, 1539-46	4
1501	False discovery rates in somatic mutation studies of cancer. 2011 , 5,	6
1500	Human genetics and genomics a decade after the release of the draft sequence of the human genome. 2011 , 5, 577-622	65
1499	Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?—Implications for cancer immunotherapy by adoptive T cell transfer. 2011 , 73, 527-30	9
1498	Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up. 2011 , 59, 857-66	10
1497	NAV3 copy number changes and target genes in basal and squamous cell cancers. 2011 , 20, 926-31	12
1496	High-resolution characterization of a hepatocellular carcinoma genome. 2011 , 43, 464-9	241
1495	A close look at cancer. 2011 , 17, 262-5	7
1494	Cancer's top papers. 2011 , 17, 278-9	
1493	Research Highlights. 2011 , 17, 294-295	
1492	Human cancers express mutator phenotypes: origin, consequences and targeting. 2011 , 11, 450-7	291
1491	The physics of cancer: the role of physical interactions and mechanical forces in metastasis. 2011 , 11, 512-22	814
1490	A decade of exploring the cancer epigenome - biological and translational implications. 2011 , 11, 726-34	2002

1489	Cancer research: past, present and future. 2011 , 11, 749-54	119
1488	Network medicine: a network-based approach to human disease. 2011 , 12, 56-68	2899
1487	Variation in the mutation rate across mammalian genomes. 2011 , 12, 756-66	287
1486	Towards novel paradigms for cancer therapy. 2011 , 30, 1-20	93
1485	NF- κ B addiction and its role in cancer: 'one size does not fit all'. 2011 , 30, 1615-30	371
1484	No association between germline allele-specific expression of TGFBR1 and colorectal cancer risk in Caucasian and Ashkenazi populations. 2011 , 104, 735-40	8
1483	Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. 2011 , 19, 320-5	59
1482	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. 2011 , 471, 104-9	489
1481	A decade's perspective on DNA sequencing technology. 2011 , 470, 198-203	605
1480	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. 2011 , 58, 1167-72	12
1479	Deep mutational scanning: assessing protein function on a massive scale. 2011 , 29, 435-42	122
1478	Analysis of cancer signaling networks by systems biology to develop therapies. 2011 , 21, 200-6	25
1477	On the intrinsic inevitability of cancer: from foetal to fatal attraction. 2011 , 21, 183-99	58
1476	On the origin of cancer: can we ignore coherence?. 2011 , 106, 380-90	25
1475	Mutational analysis of RUNX1T1 gene in acute leukemias, breast and lung carcinomas. 2011 , 35, e157-8	2
1474	An integrated genomic approach to the assessment and treatment of acute myeloid leukemia. 2011 , 38, 215-24	16
1473	EGFR-targeted therapy. 2011 , 317, 2765-71	83
1472	Evidence for upregulated repair of oxidatively induced DNA damage in human colorectal cancer. 2011 , 10, 1114-20	20

1471	Translational application of epigenetic alterations: ovarian cancer as a model. 2011 , 585, 2112-20	23
1470	The spliceosome as an indicted conspirator in myeloid malignancies. 2011 , 20, 420-3	32
1469	IL-10 elicits IFN γ -dependent tumor immune surveillance. 2011 , 20, 781-96	260
1468	New strategies in the molecular targeting of glioblastoma: how do you hit a moving target?. 2011 , 17, 6-11	17
1467	Pathways and Networks as Functional Descriptors for Human Disease and Drug Response Endpoints. 2011 , 415-442	2
1466	Epigenetics and colorectal cancer. 2011 , 8, 686-700	459
1465	Breast cancer methylomes establish an epigenomic foundation for metastasis. 2011 , 3, 75ra25	215
1464	Translating tumor antigens into cancer vaccines. 2011 , 18, 23-34	148
1463	Cancer immunology--analysis of host and tumor factors for personalized medicine. 2011 , 8, 711-9	209
1462	Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. 2011 , 18, 3694-700	45
1461	The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. 2011 , 63, 136-51	2580
1460	GATES: a rapid and powerful gene-based association test using extended Simes procedure. 2011 , 88, 283-93	280
1459	High-resolution analyses of gene copy number reveal new insights into the prognosis and progression of breast cancers. 2011 , 128, 41-3	
1458	The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations. 2011 , 30, 199-210	57
1457	Chromosomes and cancer cells. 2011 , 19, 433-44	95
1456	Alterations of the retinoblastoma gene in metastatic breast cancer. 2011 , 28, 319-26	12
1455	Assessing the value of CAN-gene mutations using MALDI-TOF MS. 2011 , 137, 1239-44	
1454	[Tyrosine kinase inhibitors in oncology]. 2011 , 52, 595-600	2

1453	Defining the cancer master switch. 2011 , 35, 1738-45	1
1452	Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 2011 , 49, 235-47	4
1451	Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. 2011 , 17, 429-33	44
1450	Expression of p53, Ki-67 and c-Myc proteins is predictive of the surgical molecular margin in colorectal carcinoma. 2011 , 17, 479-87	5
1449	Meet me halfway: when genomics meets structural bioinformatics. 2011 , 4, 281-303	10
1448	The PI3K/AKT/mTOR Signaling Pathway: Implications in the Treatment of Breast Cancer. 2011 , 3, 63-74	3
1447	Personalized medicine: a comprehensive approach in oncology. 2011 , 9, 89-90	5
1446	NOTCH Signaling and ATOH1 in Colorectal Cancers. 2011 , 7, 121-127	27
1445	Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. 2011 , 9, 119	71
1444	Deciphering causal and statistical relations of molecular aberrations and gene expressions in NCI-60 cell lines. 2011 , 5, 186	7
1443	A large scale survey reveals that chromosomal copy-number alterations significantly affect gene modules involved in cancer initiation and progression. 2011 , 4, 37	3
1442	The Roche Cancer Genome Database 2.0. 2011 , 4, 43	4
1441	Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. 2011 , 4, 68	146
1440	Integrating multiple protein-protein interaction networks to prioritize disease genes: a Bayesian regression approach. 2011 , 12 Suppl 1, S11	32
1439	Characterization of pathogenic germline mutations in human protein kinases. 2011 , 12 Suppl 4, S1	10
1438	Clinical cancer genomics: how soon is now?. 2011 , 223, 318-26	30
1437	Lessons from the deep study of rare tumours. 2011 , 224, 306-8	5
1436	Protein-protein interaction networks and subnetworks in the biology of disease. 2011 , 3, 357-67	57

1435	Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. 2011 , 103, 563-73	30
1434	Meta-analysis of heterogeneous data sources for genome-scale identification of risk genes in complex phenotypes. 2011 , 35, 318-32	28
1433	Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. 2011 , 53, 2112-21	45
1432	Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. 2011 , 3, 623-36	173
1431	Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. 2011 , 50, 82-94	64
1430	Cancer genome variation in children, adolescents, and young adults. 2011 , 117, 2262-7	4
1429	Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. 2011 , 32, E2148-75	32
1428	Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. 2011 , 32, 1028-35	9
1427	Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. 2011 , 129, 1635-42	56
1426	Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. 2011 , 33, 224-31	38
1425	The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. 2011 , 33, 332-40	203
1424	Moving closer to a prognostic DNA methylation signature in colon cancer. 2011 , 17, 1215-7	13
1423	Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110 β of phosphoinositide-3-kinase. 2011 , 10, 3731-9	8
1422	The ubiquitin+proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011 , 11, 242-6	2.2 14
1421	Genomic and epigenomic integration identifies a prognostic signature in colon cancer. 2011 , 17, 1535-45	125
1420	Quantitative structure-activity relationships for anticancer activity of 2-phenylindoles using mathematical molecular descriptors. 2011 , 7, 98-108	2
1419	[Synthetic lethality as a new concept for the treatment of cancer]. 2011 , 136, 1526-30	1
1418	Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. 2011 , 152, 2133-40	35

1417	Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. 2011 , 43, 1202-9		152
1416	MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. 2011 , 32, 1033-42		149
1415	Using Biological Networks in Protein Function Prediction and Gene Expression Analysis. 2011 , 7, 274-298		3
1414	Efficient simulation under a population genetics model of carcinogenesis. 2011 , 27, 837-43		9
1413	Olfactomedin 2: expression in the eye and interaction with other olfactomedin domain-containing proteins. 2011 , 52, 2584-92		12
1412	Emerging paradigms for the initiation of mucin-type protein O-glycosylation by the polypeptide GalNAc transferase family of glycosyltransferases. 2011 , 286, 14493-507		121
1411	Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. 2011 , 17, 7194-203		18
1410	Time to think outside the (genetic) box. 2011 , 4, 6-8		8
1409	Making sense of cancer genomic data. 2011 , 25, 534-55		260
1408	Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. 2011 , 186, 275-83		34
1407	ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. 2011 , 71, 6524-34		22
1406	Review of histopathological and molecular prognostic features in colorectal cancer. <i>Cancers</i> , 2011 , 3, 2767-810	6.6	51
1405	Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer. <i>Cancers</i> , 2011 , 3, 1141-57	6.6	21
1404	State of the art in tumor antigen and biomarker discovery. <i>Cancers</i> , 2011 , 3, 2554-96	6.6	30
1403	Conversion of tumors into autologous vaccines by intratumoral injection of β Gal glycolipids that induce anti-Gal/ β Gal epitope interaction. 2011 , 2011, 134020		8
1402	Osteosarcoma in a Marfan patient with a novel premature termination codon in the FBN1 gene. 2011 , 52, 157-65		4
1401	Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. 2011 , 71, 2706-17		99
1400	C/EBP β /EBP β oncoproteins, or C/EBP β preferentially bind NF- κ B p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction. <i>Molecular Cancer Research</i> , 2011 , 9, 1395-405	6.6	17

1399	Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. 2011 , 71, 3471-81		9
1398	Functional parsing of driver mutations in the colorectal cancer genome reveals numerous suppressors of anchorage-independent growth. 2011 , 71, 4359-65		24
1397	Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. 2011 , 3, 92ra66		599
1396	T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 4914-9	11.5	83
1395	Advancing a clinically relevant perspective of the clonal nature of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 12054-9	11.5	89
1394	A bioinformatics workflow for variant peptide detection in shotgun proteomics. 2011 , 10, M110.006536		73
1393	Mutation and epigenetic molecular clocks in cancer. 2011 , 32, 123-8		25
1392	RAD51 can inhibit PDGF-B-induced gliomagenesis and genomic instability. 2011 , 13, 1277-87		9
1391	MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model. 2011 , 71, 1302-12		31
1390	NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. 2011 , 193, 633-42		116
1389	Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. 2010 , 32, 35-48		389
1388	Activation and involvement of Ral GTPases in colorectal cancer. 2011 , 71, 206-15		64
1387	The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. 2011 , 2, 275-87		83
1386	Epigenetic changes in osteosarcoma. 2011 , 98, E62-8		22
1385	Genetic control of susceptibility to carcinogen-induced colorectal cancer in mice: the Ccs3 and Ccs5 loci regulate different aspects of tumorigenesis. 2011 , 10, 1739-49		8
1384	High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 5384-9	11.5	106
1383	Paneth cell marker expression in intestinal villi and colon crypts characterizes dietary induced risk for mouse sporadic intestinal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 10272-7	11.5	44
1382	Compensatory function of Pyk2 protein in the promotion of focal adhesion kinase (FAK)-null mammary cancer stem cell tumorigenicity and metastatic activity. 2011 , 286, 18573-82		45

1381	Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29. 2011 , 286, 21500-10		32
1380	Identifying cancer driver genes in tumor genome sequencing studies. 2011 , 27, 175-81		146
1379	A Sleeping Beauty transposon-mediated screen identifies murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 5765-70	11.5	62
1378	Epithelial phosphatidylinositol-3-kinase signaling is required for E-catenin activation and host defense against <i>Citrobacter rodentium</i> infection. 2011 , 79, 1863-72		36
1377	Cancer. Another NOTCH for cancer. <i>Science</i> , 2011 , 333, 1102-3	33.3	22
1376	Distinct patterns of somatic alterations in a lymphoblastoid and a tumor genome derived from the same individual. 2011 , 39, 6056-68		17
1375	Germline BAP1 mutations and tumor susceptibility. 2011 , 43, 925-6		35
1374	Genomic rearrangement in three dimensions. 2011 , 29, 1096-8		3
1373	Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. 2011 , 25, 1908-10		26
1372	GATA2 mutations lead to MDS and AML. 2011 , 43, 926-7		28
1371	Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform. 2011 , 105, 1574-81		13
1370	MCL1's resistance story. 2011 , 4, 300-300		
1369	Vavien: an algorithm for prioritizing candidate disease genes based on topological similarity of proteins in interaction networks. 2011 , 18, 1561-74		56
1368	K ⁺ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. <i>Science</i> , 2011 , 331, 768-72	33.3	707
1367	RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. 2011 , 10, 1563-70		75
1366	Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. 2011 , 10, M111.010462		158
1365	Genetic alterations in glioma. <i>Cancers</i> , 2011 , 3, 1129-40	6.6	19
1364	Genetic and epigenetic traits as biomarkers in colorectal cancer. <i>International Journal of Molecular Sciences</i> , 2011 , 12, 9426-39	6.3	36

1363	The phase-field model in tumor growth. 2011 , 91, 183-206		21
1362	PathScan: a tool for discerning mutational significance in groups of putative cancer genes. 2011 , 27, 1595-602		72
1361	International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics data. 2011 , 2011, bar026		382
1360	IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. 2011 , 71, 2172-82		76
1359	Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. 2011 , 7, e1002245		55
1358	Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. <i>Cancers</i> , 2011 , 3, 1383-404	6.6	108
1357	Cancer genome sequencing and its implications for personalized cancer vaccines. <i>Cancers</i> , 2011 , 3, 4191-211	2.1	17
1356	Somatic genetics empowers the mouse for modeling and interrogating developmental and disease processes. 2011 , 7, e1002110		6
1355	Accurate reconstruction of the temporal order of mutations in neoplastic progression. 2011 , 4, 1135-44		44
1354	An integrated view of cyclin E function and regulation. 2012 , 11, 57-64		116
1353	Interpretation of the consequences of mutations in protein kinases: combined use of bioinformatics and text mining. 2012 , 3, 323		7
1352	Identification of five novel modifier loci of Apc(Min) harbored in the BXH14 recombinant inbred strain. 2012 , 33, 1589-97		10
1351	A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. 2012 , 31, 1364-78		243
1350	The cancer antigenome. 2013 , 32, 194-203		172
1349	Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 1951-2011	6.3	106
1348	Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 8933-42	6.3	26
1347	Genomics of acute myeloid leukemia: the next generation. <i>Frontiers in Oncology</i> , 2012 , 2, 40	5.3	24
1346	Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence. 2012 , 31, 1494-505		21

1345	DNA methylation as clinically useful biomarkers-light at the end of the tunnel. 2012 , 5, 94-113		43
1344	Differential network entropy reveals cancer system hallmarks. 2012 , 2, 802		111
1343	Emerging Roles of ADAMTSs in Angiogenesis and Cancer. <i>Cancers</i> , 2012 , 4, 1252-99	6.6	51
1342	Oncogenic cooperation between SOCS family proteins and EGFR identified using a <i>Drosophila</i> epithelial transformation model. 2012 , 26, 1602-11		64
1341	A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. 2012 , 18, 577-84		81
1340	Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. 2012 , 40, D978-83		31
1339	Integrative functional genomics identifies RINT1 as a novel GBM oncogene. 2012 , 14, 1325-31		12
1338	A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases. 2012 , 40, e53		186
1337	Altered antisense-to-sense transcript ratios in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2820-4	11.5	48
1336	SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. 2012 , 7, 447-57		27
1335	Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. 2012 , 25, 930-7		34
1334	Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. 2012 , 18, 408-16		201
1333	Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis. 2012 , 5, ra79		96
1332	A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs. 2012 , 12, 339-55		13
1331	Receptor protein tyrosine phosphatases and cancer: new insights from structural biology. 2012 , 6, 356-64		22
1330	Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes. 2012 , 3, 550-63		15
1329	Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer. 2012 , 12, 329-38		7
1328	Synthetische Letalit als Therapiekonzept f die Behandlung maligner Neoplasien. 2012 , 33, 284-289		

1327	Dietary folate suppresses DMH-induced colon carcinogenesis in a rat model and affects DMH-induced expression of four DNA repair enzymes. 2012 , 64, 1196-203		1
1326	Argonaute2 regulation for K ⁺ channel-mediated human adipose tissue-derived stromal cells self-renewal and survival in nucleus. 2012 , 21, 1736-48		8
1325	Tumour Formation: Number of Mutations Required. 2012 ,		
1324	Role of variations within microRNA-binding sites in cancer. 2012 , 27, 205-10		37
1323	Cancer. Haploinsufficient gene selection in cancer. <i>Science</i> , 2012 , 337, 47-8	33.3	11
1322	Extensive somatic L1 retrotransposition in colorectal tumors. 2012 , 22, 2328-38		194
1321	Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. 2012 , 11, 453-66		53
1320	Genome-scale analysis of aberrant DNA methylation in colorectal cancer. 2012 , 22, 271-82		466
1319	Potential role of a navigator gene NAV3 in colorectal cancer. 2012 , 106, 517-24		23
1318	New developments in the treatment of ALK-driven malignancies. 2012 , 2, 835-852		1
1317	CDX2 is an amplified lineage-survival oncogene in colorectal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E3196-205	11.5	54
1316	Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. 2012 , 22, 736-56		529
1315	PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. 2012 , 32, 1506-17		132
1314	Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. 2012 , 72, 4383-93		204
1313	TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. 2012 , 61, 1568-75		95
1312	Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. 2012 , 22, 208-19		95
1311	Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. 2012 , 7, 701-9		52
1310	PI3Ks-drug targets in inflammation and cancer. 2012 , 58, 111-81		7

1309	Search for a gene expression signature of breast cancer local recurrence in young women. 2012 , 18, 1704-15	56
1308	Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. 2012 , 18, 688-99	113
1307	Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. 2012 , 32, 2160-7	64
1306	Convergent structural alterations define SWItch/Sucose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E252-9	11.5 161
1305	Functional impact bias reveals cancer drivers. 2012 , 40, e169	238
1304	Myeloid neoplasias: what molecular analyses are telling us. 2012 , 2012, 321246	2
1303	Invasion in multi-type populations: the role of phenotypic robustness and fluctuations. 2012 , 29, 3-20	1
1302	Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 5934-41	11.5 179
1301	New methods for finding common insertion sites and co-occurring common insertion sites in transposon- and virus-based genetic screens. 2012 , 40, 3822-33	19
1300	Genetics of adrenocortical disease: an update. 2012 , 19, 159-67	6
1299	Biomarkers, bundled payments, and colorectal cancer care. 2012 , 3, 16-22	10
1298	Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study. 2012 , 3, 87-101	8
1297	RNAi screening of the human colorectal cancer genome identifies multifunctional tumor suppressors regulating epithelial cell invasion. 2012 , 22, 1605-8	7
1296	In vitro stability of APC gene sequences and the influence of DNA repair status. 2012 , 27, 233-8	3
1295	DNA polymerase β variant Ile260Met generates global gene expression changes related to cellular transformation. 2012 , 27, 683-91	4
1294	Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. 2012 , 12, 316-28	23
1293	Pathway simulations in common oncogenic drivers of leukemic and rhabdomyosarcoma cells: a systems biology approach. 2012 , 40, 1365-90	8
1292	EDITORIAL: Molecularly targeted treatments for colorectal cancer: advances and limitations. 2012 , 12, 301-2	1

1291	Plasma miR-21: a potential diagnostic marker of colorectal cancer. 2012 , 256, 544-51	209
1290	Translational informatics in personalized medicine. 2012 , 9, 39-45	1
1289	Targeting PI3 kinase/AKT/mTOR signaling in cancer. 2012 , 17, 69-95	176
1288	Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. 2012 , 41, 1932-42	37
1287	PIK3CA mutation and methylation influences the outcome of colorectal cancer. 2012 , 3, 565-570	26
1286	- Optical Waveguide-Based Biosensors for the Detection of Breast Cancer Biomarkers. 2012 , 180-195	
1285	Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. 2012 , 88, 53-71	191
1284	A novel missense-mutation-related feature extraction scheme for 'driver' mutation identification. 2012 , 28, 2948-55	36
1283	Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. 2012 , 25, 819-31	40
1282	Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. 2012 , 164, 138-44	621
1281	The spliceosome as a target of novel antitumour drugs. 2012 , 11, 847-59	311
1280	Cancer genomics and pathology: all together now. 2012 , 62, 647-59	5
1279	Emerging real-time technologies in molecular medicine and the evolution of integrated 'pharmacomics' approaches to personalized medicine and drug discovery. 2012 , 136, 295-304	11
1278	Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. 2012 , 18, 5188-95	49
1277	β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. 2012 , 151, 1457-73	522
1276	Delving into somatic variation in sporadic melanoma. 2012 , 25, 155-70	33
1275	Synergistic effect of different levels of genomic data for cancer clinical outcome prediction. 2012 , 45, 1191-8	73
1274	Breast-cancer stem cells-beyond semantics. 2012 , 13, e43-8	117

1273	Prioritization of pathogenic mutations in the protein kinase superfamily. 2012 , 13 Suppl 4, S3	21
1272	The genetic landscape of mutations in Burkitt lymphoma. 2012 , 44, 1321-5	422
1271	Integrating the NCI-60 Data with <i>omics</i> for Drug Discovery. 2012 , 73, 420-429	2
1270	Identifying mutated proteins secreted by colon cancer cell lines using mass spectrometry. 2012 , 76 Spec No., 141-9	43
1269	Characterising Somatic Mutations in Cancer Genome by Means of Next-generation Sequencing. 2012 ,	
1268	Recurrent R-spondin fusions in colon cancer. 2012 , 488, 660-4	711
1267	A virtual pyrogram generator to resolve complex pyrosequencing results. 2012 , 14, 149-59	19
1266	A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. 2012 , 8, 1553-70	28
1265	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. 2012 , 119, 5201-10	111
1264	Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. 2012 , 5, 319-37	20
1263	Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. 2012 , 51, 1464-75	50
1262	Proteomic consequences of a single gene mutation in a colorectal cancer model. 2012 , 11, 1184-95	29
1261	Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies. 2012 , 106, 173-83	52
1260	A new branch on the tree: next-generation sequencing in the study of cancer evolution. 2012 , 23, 237-42	27
1259	Cancer stem cells: current status and evolving complexities. 2012 , 10, 717-728	943
1258	GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct. 2012 , 14, 677-83	36
1257	Overview of the cancer vaccine field: are we moving forward?. 2012 , 8, 1135-40	13
1256	Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 14586-91	11.5 76

1255	Global mutational profiling of formalin-fixed human colon cancers from a pathology archive. 2012 , 25, 1599-608		22
1254	What are we learning from the cancer genome?. 2012 , 9, 621-30		43
1253	ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2595-604	11.5	296
1252	Essential gene profiles in breast, pancreatic, and ovarian cancer cells. 2012 , 2, 172-189		221
1251	Identification of novel metastasis suppressor signaling pathways for breast cancer. 2012 , 11, 2452-7		23
1250	Inter-tumor heterogeneity. 2012 , 8, 1143-5		18
1249	New stochastic carcinogenesis model with covariates: an approach involving intracellular barrier mechanisms. 2012 , 236, 16-30		7
1248	MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting E-catenin. 2012 , 420, 787-92		129
1247	Clustered DNA methylation changes in polycomb target genes in early-stage liver cancer. 2012 , 425, 290-6		14
1246	Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. 2012 , 316, 77-84		6
1245	Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. 2012 , 324, 98-108		34
1244	The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BE235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy. 2012 , 48, 396-406		10
1243	Cancer gene discovery in the mouse. 2012 , 22, 14-20		9
1242	Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. 2012 , 491, 254-8		873
1241	The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. 2011 , 9, 77-87		75
1240	Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. 2012 , 26, 1698-701		44
1239	Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. 2012 , 31, 4567-76		192
1238	Keap1: one stone kills three birds Nrf2, IKK β and Bcl-2/Bcl-xL. 2012 , 325, 26-34		75

1237	SnapShot: breast cancer. 2012 , 22, 562-562.e1	54
1236	Genome-wide identification of significant aberrations in cancer genome. 2012 , 13, 342	27
1235	Shared ancestral susceptibility to colorectal cancer and other nutrition related diseases. 2012 , 13, 94	4
1234	Increased frequency of single base substitutions in a population of transcripts expressed in cancer cells. <i>BMC Cancer</i> , 2012 , 12, 509	4.8
1233	Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer. 2012 , 11, 38	22
1232	Harnessing the complexity of gene expression data from cancer: from single gene to structural pathway methods. 2012 , 7, 44	19
1231	Cancer core modules identification through genomic and transcriptomic changes correlation detection at network level. 2012 , 6, 64	2
1230	Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer. 2012 , 3, 3	34
1229	A taxonomy of organ-specific breast cancer metastases based on a protein-protein interaction network. 2012 , 8, 2085-96	9
1228	Cancer vaccines: are we there yet?. 2012 , 8, 1161-5	4
1227	Clinical review: Genome-wide association studies of skeletal phenotypes: what we have learned and where we are headed. 2012 , 97, E1958-77	80
1226	Metabolomic analysis of the effects of edible dry beans (<i>Phaseolus vulgaris</i> L.) on tissue lipid metabolism and carcinogenesis in rats. 2012 , 108 Suppl 1, S155-65	11
1225	Comprehensive molecular characterization of human colon and rectal cancer. 2012 , 487, 330-7	5640
1224	Nanovector delivery of siRNA for cancer therapy. 2012 , 19, 367-73	138
1223	Multiple roles for the p85 β isoform in the regulation and function of PI3K signalling and receptor trafficking. 2012 , 441, 23-37	70
1222	Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. 2012 , 137, 847-59	36
1221	Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. 2012 , 4, 142ra94	204
1220	Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. 2012 , 44, 1117-21	313

1219 Encyclopedia of Signaling Molecules. **2012**, 1488-1488

1218 Calorimetry-based profiling of blood plasma from colorectal cancer patients. **2012**, 1820, 1879-85 54

1217 Structural mutations in cancer: mechanistic and functional insights. **2012**, 28, 550-9 54

1216 Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. **2012**, 110, 69-86 45

1215 The Cell Cycle. **2012**, 451-471 4

1214 Some Research Directions. **2012**, 69-80

1213 Polyps and Tumour-Like Lesions of the Large Intestine. **2012**, 647-684

1212 Initiation of Soft Tissue Sarcomas: Muscle Stem/Progenitor Cells as Targets. **2012**, 135-144

1211 Modeling Oncogenic Signaling Networks from Gene Expression Dynamics. **2012**, 69-81

1210 Understanding Cancer Progression Using Protein Interaction Networks. **2012**, 167-195 1

1209 Phospholipase signalling networks in cancer. **2012**, 12, 782-92 141

1208 Targeted therapies: how personal should we go?. **2011**, 9, 87-97 87

1207 Is there a biological cost of protein disorder? Analysis of cancer-associated mutations. **2012**, 8, 296-307 40

1206 The Role of the Insulin-like Growth Factor-1 Receptor (IGF-1R), Phosphatase and Tensin Homolog (PTEN), c-Met, and the PI3-Kinase Pathway in Colorectal Cancer. **2012**, 8, 243-253

1205 Deubiquitinating enzyme BAP1 is involved in the formation and maintenance of the diapause embryos of *Artemia*. **2012**, 17, 577-87 9

1204 The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma. **2012**, 14, 1075-86 13

1203 Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer. **2012**, 14, 559-71 46

1202 Bile-based detection of extrahepatic cholangiocarcinoma with quantitative DNA methylation markers and its high sensitivity. **2012**, 14, 256-63 24

1201	Development of Antibody-Based Therapeutics. 2012,	5
1200	Molekulare Onkologie. 2012, 18, 1023-1028	0
1199	Brain Tumor Models to Predict Clinical Outcome: Like the Phoenix?. 2012, 3-20	1
1198	Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. 2012, 31, 4409-19	60
1197	Bioinformatics for High-Throughput Toxico-Epigenomics Studies. 2012, 569-588	1
1196	Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling. 2012, 11, 850-60	58
1195	Stem Cells and Cancer Stem Cells, Volume 7. 2012,	
1194	Phosphoinositides I: Enzymes of Synthesis and Degradation. 2012,	6
1193	Adherens Junctions: from Molecular Mechanisms to Tissue Development and Disease. 2012,	2
1192	Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium. 2012, 5, 43	13
1191	Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. 2012, 4, 89	73
1190	Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. 2012, 7, e33393	128
1189	A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. 2012, 7, e42001	60
1188	Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening. 2012, 7, e45591	26
1187	Clonal evolution of a case of treatment refractory maxillary sinus carcinoma. 2012, 7, e45614	2
1186	A screen for selective killing of cells with chromosomal instability induced by a spindle checkpoint defect. 2012, 7, e47447	14
1185	Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. 2012, 7, e51719	12
1184	Pharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma. 2012, 27, 594-604	10

1183	Inferring Genetic Interactions via a Data-Driven Second Order Model. 2012 , 3, 71	2
1182	Functions of p120ctn in development and disease. 2012 , 17, 760-83	36
1181	Genetics and Genomics in Cardiovascular Gene Discovery. 2012 , 231-259	2
1180	A better way forward: targeting hedgehog signaling in liver cancer. 2012 , 4, 277-86	3
1179	Distinct Pathologic Roles for Glycogen Synthase Kinase 3 β in Colorectal Cancer Progression. 2012 ,	2
1178	Novel Markers for Diagnosis and Prognosis of Oral Intraepithelial Neoplasia. 2012 ,	1
1177	A better way forward targeting hedgehog signaling in liver cancer. 2012 , S4, 277-286	7
1176	Cancer Genetics. 2012 , 1182-1184	
1175	Cooperative Hedgehog-EGFR signaling. 2012 , 17, 90-9	44
1174	Signal transduction pathways participating in homeostasis and malignant transformation of the intestinal tissue. 2012 , 59, 708-18	11
1173	KIF14 (kinesin family member 14). 2012 ,	1
1172	A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. 2012 , 227, 29-41	44
1171	Mechanistic modeling to investigate signaling by oncogenic Ras mutants. 2012 , 4, 117-27	4
1170	Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. 2012 , 22, 246-58	385
1169	The DNA translocase activity of FANCM protects stalled replication forks. 2012 , 21, 2005-16	56
1168	The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. 2012 , 17, 2197-212	82
1167	Epigenomic enhancer profiling defines a signature of colon cancer. <i>Science</i> , 2012 , 336, 736-9	33:3 255
1166	Frequent activating GNAS mutations in villous adenoma of the colorectum. 2012 , 228, 113-8	58

1165	[Genetic basis of leukemia: Serious consequences of chromosomal translocations]. 2012 , 41, 190-5	
1164	Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. 2012 , 4, 675-84	164
1163	Shattered and stitched chromosomes-chromothripsis and chromoanasythesis-manifestations of a new chromosome crisis?. 2012 , 51, 975-81	28
1162	Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases. 2012 , 33, 1566-75	24
1161	Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. 2012 , 131, 1790-9	37
1160	Wnt/ β catenin signaling and disease. 2012 , 149, 1192-205	377 ⁸
1159	Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. 2012 , 486, 80-4	258
1158	Physics of Cancer: The Impact of Heterogeneity. 2012 , 3, 363-382	20
1157	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. 2012 , 134, 333-43	94
1156	Estimating the order of mutations during tumorigenesis from tumor genome sequencing data. 2012 , 28, 1555-61	15
1155	How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. 2012 , 12, 621-8	121
1154	Cooperative, nanoparticle-enabled thermal therapy of breast cancer. 2012 , 1, 84-9	73
1153	Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome. 2012 , 118, 4670-80	19
1152	On oncogenes and tumor suppressor genes in the mammary gland. 2012 , 4,	6
1151	Inhibitors of the anaplastic lymphoma kinase. 2012 , 21, 985-94	46
1150	Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. 2012 , 18, 1515-23	37
1149	Oncogenomics methods and resources. 2012 , 2012,	7
1148	BRACKing news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype. 2012 , 31, 131-42	9

1147	Sequence analysis of mutations and translocations across breast cancer subtypes. 2012 , 486, 405-9	895
1146	Inactivation of X-linked tumor suppressor genes in human cancer. 2012 , 8, 463-81	22
1145	Clonal competition with alternating dominance in multiple myeloma. 2012 , 120, 1067-76	473
1144	Exploring the cancer genome in the era of next-generation sequencing. 2012 , 6, 48-55	20
1143	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. 2012 , 133, 865-80	87
1142	T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors. 2012 , 134, 61-70	4
1141	Mammalian phospholipase D physiological and pathological roles. 2012 , 204, 219-26	100
1140	NIRF/UHRF2 occupies a central position in the cell cycle network and allows coupling with the epigenetic landscape. 2012 , 586, 1570-83	30
1139	Mutational profiling of sporadic versus toxin-associated brain cancer formation: initial findings using loss of heterozygosity profiling. 2012 , 215, 427-33	2
1138	Stratified medicine for cancer therapy. 2012 , 17, 261-8	5
1137	Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights. 2012 , 39, 37-46	14
1136	Predicting recurrence after radiotherapy in head and neck cancer. 2012 , 22, 108-18	54
1135	The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. 2012 , 75, 1590-9	9
1134	Mutations and epimutations in the origin of cancer. 2012 , 318, 299-310	54
1133	Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. 2012 , 103, 535-41	61
1132	Epigenetics and blood disorders. 2012 , 158, 307-22	9
1131	Domain landscapes of somatic mutations in cancer. 2012 , 13 Suppl 4, S9	39
1130	McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. 2012 , 7 Suppl 1, S4	153

1129	Drug development in pediatric psychiatry: current status, future trends. 2012 , 6, 7	5
1128	Hereditary breast cancer: practical pursuit for clinical translation. 2012 , 19, 1723-31	23
1127	Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. 2012 , 51, 480-9	50
1126	The large-scale distribution of somatic mutations in cancer genomes. 2012 , 33, 136-43	56
1125	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. 2012 , 33, 100-3	230
1124	Candidate driver genes in microsatellite-unstable colorectal cancer. 2012 , 130, 1558-66	78
1123	Colon cancer associated transcript-1: a novel RNA expressed in malignant and pre-malignant human tissues. 2012 , 130, 1598-606	219
1122	Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism. 2012 , 35, 53-63	47
1121	Moderne Techniken der Gendiagnostik. 2012 , 45, 11-16	
1120	The "Virtual Patient" system: modeling cancer using deep sequencing technologies for personalized cancer treatment. 2012 , 7, 55-62	7
1119	Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. 2012 , 132, 29-39	70
1118	Next generation sequencing and a new era of medicine. 2013 , 62, 920-32	19
1117	Identification of novel driver tumor suppressors through functional interrogation of putative passenger mutations in colorectal cancer. 2013 , 132, 732-7	18
1116	Molecular pathways in pancreatic carcinogenesis. 2013 , 107, 8-14	62
1115	Modelling gene expression profiles related to prostate tumor progression using binary states. 2013 , 10, 37	4
1114	Embryonic mammary signature subsets are activated in Brca1 ^{-/-} and basal-like breast cancers. 2013 , 15, R25	40
1113	Integrated analysis of recurrent properties of cancer genes to identify novel drivers. 2013 , 14, R52	29
1112	Targeted therapies in colorectal cancer-an integrative view by PPM. 2013 , 4, 3	57

1111	Functional aspects of primary cilia in signaling, cell cycle and tumorigenesis. 2013 , 2, 6	127
1110	Cancer of the Colon and Gastrointestinal Tract. 2013 , 1-35	
1109	Cancer heterogeneity--a multifaceted view. 2013 , 14, 686-95	160
1108	The genetics of melanoma: recent advances. 2013 , 14, 257-79	61
1107	Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?. 2013 , 32, 673-705	15
1106	Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. 2013 , 377, 1-6	73
1105	Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. 2013 , 15, 967-77	104
1104	Sequencing PCR-amplified DNA in lipoprotein and cardiovascular disease research. 2013 , 1027, 139-55	
1103	Resistance to Immunotherapeutic Antibodies in Cancer. 2013 ,	1
1102	Joint genotype inference with germline and somatic mutations. 2013 , 14 Suppl 5, S3	4
1101	Discovery and analysis of consistent active sub-networks in cancers. 2013 , 14 Suppl 2, S7	11
1100	Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers. 2013 , 14 Suppl 3, S8	11
1099	Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. 2013 , 14, 505	25
1098	Large-scale integrative network-based analysis identifies common pathways disrupted by copy number alterations across cancers. 2013 , 14, 440	17
1097	Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. 2013 , 14, 165	28
1096	Mutation spectrum in human colorectal cancers and potential functional relevance. 2013 , 14, 32	8
1095	Genetic variation in TLR or NFkappaB pathways and the risk of breast cancer: a case-control study. <i>BMC Cancer</i> , 2013 , 13, 219	4.8 32
1094	High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2013 , 13, 169	4.8 36

1093	Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. 2013 , 18, 1447-68	107
1092	DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. 2013 , 93, 439-51	53
1091	Melanoma genotypes and phenotypes get personal. 2013 , 93, 858-67	16
1090	Deciphering signatures of mutational processes operative in human cancer. 2013 , 3, 246-59	725
1089	Cell fusion promotes chemoresistance in metastatic colon carcinoma. 2013 , 32, 2649-60	53
1088	Next Generation Sequencing in Cancer Research. 2013 ,	4
1087	Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer. 2013 , 28, 173-81	11
1086	Breast Cancer Metastasis and Drug Resistance. 2013 ,	5
1085	Breast Cancer Heterogeneity in Primary and Metastatic Disease. 2013 , 65-95	1
1084	Chemical genetics of rapamycin-insensitive TORC2 in <i>S. cerevisiae</i> . 2013 , 5, 1725-36	27
1083	Genomic insights into cancer-associated aberrant CpG island hypermethylation. 2013 , 12, 174-90	92
1082	Genome-wide association and sequencing studies on colorectal cancer. 2013 , 23, 502-11	13
1081	Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. 2013 , 155, 948-62	478
1080	Cancer genome landscapes. <i>Science</i> , 2013 , 339, 1546-58	33.3 5058
1079	Identification of candidate oncogenes in human colorectal cancers with microsatellite instability. 2013 , 145, 540-3.e22	40
1078	Epigenetics and colorectal cancer pathogenesis. <i>Cancers</i> , 2013 , 5, 676-713	6.6 159
1077	Micro and Nano Flow Systems for Bioanalysis. 2013 ,	2
1076	Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. 2013 , 4, 2610	176

1075	Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. 2013 , 155, 384-96	323
1074	Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest. 2013 , 22, 2451-61	14
1073	Mutational landscape and significance across 12 major cancer types. 2013 , 502, 333-339	2803
1072	Fundamentals of Pharmaceutical Nanoscience. 2013 ,	13
1071	Molecular Pathology of Neoplastic Gastrointestinal Diseases. 2013 ,	2
1070	Intra-relation reconstruction from inter-relation: miRNA to gene expression. 2013 , 7 Suppl 3, S8	10
1069	Whole transcriptome sequencing identifies tumor-specific mutations in human oral squamous cell carcinoma. 2013 , 6, 28	21
1068	Involvement of free radicals in breast cancer. 2013 , 2, 404	30
1067	CRAC: an integrated approach to the analysis of RNA-seq reads. 2013 , 14, R30	54
1066	Animal models of colorectal cancer. 2013 , 32, 39-61	75
1065	wKinMut: an integrated tool for the analysis and interpretation of mutations in human protein kinases. 2013 , 14, 345	5
1064	Integrating human omics data to prioritize candidate genes. 2013 , 6, 57	21
1063	Systematic genomic identification of colorectal cancer genes delineating advanced from early clinical stage and metastasis. 2013 , 6, 54	27
1062	Management of Colorectal Cancers in Older People. 2013 ,	1
1061	Biomarkers in Oncology. 2013 ,	1
1060	Markers of circulating breast cancer cells. 2013 , 61, 175-224	5
1059	Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. 2013 , 14, 125-35	112
1058	Germline BAP1 mutations predispose to renal cell carcinomas. 2013 , 92, 974-80	188

1057	Genome-wide screening for understanding the role of DNA methylation in colorectal cancer. 2013 , 5, 569-81	10
1056	Colorectal cancer stem cells and their implications for novel anticancer therapy. 2013 , 13, 461-8	
1055	Evading apoptosis in cancer. 2013 , 23, 620-33	311
1054	Next-generation sequencing in cancer research & diagnostics. 2013 , 20-40	
1053	Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. 2013 , 9, 637	192
1052	Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. 2013 , 5, 47	35
1051	Needles in a haystack: finding recurrent genomic changes in breast cancer. 2013 , 14, 304	2
1050	Delivery of gene silencing agents for breast cancer therapy. 2013 , 15, 205	25
1049	HLA ligandome tumor antigen discovery for personalized vaccine approach. 2013 , 12, 1211-7	72
1048	Genomic medicine: new frontiers and new challenges. 2013 , 59, 158-67	50
1047	Reflections on the founding of the International Cancer Genome Consortium. 2013 , 59, 18-21	5
1046	Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. 2013 , 23, 93-106	203
1045	Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. 2013 , 21, 91-100	84
1044	Parameter space exploration within dynamic simulations of signaling networks. 2013 , 10, 103-20	3
1043	Developmental signaling pathways in cancer stem cells of solid tumors. 2013 , 1830, 2481-95	133
1042	Leukemias. 2013 , 675-690	
1041	Biomarker Discovery Strategies: DNA, RNA, and Protein. 2013 , 401-416	
1040	Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. 2013 , 52, 214-24	58

1039	Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. 2013 , 34, 330-7	4
1038	MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. 2013 , 229, 99-110	58
1037	Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. 2013 , 229, 441-8	60
1036	Affinity-based microarrays for proteomic analysis of cancer tissues. 2013 , 7, 8-15	27
1035	Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/ β -catenin. 2013 , 58, 622-4	10
1034	What are the best routes to effectively model human colorectal cancer?. 2013 , 7, 178-89	35
1033	Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. 2013 , 340, 227-33	16
1032	Nervous system regulation of the cancer genome. 2013 , 30 Suppl, S10-8	32
1031	Noncanonical roles of the immune system in eliciting oncogene addiction. 2013 , 25, 246-58	10
1030	Rationale and clinical use of multitargeting anticancer agents. 2013 , 13, 536-42	27
1029	The effect of one additional driver mutation on tumor progression. 2013 , 6, 34-45	26
1028	Applying ecological and evolutionary theory to cancer: a long and winding road. 2013 , 6, 1-10	57
1027	CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. 2013 , 152, 1077-90	113
1026	A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. 2013 , 133, 2759-68	37
1025	Apoptosis drives cancer cells proliferate and metastasize. 2013 , 17, 205-11	45
1024	Molecular dissection of microsatellite instable colorectal cancer. 2013 , 3, 502-11	68
1023	The human kinome and kinase inhibition. 2013 , Chapter 2, Unit2.9	43
1022	Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. 2013 , 5, 51-63	65

1021	Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. 2013 , 98, E364-9	157
1020	Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. 2013 , 8, 79-103	125
1019	MSCs in Solid Tumors and Hematological Malignancies: From Basic Biology to Therapeutic Applications. 2013 , 209-235	
1018	Physical break-down of the classical view on cancer cell invasion and metastasis. 2013 , 92, 89-104	34
1017	Lessons from the cancer genome. 2013 , 153, 17-37	912
1016	The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. 2013 , 12, 1166-79	126
1015	Advances for studying clonal evolution in cancer. 2013 , 340, 212-9	60
1014	Genomics and epigenomics of colorectal cancer. 2013 , 5, 205-19	25
1013	Heterogeneity of tumor-induced gene expression changes in the human metabolic network. 2013 , 31, 522-9	279
1012	Clinical relevance of cancer genome sequencing. 2013 , 19, 2011-8	14
1011	Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution. 2013 , 32, 325-40	128
1010	Exome resequencing identifies potential tumor-suppressor genes that predispose to colorectal cancer. 2013 , 34, 1026-34	44
1009	Detection of cadherin-17 in human colon cancer LIM1215 cell secretome and tumour xenograft-derived interstitial fluid and plasma. 2013 , 1834, 2372-9	30
1008	Colorectal Cancer. 2013 , 722-732	
1007	Cancer genetics and the cardiotoxicity of the therapeutics. 2013 , 61, 267-74	49
1006	The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. 2013 , 13, 412-24	345
1005	Prognostic role of p53 messenger ribonucleic acid expression in patients after curative resection for stage I to III colorectal cancer: association with colon cancer stem cell markers. 2013 , 216, 1063-9	7
1004	Colorectal Cancer and Its Molecular Subsystems: Construction, Interpretation, and Validation. 2013 , 107-132	1

1003	The detection and implication of genome instability in cancer. 2013 , 32, 341-52	100
1002	Challenges for the application of DNA methylation biomarkers in molecular diagnostic testing for cancer. 2013 , 13, 283-94	19
1001	Role of targeted agents in metastatic colorectal cancer. 2013 , 8, 83-96	52
1000	RNA-Seq and human complex diseases: recent accomplishments and future perspectives. 2013 , 21, 134-42	163
999	The TRAIL of oncogenes to apoptosis. 2013 , 39, 343-54	29
998	Network Medicine: Disease Genes in Molecular Networks. 2013 , 133-151	
997	Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. 2013 , 1284, 1-5	207
996	Carcinogenesis. 2013 , 107-146	17
995	Translational utility of next-generation sequencing. 2013 , 102, 137-9	29
994	Cancer networks and beyond: interpreting mutations using the human interactome and protein structure. 2013 , 23, 219-26	19
993	Functional proteomics, human genetics and cancer biology of GIPC family members. 2013 , 45, e26	52
992	The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly. 2013 , 27, 5083-93	61
991	p120catenin alteration in cancer and its role in tumour invasion. 2013 , 368, 20130015	12
990	Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. 2013 , 11, 115-129	2
989	From human genome to cancer genome: the first decade. 2013 , 23, 1054-62	103
988	Central role of RET in thyroid cancer. 2013 , 5, a009233	68
987	GNAS is not involved in gastrointestinal tumour formation in Peutz-Jeghers syndrome. 2013 , 12, 581-2	3
986	High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. 2013 , 7, 9867-80	91

985	An integrated approach to identify causal network modules of complex diseases with application to colorectal cancer. 2013 , 20, 659-67	50
984	A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. 2013 , 19, 2061-70	46
983	Phospholipase D inhibitor enhances radiosensitivity of breast cancer cells. 2013 , 45, e38	19
982	Personalized chemotherapy profiling using cancer cell lines from selectable mice. 2013 , 19, 1139-46	21
981	Getting personal with neoantigen-based therapeutic cancer vaccines. 2013 , 1, 11-5	133
980	5-hydroxymethylcytosine profiling as an indicator of cellular state. 2013 , 5, 655-69	46
979	Zinc finger protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage. 2013 , 12, 2033-41	15
978	Identification of driver genes in microsatellite-unstable colorectal cancers. 2013 , 2, 515-523	
977	Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. 2013 , 14, 888-96	20
976	Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. 2013 , 34, 803-11	87
975	A transposon-based analysis of gene mutations related to skin cancer development. 2013 , 133, 239-48	36
974	Androgen receptor-target genes in african american prostate cancer disparities. 2013 , 2013, 763569	36
973	Chemoresistance and Cancer-Related Inflammation: Two Hallmarks of Cancer Connected by an Atypical Link, PKC δ <i>Frontiers in Oncology</i> , 2013 , 3, 232	5-3 13
972	Precancerous lesions in colorectal cancer. 2013 , 2013, 457901	17
971	Modeling tumor evolutionary dynamics. 2012 , 3, 480	8
970	The human cell surfaceome of breast tumors. 2013 , 2013, 976816	3
969	Network signatures of survival in glioblastoma multiforme. <i>PLoS Computational Biology</i> , 2013 , 9, e1003237	51
968	p110 β PI3 kinase pathway: emerging roles in cancer. <i>Frontiers in Oncology</i> , 2013 , 3, 40	5-3 36

967	A multiplexed luciferase-based screening platform for interrogating cancer-associated signal transduction in cultured cells. 2013 , e50369	5
966	Mutations in LRRC50 predispose zebrafish and humans to seminomas. 2013 , 9, e1003384	29
965	Guanine holes are prominent targets for mutation in cancer and inherited disease. 2013 , 9, e1003816	24
964	Systematic tracking of dysregulated modules identifies novel genes in cancer. 2013 , 29, 1553-61	53
963	Pathology and genetics of uveal melanoma. 2013 , 45, 18-27	23
962	Frameshift mutations of axon guidance genes ROBO1 and ROBO2 in gastric and colorectal cancers with microsatellite instability. 2013 , 45, 645-50	21
961	Implementing genomic medicine in pathology. 2013 , 20, 238-44	15
960	Tumours associated with BAP1 mutations. 2013 , 45, 116-26	192
959	N-glycoprotein SRMATlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. 2013 , 12, 1005-16	42
958	BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 2013 , 12, 2950-61	14
957	Identification of Insertion Deletion Mutations from Deep Targeted Resequencing. 2013 , 4,	1
956	Exploring functional variant discovery in non-coding regions with SInBaD. 2013 , 41, e7	20
955	Targeting Drugs to Cancer: A Tough Journey to the Tumor Cell. 2013 , 509-542	
954	The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. 2013 , 14, r106	78
953	Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. 2013 , 88, 172-81	23
952	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. 2013 , 4, 363	64
951	Genomic instability and colon carcinogenesis: from the perspective of genes. <i>Frontiers in Oncology</i> , 2013 , 3, 130	5:3 42
950	An APC:WNT Counter-Current-Like Mechanism Regulates Cell Division Along the Human Colonic Crypt Axis: A Mechanism That Explains How APC Mutations Induce Proliferative Abnormalities That Drive Colon Cancer Development. <i>Frontiers in Oncology</i> , 2013 , 3, 244	5:3 36

949	Review of biological network data and its applications. 2013 , 11, 200-10	57
948	Hierarchical Bayesian analysis of somatic mutation data in cancer. 2013 , 7,	3
947	Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas. 2013 , 26, 646-53	35
946	A new mathematical model for progression of colorectal cancer. 2013 ,	
945	Coordinated regulation of p31(Comet) and Mad2 expression is required for cellular proliferation. 2013 , 12, 3824-32	9
944	Invasive cancers are not necessarily from preformed in situ tumours - an alternative way of carcinogenesis from misplaced stem cells. 2013 , 17, 921-6	24
943	IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer. 2013 , 94, 203-11	38
942	MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). 2013 , 288, 9508-18	138
941	Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. 2013 , 19, 3925-35	13
940	The delicate balance of melanoma immunotherapy. 2013 , 2, e5	21
939	BRCC2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway. 2013 , 4, e757	17
938	Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?. 2013 , 19, 2794-6	2
937	The future of colorectal cancer: implications of screening. 2013 , 62, 1387-9	6
936	Aneuploidy in health, disease, and aging. 2013 , 201, 11-21	86
935	Genetic heterogeneity of diffuse large B-cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 1398-403	11.5 419
934	p53 mutations associated with aging-related rise in cancer incidence rates. 2013 , 12, 2468-78	27
933	DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. 2013 , 229, 173-85	62
932	POPULATION GENETICS OF NEUTRAL MUTATIONS IN EXPONENTIALLY GROWING CANCER CELL POPULATIONS. 2013 , 23, 230-250	46

931	Identification of Sleeping Beauty transposon insertions in solid tumors using linker-mediated PCR. 2013 , e50156	2
930	Will we cure cancer by sequencing thousands of genomes?. 2013 , 6, 57	2
929	Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers. 2013 , 19, 864-882	4
928	Can mouse models of cancer reliably improve clinical trial outcome?. 2013 , 3, 119-130	1
927	Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer. 2013 , 5, 27-35	2
926	Label-free whole-cell phenotypic diagnostics for cancer. 2013 , 54-67	1
925	The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer - a Comprehensive review. 2013 , 4, 281-95	64
924	Single nucleotide polymorphism array analysis of microsatellite-stable, diploid/near-diploid colorectal carcinomas without the CpG island methylator phenotype. 2013 , 5, 173-178	6
923	Advances in biophotonics detection of field carcinogenesis for colon cancer risk stratification. 2013 , 4, 251-61	42
922	DNA Damage, DNA Repair and Cancer. 2013 ,	26
921	Colorectal Cancer: A Pathology of the Colon-Rectum and A Disease of the Genome. 2013 , 03,	1
920	From QTL to QTN: candidate gene set approach and a case study in porcine IGF1-FoxO pathway. 2013 , 8, e53452	5
919	Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. 2013 , 8, e64271	61
918	TUSC1, a putative tumor suppressor gene, reduces tumor cell growth in vitro and tumor growth in vivo. 2013 , 8, e66114	23
917	The transcriptional co-repressor myeloid translocation gene 16 inhibits glycolysis and stimulates mitochondrial respiration. 2013 , 8, e68502	8
916	Targeted re-sequencing identified rs3106189 at the 5' UTR of TAPBP and rs1052918 at the 3' UTR of TCF3 to be associated with the overall survival of colorectal cancer patients. 2013 , 8, e70307	3
915	CorSig: a general framework for estimating statistical significance of correlation and its application to gene co-expression analysis. 2013 , 8, e77429	4
914	Analysis of LGR4 receptor distribution in human and mouse tissues. 2013 , 8, e78144	34

913	Development of a high-throughput three-dimensional invasion assay for anti-cancer drug discovery. 2013 , 8, e82811	23
912	Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancer. 2013 , 8, e83859	23
911	Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. 2013 , 4, 21	129
910	Drug resistance: as complex and diverse as the disease itself. 921-928	
909	Epigenetics, Probiotic Metabolites and Colon Cancer Prevention: An Overview of Progress, Opportunities and Challenges. 2013 , 1, 60-69	4
908	Identification of human disease genes from interactome network using graphlet interaction. 2014 , 9, e86142	10
907	GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers. 2014 , 9, e87966	33
906	FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells. 2014 , 9, e90370	8
905	S-score: a scoring system for the identification and prioritization of predicted cancer genes. 2014 , 9, e94147	7
904	Molecular Radiation Biology. 2014 , 43-61	0
903	Colorectal cancer: from prevention to personalized medicine. 2014 , 20, 6786-808	202
902	Controversies in Adjuvant Chemotherapy. 2014 , 177-199	1
901	Intestinal stem cells and the colorectal cancer microenvironment. 2014 , 20, 1898-909	30
900	The Complexity of Colorectal Cancer Biology â Putting Bricks on the Path to Personalized Medicine. 2014 ,	0
899	Cancer of the Colon and Gastrointestinal Tract. 2014 ,	
898	. 2014 ,	4
897	4. Der virtuelle Patient â Systembiologie als Chance fr eine individualisierte Medizin.	
896	RNA-guided isomerization of uridine to pseudouridine--pseudouridylation. 2014 , 11, 1483-94	81

895	Insights into cancer biology through next-generation sequencing. 2014 , 14 Suppl 6, s71-7	2
894	Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer. 2014 , 10, 3286-96	1
893	FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. 2014 , 74, 7487-97	44
892	CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. 2014 , 6, 1571-84	63
891	Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. 2014 , 60, 2-13	12
890	Antigen-specific vaccines for cancer treatment. 2014 , 10, 3332-46	91
889	A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. 2014 , 15, 473	52
888	Elevated DDX21 regulates c-Jun activity and rRNA processing in human breast cancers. 2014 , 16, 449	40
887	Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. 2014 , 14, 115	31
886	Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma. 2014 , 22, 589-99	11
885	RNA editing in RHOQ promotes invasion potential in colorectal cancer. 2014 , 211, 613-21	67
884	Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. 2014 , 33, 347-57	71
883	Does the immune system naturally protect against cancer?. 2014 , 5, 197	141
882	Vaccines against Cancer. 2014 ,	
881	Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers. <i>PLoS Computational Biology</i> , 2014 , 10, e1003545	5 16
880	Identification of drivers from cancer genome diversity in hepatocellular carcinoma. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 11142-60	6.3 35
879	Culturing intestinal stem cells: applications for colorectal cancer research. 2014 , 5, 169	6
878	Cancer Microenvironments as Therapeutic Targets. 2014 , 412-422	

877	Genomic landscape of metastatic colorectal cancer. 2014 , 5, 5457	49
876	Approaches for recognizing disease genes based on network. 2014 , 2014, 416323	36
875	Merkel cell polyomavirus: molecular insights into the most recently discovered human tumour virus. <i>Cancers</i> , 2014 , 6, 1267-97	6.6 27
874	Identification and analysis of driver missense mutations using rotation forest with feature selection. 2014 , 2014, 905951	1
873	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. 2014 , 15, 190	179
872	Inhibition of C-terminal binding protein attenuates transcription factor 4 signaling to selectively target colon cancer stem cells. 2014 , 13, 3506-18	20
871	Novel Lys63-linked ubiquitination of IKK α induces STAT3 signaling. 2014 , 13, 3964-76	18
870	Epigenomics â Understanding the Epigenetic Landscape of Cells. 2014 ,	
869	Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. 2014 , 5, 5812	137
868	The Age Specific Incidence Anomaly Suggests that Cancers Originate During Development. 2014 , 09, 193-204	1
867	Epigenetic Therapy of Cancer. 2014 ,	
866	Advances in Tumor Immunology and Immunotherapy. 2014 ,	0
865	Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models. 2014 , 63, 707-9	14
864	Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. 2014 , 24, 701-12	99
863	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. 2014 , 16, 779-91	116
862	Genome-wide DNA methylation analysis of formalin-fixed paraffin embedded colorectal cancer tissue. 2014 , 53, 537-48	35
861	Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. 2014 , 232, 428-35	118
860	Understanding health care delivery as a complex system: achieving best possible health outcomes for individuals and communities by focusing on interdependencies. 2014 , 20, 1005-9	28

859	Prioritization of orphan disease-causing genes using topological feature and GO similarity between proteins in interaction networks. 2014 , 57, 1064-71		17
858	Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations. 2014 , 13, 3423-35		53
857	An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor- β in human breast cancer. 2014 , 16, R57		17
856	Evolving concepts of tumor heterogeneity. 2014 , 4, 69		49
855	DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes. 2014 , 6, 44		21
854	Interaction-based discovery of functionally important genes in cancers. 2014 , 42, e18		21
853	Proteomics, genomics and transcriptomics: their emerging roles in the discovery and validation of colorectal cancer biomarkers. 2014 , 11, 179-205		21
852	Impact of chromosomal instability on colorectal cancer progression and outcome. <i>BMC Cancer</i> , 2014 , 14, 121	4.8	28
851	MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. <i>BMC Cancer</i> , 2014 , 14, 656	4.8	55
850	Mutational profiling of kinases in glioblastoma. <i>BMC Cancer</i> , 2014 , 14, 718	4.8	39
849	Oncogene withdrawal engages the immune system to induce sustained cancer regression. 2014 , 2, 24		15
848	Deep sequencing of the X chromosome reveals the proliferation history of colorectal adenomas. 2014 , 15, 437		0
847	Cancer progression modeling using static sample data. 2014 , 15, 440		18
846	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. 2014 , 2, 42		148
845	Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. 2014 , 2, 167		45
844	Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. 2014 , 74, 387-97		42
843	Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"? 2014 , 22, 555-61		35
842	CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer. 2014 , 20, 3261-71		26

841	A 'complex solution' to a 'complex' problem: tackling the complexity of cancer with botanicals. 2014 , 23, 568-78		6
840	Practicing pathology in the era of big data and personalized medicine. 2014 , 22, 1-9		29
839	Integration of Protein Network Activation Mapping Technology for Personalized Therapy. 2014 , 367-383		
838	NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. 2014 , 2014, bau015		47
837	Twist1-induced dissemination preserves epithelial identity and requires E-cadherin. 2014 , 204, 839-56		145
836	Omics Approaches in Breast Cancer. 2014 ,		8
835	Breast Cancer Genomics. 2014 , 53-103		
834	Structure-functional prediction and analysis of cancer mutation effects in protein kinases. 2014 , 2014, 653487		23
833	Prognostic Significance of E-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. <i>Frontiers in Oncology</i> , 2014 , 4, 118	5-3	50
832	Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. 2014 , 13, 21		18
831	PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 6395-400	11-5	55
830	Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. 2014 , 22, 251-256		126
829	Clinically significant missense variants in human GALNT3, GALNT8, GALNT12, and GALNT13 genes: intriguing in silico findings. 2014 , 115, 313-27		13
828	Charting the molecular links between driver and susceptibility genes in colorectal cancer. 2014 , 445, 734-8		4
827	MDM2 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. 2014 , 40, 785-800		325
826	Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. 2014 , 147, 418-29.e8		126
825	Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38 β modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. 2014 , 344, 110-118		37
824	Transitioning from genotypes to epigenotypes: why the time has come for medulloblastoma epigenomics. 2014 , 264, 171-85		36

823	The '-omics' revolution and oesophageal adenocarcinoma. 2014 , 11, 19-27	25
822	Origins of aberrant DNA methylation in acute myeloid leukemia. 2014 , 28, 1-14	98
821	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. 2014 , 143, 385-92	43
820	Genetic alterations and personalized medicine in melanoma: progress and future prospects. 2014 , 106, djt435	57
819	Masking epistasis between MYC and TGF- β pathways in antiangiogenesis-mediated colon cancer suppression. 2014 , 106, dju043	12
818	β Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. 2014 , 6, 225ra28	95
817	Genetic unraveling of colorectal cancer. 2014 , 35, 5067-82	9
816	Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. 2014 , 27, 86-95	19
815	Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm. 2014 , 35, 643-53	14
814	Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. 2014 , 35, 318-28	16
813	Overexpression of sirt7 exhibits oncogenic property and serves as a prognostic factor in colorectal cancer. 2014 , 20, 3434-45	88
812	A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. 2014 , 13, 1918-28	69
811	Cancer Immunotherapy Meets Oncology. 2014 ,	
810	Systems vaccinology for cancer vaccine development. 2014 , 13, 711-9	2
809	Molecular Testing in Cancer. 2014 ,	1
808	Prostate Cancer Genomics as a Driver of Personalized Medicine. 2014 , 233-245	1
807	Genomics of Colorectal Cancer. 2014 , 247-264	2
806	An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. 2014 , 58, 282-91	12

805	The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. 2014 , 17, 805-21	18
804	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. 2014 , 46, 588-94	124
803	Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. 2014 , 21, 205-12	60
802	Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?. 2014 , 35, 7369-82	40
801	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. 2014 , 232, 274-82	40
800	Colorectal cancer risk and patients' survival: influence of polymorphisms in genes somatically mutated in colorectal tumors. 2014 , 25, 759-69	13
799	Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer. 2014 , 9, 77-92	21
798	Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. 2014 , 11, 149-55	145
797	Temporal production of the signaling lipid phosphatidic acid by phospholipase D2 determines the output of extracellular signal-regulated kinase signaling in cancer cells. 2014 , 34, 84-95	77
796	Genomic sequencing for cancer diagnosis and therapy. 2014 , 65, 33-48	30
795	Lobular breast cancer: pathology, biology, and options for clinical intervention. 2014 , 62, 7-21	15
794	Wnt signaling in adult intestinal stem cells and cancer. 2014 , 26, 570-9	253
793	Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing. <i>Briefings in Bioinformatics</i> , 2014 , 15, 244-55	13.4 32
792	COLD-PCR enriches low-level variant DNA sequences and increases the sensitivity of genetic testing. 2014 , 1102, 623-39	6
791	Tumor heterogeneity in the clinic: is it a real problem?. 2014 , 6, 43-51	63
790	Sequential expression of miR-182 and miR-503 cooperatively targets FBXW7, contributing to the malignant transformation of colon adenoma to adenocarcinoma. 2014 , 234, 488-501	48
789	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. 2014 , 120, 2316-24	136
788	Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell. 2014 , 20, 704-15	24

787	Deletion of olfactomedin 2 induces changes in the AMPA receptor complex and impairs visual, olfactory, and motor functions in mice. 2014 , 261, 802-11	20
786	Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/ β -catenin signaling. 2014 , 106, djt373	123
785	Querying neXtProt nanopublications and their value for insights on sequence variants and tissue expression. 2014 , 29, 3-11	11
784	A network-based, integrative approach to identify genes with aberrant co-methylation in colorectal cancer. 2014 , 10, 180-90	7
783	Antinuclear antibodies defining autoimmunity pathways. 2014 , 16, 104	9
782	Molecular Diagnostics for Dermatology. 2014 ,	1
781	Endophytic fungi with antitumor activities: Their occurrence and anticancer compounds. 2016 , 42, 454-73	67
780	Risk of thrombosis in patients with β -thalassemia. 2020 , 220, 186-187	
779	Efficacité et tolérance de TNF α et tocilizumab dans la maladie de TAKAYASU: étude multicentrique européenne de 203 patients. 2020 , 41, A22	
778	Association of cagA+ Helicobacter pylori strains with high urease activity and dyspepsia in Mexican adults. 2020 , 85, 404-409	
777	In silico pathway analysis based on chromosomal instability in breast cancer patients. 2020 , 13, 168	1
776	71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results. 2020 , 31, S1446-S1447	6
775	98P Low prognostic nutritional index is independently associated with poorer survival in patients receiving immune checkpoint inhibitors. 2020 , 31, S1457	
774	A discussion of the paper "emdata18: A chemical thermodynamic database for hydrated Portland cements and alkali-activated materials" 2020 , 138, 106224	1
773	Utilising an Accelerated Delphi Process to Develop Guidance and Protocols for Telepresence Applications in Remote Robotic Surgery Training. 2020 , 22, 23-33	8
772	The Acceptability of Tools for the Data Marketplace among Firms Using Market Research Online Communities. 2020 , 176, 1613-1620	2
771	Arthroscopic Lysis of Adhesions With Manipulation for Management of Late-Presenting Stiffness After Total Knee Arthroplasty. 2020 , 6, 761-765	3
770	A 69-Year-Old Man With Chronic Cough and Recurrent Pneumonia. 2020 , 158, e283-e287	

- 769 Using citizen science to understand the prerequisites for physical activity among adolescents in low socioeconomic status neighborhoods - The NESLA study. **2020**, 65, 102387 6
- 768 Using Virtual Reality to Examine Emotional Hotspots and Intrusions in the Trauma Film Paradigm. **2020**, 9, 370-380 3
- 767 Ocular myasthenia gravis and risk factors for developing a secondary generalisation: Description of a Spanish series. **2020**,
- 766 Assessment of metals pollution in sediments and tailings of Klein Aub and Oamites mine sites, Namibia. **2020**, 2, 100006 5
- 765 Deformation heterogeneity in laser-welded Eurofer. **2020**, 161, 111860 1
- 764 AM repair of 100 million turbine blades. **2020**, 75, 381
- 763 Big ear keloid response to PDL laser. **2021**, 157, 217
- 762 A new method of interface tension measurement of a magnetic fluid drop. **2020**, 7, 101152 0
- 761 On the non-existence of negative weight derivations of the new moduli algebras of singularities. **2020**, 564, 199-246 4
- 760 Maladies neuromusculaires. **2020**, 3, eS5-eS6
- 759 Pourquoi et comment traiter l'hyperesthésie dentinaire. **2020**, 59, 52-56
- 758 Upscaled DEM-CFD model for vibrated fluidized bed based on particle-scale similarities. **2020**, 31, 4598-4618 11
- 757 Acute myocardial infarction complicating Russell's viper bite, a case report. **2020**, 315, e241
- 756 Facing the test of time: a service evaluation of maxillofacial trauma management over 5 years. **2020**, 58, e188
- 755 Temporomandibular joint dysfunction: relationship between mental health and MRI findings. **2020**, 58, e224
- 754 Pressure Injuries Among Critical Care Patients. **2020**, 32, 573-587 1
- 753 Oxidation and corrosion protection of ZG12Cr9Mo1Co1NiVNbNB (CB2) ferritic stainless steel by inorganic composite coatings at 650 °C. **2020**, 177, 109000 6
- 752 Intermittent disturbance benefits colony size, biomass and dominance of *Microcystis* in Lake Taihu under field simulation condition. **2020**, 99, 101909 7

- 751 Cardiac sarcoidosis as an incidental finding: A case report. **2020**, 49, 783-787
- 750 Highly efficient ~3.4 Th emission of Er3+-doped TeO2 based glasses via resonant energy transfer and multi-phonon relaxation processes. **2020**, 108, 110387 6
- 749 Epigenome-wide signature of infant cortisol response to stress. **2020**, 119, 104987
- 748 Graphical abstract TOC. **2020**, 30, 127707
- 747 Efficacité et tolérance du tralokinumab associé des corticostéroïdes topiques chez des patients adultes atteints de dermatite atopique modérée à sévère: résultats de l'essai ECZTRA 3 de phase 3. **2020**, 147, A340-A341
- 746 Three-dimensional (3D) vascular cell culture model for disease modeling and screening therapies. **2020**, 315, e32
- 745 IKK kinase 2 (IKK2) is not essential for platelet activation. **2020**, 315, e93
- 744 Aronia melanocarpa anthocyanin extracts are an effective regulator of suppressor of cytokine signaling 3-dependent insulin resistance in HepG2 and C2C12 cells. **2020**, 75, 104258 5
- 743 Essential anatomy for total mesorectal excision and lateral lymph node dissection, in both trans-abdominal and trans-anal perspective. **2021**, 19, e462-e474 1
- 742 Rôle des ions calcium libérés par un pansement d'alginate de calcium sur les cellules NK. **2020**, 147, A360
- 741 Primary intraosseous carcinoma arising in dentigerous cyst: Case report. **2020**, 76, 530-533 3
- 740 A Lesson From the COVID-19 Pandemic: Preparing Future Health Care Professionals. **2020**, 59, 718-719 1
- 739 15261 Lack of tuberculosis reactivation in 12,319 patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab: An ad hoc analysis of pooled safety data from 28 clinical trials. **2020**, 83, AB33
- 738 16003 Orally administered EDP1815, a monoclonal strain of Prevotella histicola, has potent systemic anti-inflammatory effects. **2020**, 83, AB52 1
- 737 13396 Public social media consultations for skin conditions: An online survey. **2020**, 83, AB119
- 736 15396 Factors affecting patient preferences between teledermatology and traditional face-to-face dermatology encounters. **2020**, 83, AB149
- 735 Corrigendum to "Gordon CE, Perrone RD. Tolvaptan or transplant: why wait?" *Kidney Int.* 2020;98:286-289. **2020**, 98, 1622
- 734 Work-family spillover stress predicts health outcomes across two decades. **2020**, 265, 113516 3

- 733 Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. **2021**, 20, 137-147.e1 3
- 732 A study of the mechanical properties and appearance of efflorescence in paving bricks under different curing environments. **2020**, 265, 120148 3
- 731 Polyurethane film prepared from ball-milled algal polyol particle and activated carbon filler for NH-N removal. *Heliyon*, **2020**, 6, e04590 3.6 13
- 730 Natural capital protection indicators: Measuring performance in achieving the Sustainable Development Goals for green growth transition. **2020**, 8, 100069 9
- 729 Surgeons and the Opioid Crisis. **2020**, 231, 648-649
- 728 Perforating foreign body causing incomplete facial paralysis. **2020**, 30, 100370
- 727 Antihypertensive drugs. **2020**, 215-226
- 726 COMPARATIVE ASSESSMENT OF INTIMA-MEDIA THICKNESS OF CAROTID ARTERY IN PATIENTS WITH BEHCETÂB DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS. **2020**, 157, A48
- 725 Extracellular Protein Radical Formation Increases After Damage to Articular Cartilage. **2020**, 159, S106
- 724 G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers. **2020**, 594, 4201-4232 24
- 723 Conceptualizing grade inflation. **2020**, 78, 102037
- 722 Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study. **2020**, 141, 185-192 0
- 721 Collaborative research or research collaboration in intensive care nursing. **2020**, 31, 161-163
- 720 Examining mediators of change in wellbeing, stress, and depression in a blended, Internet-based, ACT intervention for university students. **2020**, 22, 100343 5
- 719 Reply. **2020**, 72, 2216
- 718 Applicabilit'des stades de Demirjian et de lândice de maturation de la troisiïme molaire (IM3) de Camfiïe dans lâEstimation de lâge majeur dans une population shgalaïse. **2020**, 11, 150-157
- 717 An efficient stress intensity factor evaluation method for interacting arbitrary shaped 3D cracks. **2020**, 109, 102767 3
- 716 Identification of Novel and Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. **2020**, 11, 552971 6

715	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , 2020 , 12,	6.6	12
714	Ancient burial hints at modern bias. 2020 , 248, 22		
713	45. Identification of predicted neoantigen vaccine candidates in follicular lymphoma patients. 2020 , 244, 17		
712	Prrx1 Fibroblasts Represent a Pro-fibrotic Lineage in the Mouse Ventral Dermis. 2020 , 33, 108356		15
711	Interaction of super-critical CO2 with mudrocks: Impact on composition and mechanical properties. 2020 , 102, 103163		5
710	The Great escape? A liberal perspective on assisted suicide for prisoners. 2020 , 15, 100566		0
709	Effects of different light sources used for dental operating microscope illumination on the visual function of operators. 2020 , 62, 363-371		1
708	Tailoring NMR experiments for structural characterization of amorphous biological solids: A practical guide. 2020 , 109, 101686		11
707	[Drawing lessons from the pandemic for a new pharmacy practice]. 2020 , 59, 44-46		
706	First-principles study on stability, electronic and optical properties of Janus-functionalized ZnO monolayer and bilayer for optoelectronic device. 2020 , 181, 109749		1
705	Aims and Scope of the Volume. 2020 , ix		
704	Discretization of the system of equations for fluid flow through porous media. 2020 , 70, 261-272		
703	Sukano adds impact modifier masterbatch to portfolio for recycled PET. 2020 , 2020, 4-5		
702	Bacteriophage biocontrol to fight Listeria outbreaks in seafood. 2020 , 145, 111682		8
701	Sliver defect formation in single crystal Ni-based superalloy castings. 2020 , 196, 109138		8
700	Apport de la clinique des traumatismes dans la prise en charge de lâhyperphagie boulimique des personnes obèses. 2020 , 16, 17-19		
699	Neutrophil-lymphocyte index as prognostic factor for overall survival and disease-free survival in breast cancer patients. 2020 , 33, 137-144		
698	Metastatic breast cancer: Is systemic therapy the only effective treatment?. 2020 , 33, 169		

697	Network-based disease gene prioritization based on Protein-Protein Interaction Networks. 2020 , 9, 1		0
696	PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6
695	Progress in Neoantigen Targeted Cancer Immunotherapies. 2020 , 8, 728		12
694	Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. 2020 , 10, 8098-8110		21
693	A Genetic Analysis of Tumor Progression in Drosophila Identifies the Cohesin Complex as a Suppressor of Individual and Collective Cell Invasion. 2020 , 23, 101237		6
692	Outstanding dispersion of CeO ₂ on reduced graphene oxide. Implications for highly dispersed Pd catalysts. 2020 , 109, 108061		2
691	Identification of novel tumor suppressors for pancreatic cancer initiation and progression from normal human pancreatic acinar cells. 2020 , 138, S29-S30		1
690	Effect of Yoga and Ergonomic Interventions on Stress and AROM for Employees in Sedentary Work Environments. 2020 , 101, e56-e57		
689	Rasch Analysis of the PROMIS Self-Efficacy for Managing Symptoms in Individuals With Chronic Diseases. 2020 , 101, e61		
688	Striding Through Summer: Improvements in Gait and Function following a Gait Camp. 2020 , 101, e102		
687	Probability pooling for dependent agents in collective learning. 2020 , 288, 103371		0
686	A new graphical approach for simultaneous targeting and design of mass exchange networks. 2020 , 142, 107061		6
685	Proprioception but not cardiac interoception is related to the rubber hand illusion. 2020 , 132, 361-373		18
684	16 - Urine Cytokine Levels and Albuminuria Progression Over 2 Years in Youth With Type 2 Diabetes. 2020 , 44, S7		
683	In This Issue. 2020 , 98, 1061		
682	Understanding the role of Ca segregation on thermal stability, electrical resistivity and mechanical strength of nanostructured aluminum. 2020 , 798, 140108		9
681	Hypermethylated promoters of genes and as potential novel diagnostic biomarkers in colorectal cancer. 2020 , 12, 1677-1688		5
680	When non-coding is not enough. 2020 , 217,		4

679	Genetic Colorectal Cancer and Adenoma Risk Variants Are Associated with Increasing Cumulative Adenoma Counts. 2020 , 29, 2269-2276		3
678	Mutant Proteomics of Lung Adenocarcinomas Harboring Different Mutations. <i>Frontiers in Oncology</i> , 2020 , 10, 1494	5.3	4
677	Transient Receptor Potential (TRP) Channels in Head-and-Neck Squamous Cell Carcinomas: Diagnostic, Prognostic, and Therapeutic Potentials. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
676	Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. 2020 , 16, 2959-2979		12
675	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. <i>Cancers</i> , 2020 , 12,	6.6	17
674	Ubiquitination and Deubiquitination in Melanoma Research and Clinically Relevant Outcomes. 2020 ,		1
673	Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	5
672	Prise en charge de l'allergie chez les patients asthmatiques sévères. 2020 , 12, 2S423-2S433		
671	Computational methods for detecting cancer hotspots. 2020 , 18, 3567-3576		5
670	Improving existing analysis pipeline to identify and analyze cancer driver genes using multi-omics data. 2020 , 10, 20521		5
669	[Cervicofacial cellulitis complicated by internal jugular vein thrombosis]. 2020 , 147, 643-647		
668	Linder hypothesis revisited: Does it hold for services trade?. 2020 , 195, 109469		4
667	Observations of internal tides off the coast of Shandong Peninsula, China. 2020 , 245, 106944		3
666	Erratum to "Emergency Medical Services resource capacity and competency amid COVID-19 in the United States: preliminary findings from a national survey" [Heliyon 6 (5) (May 2020) Article e03900]. <i>Heliyon</i> , 2020 , 6, e05134	3.6	
665	Editorial Board. 2020 , 78, A2		
664	Safety and efficacy of apraglutide in patients with short bowel syndrome intestinal failure: a double-blind, crossover, randomized, placebo-controlled, phase 2 trial. 2020 , 40, 436		
663	Systemic Allergic Contact Dermatitis Due to a GORE CARDIOFORM Septal Occluder Device: A Case Report and Literature Review. 2020 , 2, 1867-1871		1
662	177: Evidence-Based Hypofractionated Radiotherapy Uptake in Europe: An Explorative Giro-Hero Analysis. 2020 , 150, S76		

- 661 Malnutrition in hospitalized patients with SARS-CoV-2 infection. **2020**, 40, 448-449 78
- 660 Lower basal net protein breakdown is linked to more impaired muscle quality, physical activity level, lung function, and protein intake in COPD patients and sedentary control subjects. **2020**, 40, 449-450
- 659 Older patients (50+ Y) declining participation in a randomized con-trolled nutritional trial have higher risk of readmissions. **2020**, 40, 465
- 658 How to establish increased protein intake in a blended lifestyle intervention in community-dwelling older adults? Subgroup-analysis of the vitamin rct. **2020**, 40, 500
- 657 Nutrition status and physical development of children with chronic kidney decease C3-C5. **2020**, 40, 520-521 1
- 656 Associations between dietary patterns and insulin resistance in patients with obstructive sleep apnea.. **2020**, 40, 535
- 655 Periodontal tissue loss and visceral fat levels in renal transplant recipients - are they related?. **2020**, 40, 542
- 654 Home-delivered between-meal snacks for fragile elderly people. **2020**, 40, 590-591
- 653 Comparing dietary intake at cancer diagnosis to recommendations and actual need. **2020**, 40, 664
- 652 Calf circumference as an indicator for muscle mass in evaluating sarcopenia. **2020**, 40, 680-681
- 651 Description, prediction and causation: Methodological challenges of studying child and adolescent development. **2020**, 46, 100867 10
- 650 Effectiveness of physical exercise toward decreased fatigue in cervical cancer. **2020**, 30, 127-131
- 649 Syndrome des antiphospholipides et anticoagulants oraux directs. **2020**, 45, S80
- 648 Editorial Board. **2020**, 92, 102493
- 647 [The role of the pharmacist in the detection of Covid-19]. **2020**, 59, 41-43 0
- 646 ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. **2020**, 182, 104922 7
- 645 Maternal separation induces retinal and peripheral blood mononuclear cell alterations across the lifespan of female rats. **2020**, 1749, 147117 3
- 644 A Bioinformatic Analysis of Integrative Mobile Genetic Elements Highlights Their Role in Bacterial Adaptation. **2020**, 28, 767 1

643	Laboratory biomarkers associated with COVID-19 severity and management. <i>Clinical Immunology</i> , 2020 , 221, 108614	9	26
642	Boride formation behaviour and their effect on tensile ductility in cast TiAl-based alloys. 2020 , 195, 109064		7
641	Management of acute stroke. Specific nursing care and treatments in the stroke unit. 2020 ,		1
640	Recent advances in fructose intake and risk of hyperuricemia. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 131, 110795	7.5	11
639	Effect of chemical structure on complexation efficiency of aromatic drugs with cyclodextrins: The example of dibenzazepine derivatives. 2020 , 250, 116957		1
638	An unconditionally stable space-time FE method for the Korteweg-de Vries equation. 2020 , 371, 113297		2
637	Strength and plasticity of amorphous ceramics with self-patterned nano-heterogeneities. 2020 , 134, 102837		4
636	Tomographic imaging of two-phase flow. 2020 , 2, 86-92		2
635	Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death. 2020 , 69, 104992		1
634	Sex-Related Changes in Lipid Status and Cardiovascular Risk at Type 2 Diabetes Mellitus Patients. 2020 , 229, 157		
633	Response to Letter to the Editor on "Diagnostic Utility of Platelet Count/Lymphocyte Count Ratio and Platelet Count/Mean Platelet Volume Ratio in Periprosthetic Joint Infection After Total Knee Arthroplasty". 2020 , 35, 3782-3783		10
632	Surgery during the COVID-19 pandemic. 2020 , 396, e77		
631	List of Referees. 2020 , 66, I		
630	Editorial Board. 2020 , 264, 121480		
629	232 National Cost Savings, Length of Stay Reduction and Preventable Cancer from Expanded Use of Point-of-Care Ultrasound for Small Bowel Obstruction. 2020 , 76, S90		
628	388 Patient-Provided Medication List Verification in the Emergency Department: Improving Compliance and Enhancing Teamwork. 2020 , 76, S149		
627	Changes in Wnt-Dependent Neuronal Morphology Underlie the Anatomical Diversification of Neocortical Homologs in Amniotes. 2020 , 31, 107592		8
626	Investigating spatial convergence of diagnosed dementia, depression and type 2 diabetes prevalence in West Adelaide, Australia. 2020 , 277, 524-530		1

625	Improving Patient Safety by Increasing Patient Access to Blood Pressure Monitoring Kits and a Follow-Up Guide for Postpartum Patients. 2020 , 49, S45	
624	Image-Guided Peripheral Nerve Cryoneurolysis for Pain Relief in Calciphylaxis. 2020 , 31, 1947-1949	0
623	Applying the servicescape model to understand student experiences of a Norwegian academic library. 2020 , 42, 101051	1
622	General care in the management of severe traumatic brain injury: Latin American consensus. 2020 , 44, 500-508	3
621	Universal germline screening for Lynch syndrome in endometrial cancer. 2020 , 159, 252	1
620	Table of Contents. 2020 , 59, A7-A12	
619	First open label study to investigate the use, safety and tolerability of octaplasg [®] in patient blood management in two cardiac surgery centres in France. 2020 , 34, S44-S45	
618	Editorial Board. 2020 , 178, 105872	
617	Let's Take Care Of Our Future. 2020 , 98, 431-432	
616	The distribution of mutations and hotspots in transcription regulators of resistance-nodulation-cell division efflux pumps in tigecycline non-susceptible <i>Acinetobacter baumannii</i> in China. 2020 , 310, 151464	4
615	Occurrence and characteristics of microplastics in the coral reef, sea grass and near shore habitats of Rameswaram Island, India. 2020 , 160, 111674	15
614	Risk of postoperative bleeding following dental extractions in patients on antithrombotic treatment. 2021 , 33, 511-517	0
613	Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients. 2020 , 10,	5
612	HotSpotAnnotations-a database for hotspot mutations and annotations in cancer. 2020 , 2020,	8
611	CARs: Beyond T Cells and T Cell-Derived Signaling Domains. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 8
610	Integrated multi-omics data analyses for exploring the co-occurring and mutually exclusive gene alteration events in colorectal cancer. 2020 , 41, 1588-1599	4
609	Updated risk factors to inform early pancreatic cancer screening and identify high risk patients. 2020 , 485, 56-65	6
608	in Breast and Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 7

607	A novel approach to identify subtype-specific network biomarkers of breast cancer survivability. 2020 , 9, 1	15
606	Update on Alterations in Cancer: Implications for Uveal Melanoma Treatment. <i>Cancers</i> , 2020 , 12, 6.6	8
605	Mathematical modeling of female breast cancer in Japan. 2020 , 13, 2050023	
604	Small molecule-induced simultaneous destabilization of E-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells. 2020 , 18, 38	3
603	Tumor Plasticity and Resistance to Immunotherapy. 2020 , 6, 432-441	46
602	Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells. 2020 , 39, 3893-3909	18
601	An Effective Graph Clustering Method to Identify Cancer Driver Modules. 2020 , 8, 271	2
600	Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. 2020 , 44, 1267-1282	15
599	From cancer to rejuvenation: incomplete regeneration as the missing link (part II: rejuvenation circle). 2020 , 6, FSO610	2
598	Drosophila as a model to understand autophagy deregulation in human disorders. 2020 , 172, 375-409	2
597	Life challenge. <i>Cancer</i> . 2020 , 1-77	
596	p73 - NAV3 axis plays a critical role in suppression of colon cancer metastasis. 2020 , 9, 12	8
595	Tumors of the Gastrointestinal System Including the Pancreas. 2020 , 691-870	
594	APC-E-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. 2020 , 21, 441-451	5
593	NAV3, a Tumor Suppressor Gene, Is Decreased in Uterine Leiomyoma Tissue and Cells. 2020 , 27, 925-934	1
592	Sensitivity analysis methods in the biomedical sciences. 2020 , 323, 108306	30
591	Prognosis, Biology, and Targeting of Dysregulation in Multiple Myeloma. 2020 , 9,	19
590	Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update. <i>Pharmaceutics</i> , 2020 , 12,	6.4 20

589	Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens. 2020 , 156, 104790		14
588	Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, and. <i>Cancers</i> , 2020 , 12,	6.6	9
587	Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation. 2020 , 30, 910-922		12
586	Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians. 2020 , 39, 4299-4311		13
585	A Multistage Murine Breast Cancer Model Reveals Long-Lived Premalignant Clones Refractory to Parity-Induced Protection. 2020 , 13, 173-184		3
584	Cooperative driver pathway discovery via fusion of multi-relational data of genes, miRNAs and pathways. <i>Briefings in Bioinformatics</i> , 2021 , 22, 1984-1999	13.4	1
583	A colorimetric method for screening α -glucosidase inhibitors from flavonoids using 3,3',5,5'-tetramethylbenzidine as a chromogenic probe. 2021 , 197, 111400		10
582	Subacute combined degeneration of the cervical and dorsal spinal cord in a 40-year-old male patient: A case report. 2021 , 16, 13-17		1
581	Pharmacovigilance in the era of social media: Discovering adverse drug events cross-relating Twitter and PubMed. 2021 , 114, 394-402		7
580	Green emission and laser properties of Ho ³⁺ doped titano lead borate (TLB) glasses for colour display applications. 2021 , 293, 121793		5
579	Effects of acoustical descriptors on speech intelligibility in Hong Kong classrooms. 2021 , 171, 107678		4
578	Editorial Board. 2021 , 402, ii		
577	Enabling improved cycling stability of hollow SnO ₂ /C composite anode for lithium-ion battery by constructing a built-in porous carbon support. 2021 , 537, 148052		11
576	Buckling analysis of gusset plates with bolted connections using finite element modeling. 2021 , 176, 106420		1
575	Exploring urban travel patterns using density-based clustering with multi-attributes from large-scaled vehicle trajectories. 2021 , 561, 125301		10
574	General principle of primary and secondary plant metabolites: Biogenesis, metabolism, and extraction. 2021 , 3-23		1
573	[Artificial Intelligence in Thoracic Radiology. A Challenge in COVID-19 Times?]. 2021 , 57, 15-16		1
572	Predicting disease-associated genes: Computational methods, databases, and evaluations. 2021 , 11, e1383		0

571	Acknowledgments. 2021 , xxiii	
570	CFD study of multiphase flow in aerated grit tank. 2021 , 39, 101698	4
569	SARS-CoV-2 RNA detection and persistence in wastewater samples: An experimental network for COVID-19 environmental surveillance in Padua, Veneto Region (NE Italy). 2021 , 760, 143329	35
568	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. 2021 , 39, 235.e5-235.e14	3
567	Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment. 2021 , 11, 609-620	7
566	Random and multi-super-ellipsoidal variables hybrid reliability analysis based on a novel active learning Kriging model. 2021 , 373, 113555	4
565	Influence of planes of anisotropy on physical and mechanical properties of freshwater limestone (Mudstone). 2021 , 268, 121174	5
564	Non-orthogonal stagnation point flow of Maxwell nano-material over a stretching cylinder. 2021 , 120, 105043	8
563	Performance degradation due to anodic failure mechanisms in lithium-ion batteries. 2021 , 502, 229145	12
562	Ketogenic diet as a potential intervention for lipedema. 2021 , 146, 110435	7
561	Achieving sustainable operation for hypersaline membrane distillation applications: A novel strategy based on the critical Reynolds number. 2021 , 499, 114833	5
560	Performance and emission characteristics analysis of Elaeocarpus Ganitrus biodiesel blend using CI engine. 2021 , 288, 119611	5
559	Si@Cu ₃ Si nano-composite prepared by facile method as high-performance anode for lithium-ion batteries. 2021 , 851, 156854	11
558	Blood biomarker algorithms for the diagnosis of mycoplasma pneumoniae respiratory infections. 2021 , 489, 112908	3
557	Global zircon analysis records a gradual rise of continental crust throughout the Neoproterozoic. 2021 , 554, 116654	16
556	Electropolishing of pure metallic titanium in a deep eutectic solvent. 2021 , 14, 102906	5
555	Sources of inefficient power generation by coal-fired thermal power plants in China: A metafrontier DEA decomposition approach. 2021 , 138, 110562	20
554	Editorial Board. 2021 , 164, 114253	

553	Uniting homeostatic plasticity and exosome biology: A revision of the conceptual framework for drug discovery in neurodegenerative diseases?. 2021 , 90, 277-306	
552	Influence of polyaniline on the photocatalytic properties of metal nanocomposites: A review. 2021 , 40, 100339	14
551	Ultra-stable soybean oil-in-water emulsions stabilized by a polymeric surfactant derived from soybean oil. 2021 , 160, 113093	3
550	Mechanical, electronic and optical properties of K ₂ TeX ₆ (X=Cl, Br, I) perovskite derivatives using density functional theory. 2021 , 123, 105579	3
549	Application of microdosimetric concepts in CaCO ₃ :Ce ³⁺ /Dy ³⁺ for megalevel radiation dosimetry. 2021 , 487, 12-24	0
548	A review on synthesis, characterization and application of nanoencapsulated phase change materials for thermal energy storage systems. 2021 , 185, 116326	18
547	Heat transfer analysis of tokamak in-vessel coil water-cooling channel joint. 2021 , 162, 112106	
546	A modeling study on utilizing ultra-thin inorganic HTLs in inverted p-n homojunction perovskite solar cells. 2021 , 213, 1-12	12
545	The characteristics and roles of p53/TrCP1/2 in carcinogenesis. 2021 , 288, 3351-3374	7
544	Full-thickness cartilage graft myringoplasty combined with topical application of bFGF for repair of perforations with extensive epithelialization. 2021 , 48, 601-608	0
543	Exploring the complex relationships and drivers of ecosystem services across different geomorphological types in the Beijing-Tianjin-Hebei region, China (2000-2018). 2021 , 121, 107116	12
542	A simple solution for prefabricated vertical drain with surcharge preloading combined with vacuum consolidation. 2021 , 49, 304-322	5
541	Simulating two-phase flow and geomechanical deformation in fractured karst reservoirs based on a coupled hydro-mechanical model. 2021 , 137, 104543	4
540	Single-pixel imaging for dynamic targets via a non-diffracting beam. 2021 , 139, 106450	3
539	Chromophoric dissolved organic matter in inland waters: Present knowledge and future challenges. 2021 , 759, 143550	20
538	Corrigendum to "Morin decreases cortical pyramidal neuron degeneration via inhibition of neuroinflammation in mouse model of schizophrenia" Int. Immunopharmacol. 70 (2019) 338-353]. 2021 , 90, 107197	
537	Theoretical versus empirical secular change in zircon composition. 2021 , 554, 116660	6
536	Experimental determination of cooling and spray characteristics of the water electrospray. 2021 , 120, 105046	4

535	Design and synthesize hollow spindle Ni-doped Co ₉ S ₈ @ZnS composites and their enhanced cycle performance. 2021 , 853, 157118	7
534	The study of Canadian Arctic freshwater system toward radioactive contamination - status in 1999. 2021 , 226, 106454	
533	Isolation of clinically significant microorganisms from prosthetic joint tissue using BacT/ALERT paediatric blood culture bottles compared with solid culture media and enrichment broth. 2021 , 53, 515-519	
532	Recenser et prévenir le handicap, plutôt que lutter contre les discriminations. Les effets du handicap dans la fonction publique française. 2021 , 15, 71-88	2
531	Transfer learning and SE-ResNet152 networks-based for small-scale unbalanced fish species identification. 2021 , 180, 105878	5
530	Foreword. 2021 , 38, xi-xii	
529	Experimental study on the spontaneous imbibition characteristics of accumulated coal grains. 2021 , 288, 119634	3
528	One-pot synthesis of supported Ni@Al ₂ O ₃ catalysts with uniform small-sized Ni for hydrogen generation via ammonia decomposition. 2021 , 46, 4045-4054	14
527	Surface quality of cemented tungsten carbide finished by direct cutting using diamond-coated carbide end mill. 2021 , 61, 83-99	2
526	Adhesion of spider cribellate silk enhanced in high humidity by mechanical plasticization of the underlying fiber. 2021 , 114, 104200	3
525	Aged-based differences in spatial language skills from 6 to 10 years: Relations with spatial and mathematics skills. 2021 , 73, 101417	4
524	Experimental and CFD investigation of spiral tube heat exchanger. 2021 , 37, 3689-3696	3
523	Sink production and grain-filling ability of a new high-yielding rice variety, Kitagenki. 2021 , 260, 107991	5
522	Investigating the effect of heat treatment on B ₄ C reinforced aluminum metal matrix composites. 2021 , 45, 100-104	
521	A numerical differentiation method based on legendre expansion with super order Tikhonov regularization. 2021 , 393, 125811	0
520	Self-destructive barite filter cake in water-based and oil-based drilling fluids. 2021 , 197, 107963	6
519	Effects of organic additives on calcium hydroxide crystallisation during lime slaking. 2021 , 139, 106254	4
518	Utilization of PET bottles and plastic granules in geopolymer concrete. 2021 , 42, 444-449	4

517	Capacity credit evaluation of wind energy using a robust secant method incorporating improved importance sampling. 2021 , 43, 100892	3
516	The role and therapeutic implications of PI3K signaling pathway in cancer. 2021 , 123, 39-41	3
515	Applying behavioral economics to reduce broken dental appointments. 2021 , 152, 3-7	
514	Alteration of soil rhizobial populations by rabbit latrines could impair symbiotic nitrogen fixation in the insular alpine ecosystem of Teide National Park. 2021 , 160, 103850	0
513	Clinical phenotype associated with TANGO2 gene mutation. 2021 , 28, 80-86	1
512	The Anterolateral Ligament of the Knee: An Updated Systematic Review of Anatomy, Biomechanics, and Clinical Outcomes. 2021 , 37, 1654-1666	7
511	Highly sensitive and stable self-powered biosensing for exosomes based on dual metal-organic frameworks nanocarriers. 2021 , 176, 112907	53
510	Reactive oxygen species-responsive and scavenging polyurethane nanoparticles for treatment of osteoarthritis in vivo. 2021 , 409, 128147	11
509	Commodity anti-counterfeiting decision in e-commerce trade based on machine learning and Internet of Things. 2021 , 76, 103504	1
508	The association between antidepressant use and assisted reproductive technology (ART) treatment in Danish women: A national registry-based cohort study. 2021 , 258, 401-408	1
507	Differences of bacterial communities in two full-scale A2/O municipal wastewater treatment plants and their effects on effluent total nitrogen removal. 2021 , 21, 101317	4
506	Erratum to: Xiaoyu Li, Youling Gong, Dan Li, et al. Low-Dose Radiation Therapy Promotes Radiation Pneumonitis by Activating NLRP3 Inflammasome. <i>Int J Radiat Oncol Biol Phys</i> 2020;107(4):804-814. 2021 , 109, 837	
505	Cancer patients' experience of oncology services in Assam, India.. 2021 , 27, 100267	0
504	Research Techniques Made Simple: Experimental Methodology for Imaging Mass Cytometry. 2021 , 141, 467-473.e1	1
503	Non-structural carbohydrates coordinate tree peony flowering both as energy substrates and as sugar signaling triggers, with the bracts playing an essential role. 2021 , 159, 80-88	5
502	Relation entre la localisation des pneumopathies et la courbure de la scoliose lors d'une infection pulmonaire chez des patients pédiatriques atteints de pathologies neuromusculaires et neurologiques. 2021 , 13, 78	
501	Impact de la bronchectasie sur le contrôle de l'asthme. 2021 , 13, 88-89	
500	Place de la chirurgie dans la prise en charge des tumeurs desmoïdes thoraciques. 2021 , 13, 126-127	

499	Accès universel aux tests de sensibilité aux antituberculeux: cas du GeneXpert ^Abidjan. 2021 , 13, 232	
498	Controllable synthesis and luminescence properties of one-dimensional La ₂ O ₃ and La ₂ O ₃ :Ln ³⁺ (Ln = Er, Eu, Tb) nanorods with different aspect ratios. 2021 , 229, 117663	1
497	Remote handling systems for the ISAC and ARIEL high-power fission and spallation ISOL target facilities at TRIUMF. 2021 , 53, 1378-1389	2
496	Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. 2021 , 72, 65-75	14
495	Analyzing Kinase Similarity in Small Molecule and Protein Structural Space to Explore the Limits of Multi-Target Screening. 2021 , 26,	0
494	Cancer Vaccines: Antigen Selection Strategy. 2021 , 9,	7
493	A Traceable Cancer Model: DNA Damage, Fragile Site-SMGs, Mitotic Slippage, 4n-Genome-Reduction to Fitness-Gained, Initiating, 2n First Cells. 2021 , 12, 365-386	1
492	Phospholipase Signaling in Breast Cancer. 2021 , 1187, 23-52	0
491	Cell cycle stress in normal human cells: A route to "first cells" (with/without fitness gain) and cancer-like cell-shape changes. 2021 ,	4
490	Bioinformatics à computer programming. 2021 , 125-148	
489	Aim in Genomics. 2021 , 1-15	
488	Genomic Variation, Evolvability, and the Paradox of Mental Illness. 2020 , 11, 593233	0
487	Cancer and genomic instability. 2021 , 495-519	
486	A short review of the genes involved in the development and progression of colorectal cancer. 2021 , 45, 483-487	0
485	Lactate reloaded à evaluation of the importance of lactate monitoring in the management of adult sepsis in the emergency department. 2021 , 45, 445-449	0
484	Concurrent depletion of Vps37 proteins evokes ESCRT-I destabilization and profound cellular stress responses. 2021 , 134,	2
483	Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders. 2021 , 169, 118-136	22
482	Systematic characterization of mutations altering protein degradation in human cancers. 2021 , 81, 1292-1308. 11	

481	Retinoblastoma tumor cell proliferation is negatively associated with an immune gene expression signature and increased immune cells. 2021 , 101, 701-718		1
480	Advances in Rodent Models for Breast Cancer Formation, Progression, and Therapeutic Testing. <i>Frontiers in Oncology</i> , 2021 , 11, 593337	5.3	2
479	Case Report: Cetuximab in Combination With Chemotherapy for the Treatment of Multifocal Hepatic Metastases From Colorectal Cancer Guided by Genetic Tests. <i>Frontiers in Oncology</i> , 2021 , 11, 612171	5.3	1
478	The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores. 2021 , 154, 214-215		
477	Whole exome sequencing of a gut-associated lymphoid tissue neoplasm points to precursor or early form of sporadic colon carcinoma. 2021 , 220, 153406		
476	From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy. 2021 , 26,		19
475	Non-coding mutations reveal cancer driver cistromes in luminal breast cancer.		
474	Cancer as a form of life: Musings of the cancer and evolution symposium. 2021 , 165, 120-139		4
473	Identification of cancer driver genes using Sleeping Beauty transposon mutagenesis. 2021 , 112, 2089-2096		2
472	Potential role for the tumor suppressor CYLD in brain and notochord development. 2021 , 12, 1900-1908		3
471	Kap- β /Transportin mediates Ectenin nuclear transport in Wnt signaling.		
470	Microbe-based therapies for colorectal cancer: Advantages and limitations. 2021 ,		5
469	Organoids in cancer research: a review for pathologist-scientists. 2021 , 254, 395-404		2
468	Identification of driver genes based on gene mutational effects and network centrality. 2021 , 22, 457		0
467	Identifying Novel Actionable Targets in Colon Cancer. 2021 , 9,		3
466	Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
465	The metabolome and lipidome of colorectal adenomas and cancers.		
464	Molecular alterations in basal cell carcinoma subtypes. 2021 , 11, 13206		5

463	Identification of Common Driver Gene Modules and Associations between Cancers through Integrated Network Analysis. 2021 , 5, 2100006		1
462	Evolution of the open-access CIViC knowledgebase is driven by the needs of the cancer variant interpretation community.		
461	Correlations between Urinary Monoethylhexyl Phthalate Concentration in Healthy Individuals, Individuals with Colorectal Adenomas, and Individuals with Colorectal Cancer. 2021 , 69, 7127-7136		0
460	The histomorphological and molecular landscape of colorectal adenomas and serrated lesions. 2021 , 113, 218-229		2
459	Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies. <i>Cancers</i> , 2021 , 13,	6.6	0
458	PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. 2021 , 18, 3418-3428		6
457	Mutational landscape of plasma cell-free DNA identifies molecular features associated with therapeutic response in patients with colon cancer. A pilot study. 2021 , 36, 358-368		1
456	An MST4-pEcatenin Signaling Axis Controls Intestinal Stem Cell and Tumorigenesis. 2021 , 8, e2004850		2
455	YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. 2021 , 475, 205-221		12
454	Tumour heterogeneity and evolutionary dynamics in colorectal cancer. 2021 , 10, 53		4
453	Cancer - dysregulation of the cell cycle and transduction of cascade signals. 2021 , 11, 90-100		
452	Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. 2021 , 14, 765-775		0
451	Novel somatic variants involved in biochemical activity of pure growth hormone-secreting pituitary adenoma without GNAS variant. 2021 , 11, 16530		1
450	Potential of olive oil and its phenolic compounds as therapeutic intervention against colorectal cancer: a comprehensive review. 2021 , 1-17		4
449	Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?. 2021 , 14, 101131		4
448	Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells. 2021 , 122, 1737-1748		0
447	Deep Subspace Mutual Learning For Cancer Subtypes Prediction. 2021 ,		3
446	Treatment strategies for mosaic overgrowth syndromes of the PI3K-AKT-mTOR pathway. 2021 ,		1

445	Gut Microbiota in Lung Cancer: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
444	Mutations in Noncoding -Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer. <i>Molecular Cancer Research</i> , 2021 ,	6.6	0
443	NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. 2021 , 7, eabc8145		1
442	Naked cuticle inhibits wingless signaling in Drosophila wing development. 2021 , 576, 1-6		
441	A Dual PI3K/HDAC Inhibitor Downregulates Oncogenic Pathways in Hematologic Tumors and. 2021 , 12, 741697		1
440	A protein interaction landscape of breast cancer. <i>Science</i> , 2021 , 374, eabf3066	33.3	4
439	Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients. 2021 , 12, 5099-5109		2
438	Risk of lung cancer due to external environmental factor and epidemiological data analysis. 2021 , 18, 6079-6094		1
437	Co n s u h d o r y . P a r a l e l y v c h o v i b u n k a l i d 2021,		
436	Overexpression of ICAT Inhibits the Progression of Colorectal Cancer by Binding with E-Catenin in the Cytoplasm. 2021 , 20, 15330338211041253		2
435	Identification of significantly mutated subnetworks in the breast cancer genome. 2021 , 11, 642		
434	A network-based analysis of disease modules from a taxonomic perspective. 2021 , PP,		
433	Whole Genome Resequencing and 1000 Genomes Project.		1
432	Genetic Susceptibility and High Risk Groups for Pancreatic Cancer. 2010 , 565-600		1
431	Genetic Alterations in Colorectal Cancer in Older Patients. 2013 , 9-20		1
430	Somatic Alterations and Implications in Breast Cancer. 2009 , 183-213		1
429	Classification, Clinical Features, and Molecular Genetic Models. 2010 , 1-21		1
428	Hereditary Colorectal Cancer. 2011 , 643-668		1

427	Pathways and Crossroads to Colorectal Cancer. 2011 , 369-394	3
426	The Human Genome, Microbiomes, and Disease. 2011 , 1-14	3
425	Chicken Models of Retroviral Insertional Mutagenesis. 2011 , 77-112	1
424	Integrating omics Data for Quantitative and Systems Pharmacology in Translational Oncology. 2013 , 187-206	1
423	Complexity in Health: An Introduction. 2013 , 1-17	19
422	The EPR Effect in Cancer Therapy. 2013 , 621-632	14
421	Molecular Mechanisms of Colorectal Carcinogenesis. 2013 , 25-65	5
420	The PI3K Pathway in Colorectal Cancers. 2013 , 157-199	1
419	Fully automated fluorescence-based four-color multiplex assay for co-detection of microRNA and protein biomarkers in clinical tissue specimens. 2014 , 1211, 151-70	12
418	Epigenetics of colorectal cancer. 2015 , 1238, 405-24	16
417	Biomolecular pathway databases. 2010 , 609, 129-44	18
416	Translational Control of Cancer: Implications for Targeted Therapy. 2009 , 237-255	1
415	Analysis of the TLR/NF-kappaB pathway in antigen-presenting cells in malignancies promoted by inflammation. 2009 , 512, 99-117	1
414	Preclinical Tumor Response End Points. 2011 , 571-605	1
413	Tumor-Specific Mutations as Targets for Cancer Immunotherapy. 2011 , 151-172	1
412	Cancer biology. 2011 , 731, 1-11	15
411	Final Thoughts: Complexity and Controversy Surrounding the Cancer Stem Cell Paradigm. 2011 , 433-464	1
410	Heterogeneity of Breast Cancer: Gene Signatures and Beyond. 2012 , 13-25	2

409	Melanoma Antigens Recognized by T Lymphocytes. 2012 , 187-205	2
408	O-glycoprotein biosynthesis: site localization by Edman degradation and site prediction based on random peptide substrates. 2012 , 842, 81-108	3
407	Predicting the functional consequences of somatic missense mutations found in tumors. 2014 , 1101, 135-59	8
406	ERBB4 mutation analysis: emerging molecular target for melanoma treatment. 2014 , 1102, 461-80	16
405	The Role of FBXW Subfamily of F-box Proteins in Tumorigenesis. 2014 , 15-45	2
404	mRNA Vaccination and Personalized Cancer Therapy. 2014 , 89-100	2
403	Simultaneous Inference of Cancer Pathways and Tumor Progression from Cross-Sectional Mutation Data. 2014 , 250-264	6
402	Branching Process Models of Cancer. 2015 , 1-63	11
401	Targeting Heat Shock Proteins in Colorectal Cancer. 2015 , 345-379	2
400	The Biology of AYA Cancers. 2017 , 43-67	3
399	Algorithms for Detecting Significantly Mutated Pathways in Cancer. 2010 , 506-521	14
398	UDP-N-Acetyl-Alpha-D-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferases (ppGalNAc-Ts). 2014 , 495-511	2
397	Molecular Parameters for Prognostic and Predictive Assessment in Colorectal Cancer. 2013 , 41-62	2
396	Application of Bioinformatics in Cancer Research. 2010 , 211-233	2
395	Adherens junctions and cancer. 2012 , 60, 379-414	42
394	Pancreatic Cancer Genomics. 2013 , 219-253	1
393	Targeting SCF E3 Ligases for Cancer Therapies. 2020 , 1217, 123-146	17
392	Colorectal Cancer. 2009 , 879-897	2

391	Introduction of Epigenetic Targets in Drug Discovery and Current Status of Epi-Drugs and Epi-Probes. 2016 , 1-20		2
390	Progressing from Gene Mutations to Cancer. 2008 , 207-222		1
389	Molecular Diagnosis in Hematopathology. 2011 , 56-80		2
388	Molecular Oncology of Breast Cancer. 2009 , 501-531		1
387	Neoplasia. 2010 , 259-330		25
386	Untangling a complex web: Computational analyses of tumor molecular profiles to decode driver mechanisms. 2020 , 47, 595-609		0
385	BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress. 2019 , 476, 3053-3066		13
384	p110PI3K as a therapeutic target of solid tumours. 2020 , 134, 1377-1397		7
383	Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening. 2020 , 12, 630-643		21
382	Pan-cancer scale landscape of simple somatic mutations.		1
381	Every which way? On predicting tumor evolution using cancer progression models.		0
380	Critical Analysis of Strand-Biased Somatic Mutation Signatures in TP53 versus Ig Genes, in Genome-Wide Data and the Etiology of Cancer. 2013 , 2013, 1-18		9
379	Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3629-38	15.9	50
378	Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. <i>Journal of Clinical Investigation</i> , 2009 , 119, 454-64	15.9	168
377	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3395-407	15.9	207
376	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. <i>Journal of Clinical Investigation</i> , 2010 , 120, 3296-309	15.9	111
375	Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. <i>Journal of Clinical Investigation</i> , 2010 , 120, 3310-25	15.9	78
374	PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2655-8	15.9	29

373	Heterogeneity in breast cancer. <i>Journal of Clinical Investigation</i> , 2011 , 121, 3786-8	15.9	559
372	Cancer genome landscape: a radiologist's guide to cancer genome medicine with imaging correlates. 2019 , 10, 111		2
371	Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples. <i>PLoS Computational Biology</i> , 2017 , 13, e1005428	5	15
370	NetNorM: Capturing cancer-relevant information in somatic exome mutation data with gene networks for cancer stratification and prognosis. <i>PLoS Computational Biology</i> , 2017 , 13, e1005573	5	16
369	Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. 2008 , 5, e114		113
368	Genome wide identification of recessive cancer genes by combinatorial mutation analysis. 2008 , 3, e3380		10
367	Absence of AKT1 mutations in glioblastoma. 2009 , 4, e5638		14
366	Targeted resequencing and analysis of the Diamond-Blackfan anemia disease locus RPS19. 2009 , 4, e6172		10
365	Parallel routes of human carcinoma development: implications of the age-specific incidence data. 2009 , 4, e7053		4
364	Bi-directional SIFT predicts a subset of activating mutations. 2009 , 4, e8311		27
363	Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. 2009 , 4, e8357		116
362	Prediction and testing of biological networks underlying intestinal cancer. 2010 , 5, e12497		11
361	Genetic and molecular functional characterization of variants within TNFSF13B, a positional candidate preeclampsia susceptibility gene on 13q. 2010 , 5, e12993		14
360	Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. 2010 , 5, e13091		263
359	DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. 2010 , 5, e13978		85
358	Somatic mutagenesis with a Sleeping Beauty transposon system leads to solid tumor formation in zebrafish. 2011 , 6, e18826		24
357	Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. 2011 , 6, e21639		16
356	Age-specific incidence data indicate four mutations are required for human testicular cancers. 2011 , 6, e25978		6

355	The temporal order of genetic and pathway alterations in tumorigenesis. 2011 , 6, e27136	76
354	Cancer gene prioritization for targeted resequencing using FitSNP scores. 2012 , 7, e31333	2
353	ER-alpha-cDNA as part of a bicistronic transcript gives rise to high frequency, long term, receptor expressing cell clones. 2012 , 7, e31977	2
352	Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. 2012 , 7, e37430	6
351	TARGETgene: a tool for identification of potential therapeutic targets in cancer. 2012 , 7, e43305	14
350	A predictive framework for integrating disparate genomic data types using sample-specific gene set enrichment analysis and multi-task learning. 2012 , 7, e44635	4
349	Somatic mutations of PIK3R1 promote gliomagenesis. 2012 , 7, e49466	40
348	Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters. 2012 , 7, e51205	15
347	Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells. 2012 , 7, e51449	32
346	High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. 2012 , 7, e52795	30
345	Exome capture sequencing of adenoma reveals genetic alterations in multiple cellular pathways at the early stage of colorectal tumorigenesis. 2013 , 8, e53310	31
344	The spectrum of SWI/SNF mutations, ubiquitous in human cancers. 2013 , 8, e55119	351
343	APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway. 2013 , 8, e55298	28
342	High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. 2013 , 8, e56185	21
341	Mammalian TIMELESS is involved in period determination and DNA damage-dependent phase advancing of the circadian clock. 2013 , 8, e56623	48
340	Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. 2013 , 8, e58731	25
339	High myeloperoxidase positive cell infiltration in colorectal cancer is an independent favorable prognostic factor. 2013 , 8, e64814	75
338	The relative timing of mutations in a breast cancer genome. 2013 , 8, e64991	17

337	ToP: a trend-of-disease-progression procedure works well for identifying cancer genes from multi-state cohort gene expression data for human colorectal cancer. 2013 , 8, e65683	11
336	Cancer missense mutations alter binding properties of proteins and their interaction networks. 2013 , 8, e66273	69
335	Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. 2013 , 8, e78086	21
334	Mammary cells with active Wnt signaling resist ErbB2-induced tumorigenesis. 2013 , 8, e78720	7
333	Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis. 2013 , 8, e79282	15
332	Variants of the PPARD gene and their clinicopathological significance in colorectal cancer. 2013 , 8, e83952	4
331	Loss of connectivity in cancer co-expression networks. 2014 , 9, e87075	48
330	A high throughput screening assay system for the identification of small molecule inhibitors of gsp. 2014 , 9, e90766	13
329	Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway. 2014 , 9, e107202	37
328	MiR-203 suppresses ZNF217 upregulation in colorectal cancer and its oncogenicity. 2015 , 10, e0116170	30
327	Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples. 2015 , 10, e0127146	27
326	A null model for Pearson coexpression networks. 2015 , 10, e0128115	7
325	Exclusive Association of p53 Mutation with Super-High Methylation of Tumor Suppressor Genes in the p53 Pathway in a Unique Gastric Cancer Phenotype. 2015 , 10, e0139902	9
324	Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. 2015 , 10, e0144708	28
323	Application of Circulating Tumor DNA as a Non-Invasive Tool for Monitoring the Progression of Colorectal Cancer. 2016 , 11, e0159708	25
322	Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway. 2017 , 12, e0170551	35
321	Early mutation bursts in colorectal tumors. 2017 , 12, e0172516	1
320	Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures. 2020 , 15, e0239197	4

319	Molecular damage in cancer: an argument for mTOR-driven aging. 2011 , 3, 1130-41	72
318	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. 2016 , 7, 60712-60722	79
317	Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity. 2016 , 7, 76047-76061	12
316	The crosstalk between microRNAs and the Wnt/ β -catenin signaling pathway in cancer. 2017 , 8, 14089-14106	86
315	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. 2013 , 4, 1931-2	9
314	Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer. 2017 , 8, 7852-7866	18
313	Targeting IL-11 signaling in colon cancer. 2013 , 4, 1860-1	20
312	High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes. 2017 , 8, 5160-5178	42
311	Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. 2017 , 8, 6579-6588	16
310	Genomic characteristics of pancreatic squamous cell carcinoma, an investigation by using high throughput sequencing after in-solution hybrid capture. 2017 , 8, 14620-14635	9
309	Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma. 2017 , 8, 23760-23774	14
308	Potential biomarkers of DNA replication stress in cancer. 2017 , 8, 36996-37008	13
307	The diagnostic and prognostic value of hypermethylation in colorectal cancer, a meta-analysis and literature review. 2017 , 8, 89142-89148	9
306	RRS1 silencing suppresses colorectal cancer cell proliferation and tumorigenesis by inhibiting G2/M progression and angiogenesis. 2017 , 8, 82968-82980	22
305	Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. 2014 , 5, 6102-12	47
304	Targeting translation dependence in cancer. 2011 , 2, 76-88	46
303	Trends in colorectal cancer mortality in hispanics: a SEER analysis. 2017 , 8, 108771-108777	12
302	NCOA5 promotes proliferation, migration and invasion of colorectal cancer cells via activation of PI3K/AKT pathway. 2017 , 8, 107932-107946	19

301	IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients. 2011 , 2, 178-85	55
300	The DNA2 nuclease/helicase is an estrogen-dependent gene mutated in breast and ovarian cancers. 2014 , 5, 9396-409	21
299	Mcl-1 ubiquitination and destruction. 2011 , 2, 239-44	70
298	Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. 2014 , 5, 8039-51	23
297	An improved method for culturing patient-derived colorectal cancer spheroids. 2018 , 9, 21950-21964	19
296	Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. 2018 , 9, 23960-23974	6
295	SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer. 2018 , 9, 30661-30678	26
294	Survival correlation of immune response in human cancers. 2019 , 10, 6885-6897	1
293	Clinical implications of chromatin accessibility in human cancers. 2020 , 11, 1666-1678	3
292	FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15. 2015 , 6, 9240-56	25
291	Putative effectors for prognosis in lung adenocarcinoma are ethnic and gender specific. 2015 , 6, 19483-99	4
290	NCI's provocative questions on cancer: some answers to ignite discussion. 2011 , 2, 1352-67	46
289	Identification of GALNT14 as a novel neuroblastoma predisposition gene. 2015 , 6, 26335-46	31
288	Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. 2015 , 6, 32368-79	17
287	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. 2015 , 6, 39538-49	23
286	Identification of ovarian cancer subtype-specific network modules and candidate drivers through an integrative genomics approach. 2016 , 7, 4298-309	17
285	Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. 2016 , 7, 28356-68	12
284	Heat shock protein 47 promotes tumor survival and therapy resistance by modulating AKT signaling PHLPP1 in colorectal cancer. 2020 , 17, 343-356	4

283	Evolving insights: how DNA repair pathways impact cancer evolution. 2020 , 17, 805-827	8
282	Increasing incidence of colon cancer in patients . 2016 , 4, 164	9
281	Querying NeXtProt Nanopublications and Their Value for Insights on Sequence Variants and Tissue Expression.	2
280	DNA Double Strand Break Repair - Related Synthetic Lethality. 2019 , 26, 1446-1482	6
279	The mutator phenotype in cancer: molecular mechanisms and targeting strategies. 2010 , 11, 1296-303	32
278	Racial Disparities in the Molecular Landscape of Cancer. 2018 , 38, 2235-2240	20
277	Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. 2016 , 13, 12-8	13
276	Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression. <i>Frontiers in Oncology</i> , 2020 , 10, 610104	53 6
275	The application of massively parallel sequencing technologies in diagnostics. 2010 , 2, 59	4
274	Mutation Detection of K-ras Gene in Paraffin-embedded Colorectal Cancer Tissues by Using Chip-based TGCE*. 2010 , 37, 794-800	3
273	Modifier-concept of colorectal carcinogenesis: lipidomics as a technical tool in pathway analysis. 2010 , 16, 1820-7	5
272	SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. 2011 , 17, 2028-36	44
271	Molecular classification of colorectal carcinomas: the genotype-to-phenotype relation. 2013 , 19, 8163-7	13
270	miR-132 inhibits colorectal cancer invasion and metastasis via directly targeting ZEB2. 2014 , 20, 6515-22	85
269	p38 β MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. 2014 , 20, 9744-58	151
268	Establishment and characterization of cell lines from chromosomal instable colorectal cancer. 2015 , 21, 164-76	19
267	Field cancerisation in colorectal cancer: a new frontier or pastures past?. 2015 , 21, 3763-72	21
266	Non-coding landscapes of colorectal cancer. 2015 , 21, 11709-39	59

265	Integration of genome scale data for identifying new players in colorectal cancer. 2016 , 22, 534-45	3
264	Integrated genomic and methylation profile analysis to identify candidate tumor marker genes in patients with colorectal cancer. 2019 , 18, 4503-4514	2
263	Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer. 2020 , 19, 3617-3626	4
262	Comprehensive characterization of driver genes in diffuse large B cell lymphoma. 2020 , 20, 382-390	3
261	Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer. 2020 , 20, 1734-1742	4
260	Next-Generation Sequencing for Drug Designing and Development: An Omics Approach for Cancer Treatment. 2017 , 13, 709-723	3
259	Drosophila as a model for chromosomal instability. 2015 , 02, 001-012	3
258	The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma. 2018 , 52, 37-44	9
257	The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. 2013 , Suppl 5,	16
256	Wound Healing Is a First Response in a Cancerous Pathway: Hyperplasia Developments to 4n Cell Cycling in Dysplasia Linked to Rb-Inactivation. 2015 , 06, 906-916	6
255	Mitotic Slippage Process Concealed Cancer-Sought Chromosome Instability Mechanism (S-CIN). 2017 , 08, 608-623	6
254	Genomic Instability in Cancer II: 4N-Skewed (90%#176;) Reductive Division via Fragile Sites to Fitness Increase for Solid and Hematological Cancer Beginnings. 2019 , 10, 537-564	4
253	Near-Dead Cells to Special Tetraploidy to First Cells to Cancer Diagnostic Morphology: Unlikely Therapy-Gain from For-Profit Industrial Goliath. 2020 , 11, 410-432	3
252	Prognostic Value of Combined; Cox-2, Cyclin D1 and P21 Expression in Colorectal Cancer (CRC) Patients: An Immunohistochemical Study. 2018 , 08, 106-121	2
251	Epigenetic field defects in progression to cancer. 2013 , 5, 43-9	27
250	Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma. 2016 , 8, 1119-1127	11
249	Holistic cancer genome profiling for every patient. 2020 , 150, w20158	3
248	Biomarkers for the lung cancer diagnosis and their advances in proteomics. 2008 , 41, 615-25	112

247	Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer. 2009 , 42, 535-9	47
246	Genetic interactions in translational research on cancer. 2011 , 1, 14	3
245	Synthetic Lethality in Anticancer Drug Discovery and Target Identification. 2012 , 3, 352-361	2
244	Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. 2011 , 30, 415-25	66
243	Four molecular subtypes of colorectal cancer and their precursor lesions. 2011 , 135, 698-703	65
242	Molecular Docking analysis of the TNIK Receptor protein with a potential Inhibitor from the NPACT databas. 2020 , 16, 387-392	3
241	PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. 2012 , 67, 1285-90	37
240	Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer. 2014 , 15, 9327-33	8
239	Tumor Biology and Natural History. 2021 , 15-31	
238	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. 2021 , 5, 95	1
237	Synchronous Rectal Tumours with Different Molecular and Genetic Phenotypes Occurring in a Patient with Lynch Syndrome. 2021 , 13, 8009-8015	
236	Nanomedicines in B cell-targeting therapies. 2021 , 137, 1-1	1
235	Systematic Analysis of FASTK Gene Family Alterations in Cancer. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 3
234	Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. 2021 , 13, 1355-1367	0
233	mRNA coexpression patterns of Wnt pathway components and their clinicopathological associations in breast and colorectal cancer. 2021 , 227, 153649	
232	Ubr5.	
231	Krüppel-like Factors in Cancers. 2009 , 205-219	
230	Concepts and Mechanisms of Breast Cancer Metastasis. 2009 , 549-564	

- 229 Cancer Stem Cells in Colorectal Cancer. **2009**, 223-250
- 228 Genomic Identification of Significant Targets in Brain Cancer. **2009**, 395-413
- 227 An Oncogene-Induced DNA Replication Stress Model for Cancer Development. **2009**, 47-63
- 226 Emerging technologies for the genomic analysis of cancer. **2009**, 1, 35
- 225 Loss of Cadherin-Catenin Adhesion System in Invasive Cancer Cells. **2010**, 33-66 2
- 224 Recent Advances in Cancer Genomics and Cancer-Associated Genes Discovery. **2010**, 11-29
- 223 Carcinogenesis and Carcinogens that are also Genotoxic.
- 222 Biology of Non-small Cell Lung Cancer. **2010**, 1080-1097 1
- 221 Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis. **2010**, 41-76 1
- 220 Methylation Detection and Epigenomics in Pancreatic Cancer. **2010**, 181-204
- 219 Mosaic Cancer Mouse Models and Functional Oncogenomics in Hepatocellular Carcinoma. **2010**, 189-196 1
- 218 Analysis of Inherited and Acquired Genetic Variation. **2010**, 13-31
- 217 Basic Principles of Cancer Genetics. **2010**, 1-22
- 216 Well-Differentiated Thyroid Follicular Carcinoma. **2010**, 73-93
- 215 DNA Biomarkers in the Diagnosis and Management of Cancer. **2010**, 165-184
- 214 Molecular Biology. 1-22
- 213 [Identifying candidate cancer genes based on co-evolving gene modules]. **2010**, 32, 694-700
- 212 Gene Discovery by MMTV Mediated Insertional Mutagenesis. **2011**, 39-75

211 Cancer Genome Sequencing.

210 The Hallmarks of Cancer Revisited Through Systems Biology and Network Modelling. **2011**, 245-266

1

209 The Genetic Origins of Brain Tumors. **2011**, 1133-1140

208 Dermatoonkologie. **2011**, 69-102

207 Dynamic Simulations of Pathways Downstream of ERBB-Family: Exploration of Parameter Space and Effects of Its Variation on Network Behavior. **2011**, 229-241

206 Transcriptomics and Cancer Risk Assessment. 195-205

205 A proposal: a comprehensive platform to characterize tumors in Chinese and improve success in cancer drug discovery and development. **2011**, 30, 363-7

204 Recombinant protein vaccination for antigen-specific cancer immunotherapy. **2011**, 87-102

203 Aging and Cancer: The IGF-I Connection. **2012**, 25-36

202 Insertional Mutagenesis for Generating Mouse Models of Cancer. **2012**, 57-82

201 Epigenomic Analysis in Toxicology.

200 DNA Damage Checkpoint Signaling Pathways in Human Cancer. **2012**, 23-37

199 Viral-Encoded Genes and Cancer. **2012**, 81-99

0

198 Cancer Genetics. **2012**, e44-e46

197 Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology. **2012**, 183-240

196 Development and Clinical Implementation of Reverse Phase Protein Microarrays for Protein Network Activation Mapping: Personalized Cancer Therapy. **2012**, 309-323

195 Novel Methods in the Study of the Breast Cancer Genome: Towards a Better Understanding of the Disease of Breast Cancer. **2012**, 03, 797-809

194 Dynamic Simulations of Pathways Downstream of TGF β /Wnt and EGF-Family Growth Factors, in Colorectal Cancer, including Mutations and Treatments with Onco-Protein Inhibitors. **2012**, 127-142

193 Germline Copy Number Variation and Cancer Risk.

192 Nanomedicine: Emerging Field of Nanotechnology to Human Health. **2012**, 13-54

191 Molecular Pathology of Colon and Small Bowel Cancers: Sporadic Type. **2013**, 131-140

190 Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. **2013**, 125-141

189 Mutational Activation of KRAS and BRAF in Colorectal Cancer. **2013**, 121-156

1

188 Cancer Chemotherapy. **2013**, 401-427

1

187 TYPES OF DNA DAMAGE. **2013**, 115-118

186 Comprehensive Genomic Alterations in Common Cancer Cell Lines Revealed by Exome Sequencing. **2013**, 165-182

185 Colorectal Cancer Genome and Its Implications. **2013**, 247-265

184 Copy-Number Alterations in the Colorectal Cancer Genome. **2013**, 267-287

183 Krebsprävention. **2013**, 161-192

182 Translating genomic research into clinical practice: promise and pitfalls. **2013**, 15-23

4

181 Mouse Models to Study DNA Methylation in Cancer Research. **2014**, 43-66

180 Statistical tools and R software for cancer driver probabilities. **2014**, 1101, 113-34

179 Heat-Shock Protein-Based Cancer Immunotherapy. **2014**, 37-56

178 RAS Genes and Cancer. **2014**, 157-171

177 Molecular Pathology of Gastrointestinal Tumors. **2014**, 189-209

176 Genetic and Epigenetic Alterations in Cancer. **2014**, 188-203

- 175 Molecular Networks âRepresentation and Analysis. **2014**, 399-418
- 174 Basics of Nucleic Acids and Molecular Biology. **2014**, 5-26
- 173 Two-stage model of carcinogenic mutations with the influence of delays. **2014**, 19, 2501-2519 1
- 172 In Silico Disease Models of Breast Cancer. **2014**, 315-331
- 171 Genomic Applications in Colorectal and Pancreatic Tumors. **2015**, 415-434
- 170 Basis for Molecular Genetics in Cancer. **2015**, 15-30
- 169 Targeted Therapy and Novel Agents for the Treatment of Gastric Cancer: A View Toward the Future. **2015**, 317-330
- 168 Impact of Energy Balance on Chemically Induced Mammary Carcinogenesis in a Rat. **2015**, 175-196
- 167 Somatic Mutations in Overgrowth Syndromes. **2015**, 153-165
- 166 Colorectal Cancer Stem Cells. **2015**, 227-245
- 165 Neoplasia of the Gastrointestinal Tract. 587-616
- 164 Chapter 9:Novel Data Streams in the Assessment of Mutagenicity and Carcinogenicity: Implications for Cancer Hazard Assessment. **2016**, 247-279
- 163 Encyclopedia of Signaling Molecules. **2016**, 1-4
- 162 Mismatch Repair. **2016**, 305-339 0
- 161 Cancer Prevention? Fundamental Genomic Alterations Are Present in Preneoplasia, Including Function of High Frequency Selected Mutations (HFSMs). **2016**, 07, 416-426 2
- 160 Evaluating the Evaluation of Cancer Driver Genes. 1
- 159 The Intersection of Epidemiology and Pathology. **2017**, 3-9
- 158 Pathology and Molecular Pathology of Colorectal Cancer. **2017**, 409-446 0

- 157 Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions.
- 156 High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes.
- 155 An exactly solvable, spatial model of mutation accumulation in cancer.
- 154 The more the messier: centrosome amplification as a novel biomarker for personalized treatment of colorectal cancers. **2016**, 30, 441-451 6
- 153 A lottery simulation model for predicting cancer risk based on the strength and abundance of individual mutations.
- 152 Molecular Detection and Diagnosis of Cancer. **2017**, 797-809 1
- 151 An Overview of Cancer Genes. **2017**, 121-142
- 150 Personalised Genomics and Molecular Profiles in Colorectal Cancer: Towards Precision Cancer Care. **2017**, 261-285
- 149 The landscape of somatic mutation in sporadic Chinese colorectal cancer.
- 148 An immunohistochemical study of histone H1.5 in correlation with clinicopathologic features of invasive duct carcinoma (not otherwise specified). **2017**, 37, 339-344
- 147 Effect sizes of somatic mutations in cancer. 1
- 146 Genomic Instability in Cancer I: DNA-Repair Triggering Primitive Hereditary 4n-Skewed, Amitotic Division-System, the Culprit in EMT/MET/Metaplasia Cancer-Concepts. **2018**, 09, 974-997 5
- 145 Multi-target analysis of neoplasms for the evaluation of tumor progression: stochastic approach of biologic processes. **2018**, 5, 14-62
- 144 Encyclopedia of Signaling Molecules. **2018**, 4294-4298
- 143 Clonal Evolution: Driver/Passenger Mutation Model in CLL. **2018**, 111-132
- 142 MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2.
- 141 Human Genome. **2018**, 273-289
- 140 MYC Dysregulates Mitotic Spindle Function Creating a Dependency on TPX2.

- 139 Expression-based analyses indicate a central role for hypoxia in driving tumor plasticity through microenvironment remodeling and chromosomal instability.
- 138 THE ROLE OF THE EPITHELIALLY-MESENCHYMAL TRANSITION IN THE DEVELOPMENT OF COLORECTAL CANCER (review). **2018**, 111-117 2
- 137 EXPOsOMICS: Meet-in-the-Middle and Network Perturbation. **2019**, 349-392
- 136 Arrayed shRNA Screening to Identify Suppressors of Anchorage-Independent Growth. **2019**, 1907, 115-123
- 135 Circulating Tumor DNA in Colorectal Cancer—From Concept to Clinic. **2019**, 15, 33
- 134 KRAS as Potential Target in Colorectal Cancer Therapy. **2019**, 389-424 0
- 133 Effects of germline and somatic events in candidate BRCAness genes on breast-tumor signatures.
- 132 Pathogenic Genes Selection Model of Genetic Disease based on Network Motifs Slicing Feedback. **2019**, 16, 392-401
- 131 Carausius morosus (Phasmatodea) Homologues of Human Genes with Elevated Expression in the Colon. **2019**, 7,
- 130 Mutations in Cancer Driver Genes: An Insight into Prostate Cancer Progression. **2019**, 1-7
- 129 Targeted molecular profiling of genetic alterations in colorectal cancer using next-generation sequencing. **2020**, 19, 1137-1144
- 128 Concurrent depletion of Vps37 proteins evokes ESCRT-I destabilization and profound cellular stress responses.
- 127 Insertional mutagenesis defines drivers and evolutionary relationships in pancreatic cancer metastasis.
- 126 Genomic and molecular alterations associated with early-onset and adolescent and young adult colorectal cancer. **2020**, 9, CRC30 1
- 125 Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization. **2021**, 119, 51-58 1
- 124 Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?. 0
- 123 Comparative mutational analysis of distal colon cancer with rectal cancer. **2020**, 19, 1781-1788 1
- 122 Concurrent Wnt pathway component expression in breast and colorectal cancer. **2020**, 216, 153005 1

121	Mtg16-dependent repression of E protein activity is required for early lymphopoiesis.	0
120	Hurdles in Cancer Immunotherapy. 2021 , 597-635	
119	Analysis of DNA methylation-driven genes for predicting the prognosis of patients with colorectal cancer. 2020 , 12, 22814-22839	2
118	Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. 2009 , 16, 56-8	4
117	Somatic mutation signatures of cancer. 2008 , 202-6	1
116	Impact of the next generation DNA sequencers. 2009 , 2, 193-202	6
115	KRAS Testing: Optimizing Cancer Therapy. 2009 , 6, 7-9	2
114	Emerging tactical strategies for fighting the war on cancer based on the genetic landscape. 2011 , 3, 251-8	1
113	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. 2013 , 4, 1919-1932	1
112	Molecular genetics of colorectal cancer. 2014 , 27, 9-14	105
111	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. 2015 , 5, 72-86	10
110	Advanced colorectal adenoma related gene expression signature may predict prognostic for colorectal cancer patients with adenoma-carcinoma sequence. 2015 , 8, 4883-98	4
109	Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. 2015 , 8, 215-24	34
108	Into the eye of the storm: breast cancer's somatic mutation landscape points to DNA damage and repair. 2013 , 2, 59-61	1
107	GNAS gene mutation may be present only transiently during colorectal tumorigenesis. 2016 , 7, 24-31	7
106	Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. 2017 , 3, 105-111	40
105	Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods. 2017 , 11, 250-261	14
104	Genomics of adult and pediatric solid tumors. 2018 , 8, 1356-1386	12

103	Molecular pathology and patient care. 2010 , 107, 86-93		1
102	Nuclear factor-erythroid 2-related factor 3 (NRF3) is low expressed in colorectal cancer and its down-regulation promotes colorectal cancer malignance through activating EGFR and p38/MAPK. 2019 , 9, 511-528		3
101	[inhibits brain metastasis of lung cancer through multiple active ingredients acting on multiple targets, pathways and biological functions]. 2021 , 41, 1319-1328		1
100	DCMP: database of cancer mutant protein domains. 2021 , 2021,		
99	Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). 2021 , 1		1
98	Modeling the pathway of breast cancer in the Middle East. 2021 ,		1
97	Mining sponge phenomena in RNA expression data. 2021 , 2150022		
96	Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma. 2021 , 8, 755657		0
95	Tools used to assay genomic instability in cancers and cancer meiomitosis. 2021 , 16, 159		1
94	Rewiring glucose metabolism improves 5-FU efficacy in glycolytic p53-deficient colorectal tumors.		
93	Mucin-Type O-GalNAc Glycosylation in Health and Disease. 2021 , 1325, 25-60		5
92	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making.. 2021 , 11,		1
91	A proposed Information-Based modality for the treatment of cancer.. 2021 , 211, 104587		0
90	Precision medicine for metastatic colorectal cancer in clinical practice.. 2022 , 14, 17588359211072703		2
89	Dietary Fat Intake and Mutations in Colorectal Cancer in a Moroccan Population.. 2022 , 14,		1
88	Cohesin in DNA damage response and double-strand break repair.. 2022 , 1-18		1
87	Involvement of activator protein-1 family members in Ectatinin and p300 association on the genome of PANC-1 cells.. <i>Helijon</i> , 2022 , 8, e08890	3.6	0
86	Towards equitable and trustworthy genomics research.. <i>EBioMedicine</i> , 2022 , 76, 103879	8.8	1

85	Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.. <i>Gastric Cancer</i> , 2022 , 1	7.6	1
84	Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies. <i>Advances in Computational Intelligence and Robotics Book Series</i> , 2022 , 109-136	0.4	
83	MDICC: novel method for multi-omics data integration and cancer subtype identification.. <i>Briefings in Bioinformatics</i> , 2022 ,	13.4	1
82	Aim in Genomics. 2022 , 1073-1086		
81	Drug Repurposing Strategies for Non-Cancer to Cancer Therapeutics.. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022 ,	2.2	0
80	Clinical Oncogenomics and Personalized Medicine in Colorectal Cancer for the Surgeon: What We Need to Know and What the Future Holds. <i>SN Comprehensive Clinical Medicine</i> , 2022 , 4, 1	2.7	
79	Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
78	Surgery, Chemotherapy and Radiotherapy May Promote Cancer Growth Speeds and Shorten Patient Lives. <i>Global Journal of Cancer Therapy</i> , 2022 , 8, 046-049	0.3	0
77	Clinical, Pathologic, and Molecular-Genetic Aspects of Colorectal Polyps.. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2022 , 32, 313-328	3.3	0
76	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.. <i>Clinical Immunology</i> , 2022 , 108962	9	1
75	Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer.. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2022 , 32, 177-194	3.3	2
74	Liver Endothelium Promotes HER3-mediated Cell Survival in Colorectal Cancer with Wild-type and Mutant KRAS.. <i>Molecular Cancer Research</i> , 2022 ,	6.6	0
73	Microbiome in cancer: Role in carcinogenesis and impact in therapeutic strategies.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 149, 112898	7.5	6
72	Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled receptors expressed in tumors.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	0
71	Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?. <i>PLoS Computational Biology</i> , 2021 , 17, e1009055	5	0
70	RAD52 influences the effect of BRCA1/2 missense variants on homologous recombination and gene reversion in <i>Saccharomyces cerevisiae</i> .. <i>FEMS Yeast Research</i> , 2022 ,	3.1	0
69	Growth factor independence underpins a paroxysmal, aggressive Wnt5a/EphA2 phenotype in glioblastoma stem cells, conducive to experimental combinatorial therapy.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 139	12.8	1
68	Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	0

67 Systems biology of cancer progression. 1-6

66 Pancreatic cancer. 409-420

65 Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517

64 Table_1.xlsx. 2019,

63 Data_Sheet_1.PDF. 2020,

62 Data_Sheet_2.xlsx. 2020,

61 Data_Sheet_3.pdf. 2020,

60 Cancer-Associated Fibroblasts and Squamous Epithelial Cells Constitute a Unique Microenvironment in a Mouse Model of Inflammation-Induced Colon Cancer. *Frontiers in Oncology*, 2022, 12, 5.3 0

59 The Characterization and Outcomes of Colorectal Malignancy in Patients ≥40 Years of Age: A Single-Center Experience.. *American Surgeon*, 2022, 31348221096589 0.8

58 Common Cancers and Their Genetic Alterations. 2022, 317-354

57 Mechanistic Effects of Estrogens on Breast Cancer. *Cancer Journal (Sudbury, Mass)*, 2022, 28, 224-240 2.2 0

56 SpBLRSR: Schatten p-norm constrained bounded low-rank subspace recovery for predicting N7-methylguanosine (m7G)-disease associations. *Current Bioinformatics*, 2022, 17, 4.7

55 Circulating tumor DNA: current challenges for clinical utility. *Journal of Clinical Investigation*, 2022, 132, 15.9 1

54 Waiting times in a branching process model of colorectal cancer initiation. 0

53 Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?. *Cancers*, 2022, 14, 3253 6.6 0

52 Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. *Cancer Communications*, 9.4 2

51 Tumor specificity of WNT ligands and receptors reveals universal squamous cell carcinoma oncogenes. *BMC Cancer*, 2022, 22, 4.8 0

50 Corrupted devolution: How normal cells are reborn as cancer precursors. *International Journal of Biochemistry and Cell Biology*, 2022, 149, 106263 5.6

- 49 Local Anesthetics and Cancer. **2023**, 117-127
- 48 The metabolic addiction of cancer stem cells. *Frontiers in Oncology*, 12, 53 ○
- 47 Cancer: Immunology and Immunotherapy. **2022**, 159-164
- 46 Game-theoretic link relevance indexing on genome-wide expression dataset identifies putative salient genes with potential etiological and diapeutics role in colorectal cancer. **2022**, 12,
- 45 Using empirical biological knowledge to infer regulatory networks from multi-omics data. **2022**, 23, 1
- 44 Cruciferous vegetables as a treasure of functional foods bioactive compounds: Targeting p53 family in gastrointestinal tract and associated cancers. 9, 1
- 43 Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application. **2022**, 546, 215840
- 42 Augmented leptin-induced trefoil factor 3 expression and epidermal growth factor receptor transactivation differentially influences neoplasia progression in the stomach and colorectum of dietary fat-induced obese mice. **2022**, 729, 109379 ○
- 41 Prediction of cancer driver genes through integrated analysis of differentially expressed genes at the individual level. ○
- 40 Novel UHRF1-MYC Axis in Acute Lymphoblastic Leukemia. **2022**, 14, 4262 ○
- 39 Identification and verification of CCNB1 as a potential prognostic biomarker by comprehensive analysis. **2022**, 12, ○
- 38 Disruptions in cell fate decisions and transformed enteroendocrine cells drive intestinal tumorigenesis in *Drosophila*. ○
- 37 From organoids to bedside: advances in modeling, decoding and targeting of colorectal cancer. ○
- 36 Secondary bile acids mediate high fat diet-induced upregulation of R-spondin 3 and intestinal epithelial proliferation. ○
- 35 Investigation of cell signalings and therapeutic targets in PTPRK-RSPO3 fusion-positive colorectal cancer. **2022**, 17, e0274555 ○
- 34 Kap-β/Transportin mediates E-catenin nuclear transport in Wnt signaling. 11, ○
- 33 Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRASG12D glycolytic colorectal tumors. **2022**, 5, ○
- 32 Cancer Genomics and Evolution. 1-30 ○

31	Sensitization of Patient-Derived Colorectal Cancer Organoids to Photon and Proton Radiation by Targeting DNA Damage Response Mechanisms. 2022 , 14, 4984	0
30	Evolvability and emergence of tumor heterogeneity as a space-time function. 2023 , 161, 156061	0
29	CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase.	1
28	Methylation of CpG island promoters at ZNF625, LONRF2, SDC2 and WDR17 in a patient with numerous non-granular type laterally spreading tumors and colorectal cancer: A case report. 2022 , 25,	0
27	Understanding of "Networks" In Vitro and/or In Vivo. 2016 , 344-355	0
26	Circulating Tumour DNA and Risk-Stratified Surveillance Strategies for Patients with Colorectal Liver Metastases. 2022 , 557-562	0
25	A Cancer Theory: The Central Nervous System's Adaptive Changes Make Chronic Diseases Incurable. 2019 , 1, 38-62	0
24	Intersection of network medicine and machine learning towards investigating the key biomarkers and pathways underlying amyotrophic lateral sclerosis: a systematic review. 2022 , 23,	0
23	How ctDNA Changing the Landscape of Management of Colorectal Cancers. 1, 33-40	0
22	Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma. 12,	0
21	Molecular Classification of Appendiceal Adenocarcinoma.	0
20	Transcriptional activity mediated by β CATENIN and TCF/LEF family members is completely dispensable for survival of multiple human colorectal cancer cell lines.	0
19	Transcriptional activity mediated by β CATENIN and TCF/LEF family members is completely dispensable for survival and propagation of multiple human colorectal cancer cell lines. 2023 , 13,	0
18	FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients. 12,	0
17	Single-cell profiling reveals differences between human classical adenocarcinoma and mucinous adenocarcinoma. 2023 , 6,	0
16	An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis. 2023 , 15, 736	0
15	Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations. 2023 , 13, 673	0
14	From the Catastrophic Objective Irreproducibility of Cancer Research and Unavoidable Failures of Molecular Targeted Therapies to the Sparkling Hope of Supramolecular Targeted Strategies. 2023 , 24, 2796	0

- 13 Targeting BAP1 with small compound inhibitor for colon cancer treatment. **2023**, 13, ○
- 12 DNA methylation in peripheral blood leukocytes for the association with glucose metabolism and invasive breast cancer. **2023**, 15, ○
- 11 Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition. **2023**, 73, 189-199 ○
- 10 Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178 ○
- 9 Real-world data for precision cancer medicineâ European perspective. ○
- 8 Tumour Suppressor Neuron Navigator 3 and Matrix Metalloproteinase 14 are Co-expressed in Most Melanomas but Downregulated in Thick Tumours. 103, adv00883 ○
- 7 Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas. ○
- 6 Predicting the Driver Variants and Mutations in Lung Cancer Genome using Transcriptional Regulation Network. **2023**, ○
- 5 The Role of Genetic Mutations in Mitochondrial-Driven Cancer Growth in Selected Tumors: Breast and Gynecological Malignancies. **2023**, 13, 996 ○
- 4 Accelerating the understanding of cancer biology through the lens of genomics. **2023**, 186, 1755-1771 ○
- 3 Identification of Novel Candidate Genes for Familial Thyroid Cancer by Whole Exome Sequencing. **2023**, 24, 7843 ○
- 2 The role of Wnt, ARL4C, and Sema3A in developmental process and disease pathogenesis. ○
- 1 Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1 , an ancillary of JCOG0910. ○